Pyrido[4,3-d]pyrimidine compounds as TLR7 / 8 agonists

Pyrido[4,3-d]pyrimidine compounds are developed as TLR7/8 agonists to address the need for safer and more effective therapeutic agents, activating immune responses for treating infections and tumors by modulating TLR7/8 receptors.

JP2024545185AActive Publication Date: 2024-12-05SHANGHAI VISONPHARMA CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024534650
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-16
Filing Date
2022-12-08
Publication Date
2024-12-05
Estimated Expiration
2042-12-08

AI Technical Summary

Technical Problem

There is a need for highly active and safer therapeutically effective Toll-like receptor 7/8 (TLR7/8) agonists to modulate inflammatory responses for treating diseases such as type 1 diabetes, sepsis, cancer, and viral infections, as current TLR7/8 agonists are not sufficiently effective or safe.

Method used

Development of pyrido[4,3-d]pyrimidine compounds with specific structural features that act as TLR7/8 agonists, including various substituents and heterocyclic groups, to enhance their agonistic activity and safety profile.

Benefits of technology

The pyrido[4,3-d]pyrimidine compounds effectively activate TLR7/8 receptors, inducing antiviral and anti-tumor responses, enhancing immune cell activation, and providing a safer therapeutic option for treating infections and tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545185000001_ABST
    Figure 2024545185000001_ABST
Patent Text Reader

Abstract

Toll-like receptor agonists and their preparation and use. Specifically, the compounds of formula I and their preparation and use as TLR7 and / or TLR8 agonists. The compounds are useful in the preparation of pharmaceutical compositions for treating or preventing tumors or viral infections.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Technical Field The present invention relates to the fields of chemistry and medicine, in particular to pyrido[4,3-d]pyrimidine compounds as TLR7 / 8 agonists, and their preparation methods and uses. [Background technology]

[0002] Background technology Toll-like receptors (TLRs) are structurally conserved proteins that form the first barrier in the innate immune response. By recognizing various pathogen-associated molecular patterns (PAMPs), TLRs recognize invading microorganisms and endogenous molecules released after tissue injury or non-physiological cell death, and activate signal cascades that lead to the production of pro-inflammatory cytokines. Inflammatory processes are crucial for the occurrence and development of many diseases, such as type 1 diabetes, sepsis, cancer, and viral infectious diseases. Therefore, small molecule TLRs modulators are promising strategies to treat related diseases by controlling inflammatory responses.

[0003] The human TLRs family has 10 known members and is a type I transmembrane protein characterized by a leucine-rich extracellular domain and an intracellular tail that contains the conserved Toll / interleukin (IL)-1 receptor (TIR) ​​domain. In this family, TLR3, TLR7, TLR8 and TLR9 are located in the endosomal compartment.

[0004] Both TLR7 and TLR8 can recognize single-stranded RNA virus-derived RNA molecules (ssRNA). TLR7 is mainly expressed in plasmacytoid dendritic cells and B cells. TLR8 is mainly distributed in mDCs, macrophages, and monocytes, and is also expressed in T cells. Stimulation of TLR7 induces the production of type I interferons, mainly including interferon-α (IFN-α), and leads to the transcription of interferon-inducible genes (ISGs). Interferon-α is one of the main therapeutic agents for chronic hepatitis B or C. TLR8 is mainly distributed in mDCs, macrophages, and monocytes, and is also expressed in T cells. Activation of TLR8 mainly induces pro-inflammatory responses and stimulates immune cells to secrete pro-inflammatory cytokines, including tumor necrosis-α (TNF-α), IL-6, etc. There is an overlap in the distribution and downstream signaling pathways of TLR7 / 8, so they are functionally similar. Activation of TLR7 / 8 can exert direct antiviral activity through type I interferon response, regulate innate immunity through pro-inflammatory response to promote activation of NK and NKT cells, and induce adaptive immunity, improve antigen presentation and activate dendritic cells, thereby enhancing T cell responses and promoting differentiation of antibody-producing B cells. The development of TLR7 / 8 agonists is of great clinical value in both antiviral and antitumor therapy, and is also useful for antibody conjugate drugs and vaccine adjuvants. Although there are currently several relevant TLR7 / 8 agonist applications, there is still a need for further development of highly active, safer and therapeutically effective TLR7 / 8 agonists. Summary of the Invention

[0005] Summary of the Invention The object of the present invention is to provide TLR7 / 8 agonists which are highly active, safer and therapeutically highly effective. In a first aspect, the present invention provides a compound represented by Formula I or Formula II, a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof. [ka] (however, L1 is selected from the group consisting of -O-, -NH-, -S-, -S(=O)- or -S(=O)2-. R1 is H, C 1-12 Alkyl, hydroxy-substituted C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 cycloalkyl or 4-12 membered heterocycloalkyl groups, wherein R1 may further comprise one or more R a may be substituted with a substituent, and R a is hydrogen, halogen, hydroxyl group, cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 Cycloalkyl groups, -NR a1 R a2 , -NHC(=O)-R a3 , one or more R a4 5-6 membered heteroaryl group substituted with -OC(=O)R a5 , -C(=O)R a5 , -OC(=O)OR a5 , -C(=O)OR a5 is selected from the group consisting of:

[0006] R a1 , R a2 , R a3 or R a4 is C 1-6 Alkyl group, C 1-6 Haloalkyl group, C 3-6 It is selected from the group consisting of cycloalkyl groups. R a5 is C 1-24 Alkyl group, C 1-24 Haloalkyl groups, C with 1-10 heteroatoms 1-24 heteroalkyl groups, where said heteroatoms are one or more selected from NH, N, O and S. X is N or CR2. X1 is H or NH2. X2 is selected from the group consisting of substituted or unsubstituted C1-C8 alkylene groups. R2 and R3 are each independently hydrogen, halogen, cyano, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 A cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, a 5- to 8-membered heterocyclic aryl group, or a 5- to 8-membered aryl group, wherein R2 and R3 may be further substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, or amino groups.

[0007] k is 0 or 1. m is 0, 1, 2, 3, 4, 5, 6, 7 or 8. [ka] represents a single bond or a double bond. B does not exist or C 3-12 Cycloalkyl groups, 4-12 membered heterocycloalkyl groups, C 6-12 an aryl group, a 5-12 membered heteroaryl group, or [ka] wherein each A is selected from C, CH, or N, and R6 and R7 together with the carbon atom adjacent thereto are selected from the group consisting of C 4-7 Cycloalkylene group or C 4-7 A heterocycloalkylene group is formed, 4-7 Any one or more methylene groups in the cycloalkylene group or the 4- to 7-membered heterocycloalkylene group may be independently replaced with a carbonyl group or S(=O)2. In the 4- to 7-membered heterocycloalkylene group, the heteroatom is selected from N, O, and S, and the number of heteroatoms is 1 to 3.

[0008] L2 is -(CR b R c ) p -(NR d) q -, -O-, -S-, -(CR b R c ) p -C(=O)-, -(CR b R c ) p -C(=O)NH-, -(CR b R c ) p -NHC(=O)-, -S(=O)- or -S(=O)-, where R b , R c is hydrogen, halogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl group, 4-6 membered heterocycloalkyl group or C 1-6 haloalkyl groups; R d is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups, C 1-6 Haloalkyl or hydroxy substituted C 1-6 alkyl groups, p is 0, 1, 2, 3, 4, 5 or 6, and q is 0 or 1.

[0009] R4 is hydrogen, halogen, cyano group, amino group, hydroxyl group, C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 Cycloalkyl groups, 4-12 membered heterocyclic groups, C 6-12 aryl or 5-12 membered heteroaryl; and R4 is optionally selected from the group consisting of one or more R e may be substituted with a substituent, where R e is hydrogen, halogen, hydroxyl group, carboxylic acid, amino group, C 1-6 Alkyl group, one or more R e1 C replaced with 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, C 3-12 Cycloalkyl groups, 4-12 membered heterocycloalkyl groups, C6-12 Aryl groups, 5-12 membered heteroaryl groups, -N(R e2 R e3 R e4 ), -C(=O)OR e2 , -C(=O)NH-R e2 , -S(=O)2-R e2 is selected from the group consisting of:

[0010] R e1 is a halogen, a hydroxyl group, -P(O)(OR e2 ) 2. R e2 , R e3 is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, C 1-6 Haloalkyl or hydroxy substituted C 1-6 The alkyl group is selected from the group consisting of alkyl groups. R e4 does not exist or C 1-6 Alkyl group, C 3-6 Cycloalkyl group or C 1-6 It is selected from the group consisting of haloalkyl groups. R5 is a halogen, a hydroxyl group, a cyano group, an amino group, or C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups, C 1-6 Haloalkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, -C(=O)OR f , -C(=O)NH-R f , -S(=O)2-R f where R f is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl group or C 1-6 It is selected from the group consisting of haloalkyl groups. n is 1, 2, 3, 4, 5 or 6.

[0011] wherein each of said heterocyclic groups may be saturated or partially unsaturated (but without aromatic structures), and in said heterocyclic groups, the heteroatoms are selected from N, O, S, and the number of heteroatoms is 1, 2, 3 or 4 (preferably 1 or 2); in said heteroaryl groups, the heteroatoms are selected from N, O, S, and the number of heteroatoms is 1, 2 or 3. In another preferred embodiment, L1 is selected from the group consisting of -O-, -NH-, or -S-. In another preferred embodiment, R1 is C 1-12 Alkyl, hydroxy-substituted C 1-12 Alkyl group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 cycloalkyl or 4-12 membered heterocycloalkyl groups, and R1 may further comprise one or more R a may be substituted with a substituent, and R a is a halogen, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 Cycloalkyl groups, -OC(=O)R a5 , -C(=O)R a5 , -OC(=O)OR a5 , -C(=O)OR a5 is selected from the group consisting of:

[0012] In another preferred embodiment, R1 is C 1-12 Alkyl, hydroxy-substituted C 1-12 Alkyl group, C 2-12 Alkenyl group, C 2-12 alkynyl groups, and said R1 may further comprise one or more R a may be substituted with a substituent, and R a is a halogen, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 Cycloalkyl groups, -OC(=O)R a5 , -C(=O)R a5 , -OC(=O)ORa5 , -C(=O)OR a5 is selected from the group consisting of: In another preferred embodiment, R1 is C 1-12 Alkyl, hydroxy-substituted C 1-12 alkyl groups, and R1 may further comprise one or more R a may be substituted with a substituent, and R a is C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, -OC(=O)R a5 , -C(=O)R a5 , -OC(=O)OR a5 , -C(=O)OR a5 is selected from the group consisting of:

[0013] In another preferred embodiment, the compound of formula I has a structure selected from the following group: [ka]

[0014] In another preferred embodiment, B is absent or C 3-8 Cycloalkyl groups, 4-7 membered heterocyclic groups, C 6-10 an aryl group, or [ka] is selected from the group consisting of: In another preferred embodiment, B is absent or selected from the group consisting of a phenyl group and a pyridyl group. In another preferred embodiment, L2 is -(CR b R c ) p -(NR d ) q -, -O-, -S-, -(CR b R c ) p -C(=O)-, -(CR b R c ) p -C(=O)NH-, -(CRb R c ) p -NHC(=O)-, -S(=O)- or -S(=O)-, where R b , R c is hydrogen, halogen, C 1-6 alkyl groups; R d is hydrogen or C 1-6 In the alkyl group, p is 0, 1, 2 or 3 and q is 0 or 1.

[0015] In another preferred embodiment, L2 is -(CH2) p -, -(CH2) p -NR d -, -O-, -S-, -(CH2) p -C(=O)-, -(CH2) p -C(=O)NH-, -(CH2) p -NHC(=O)-, -S(=O)-, where R d is hydrogen or C 1-6 In the alkyl group, p is 0, 1, 2 or 3. In another preferred embodiment, R4 is hydrogen, a halogen, an amino group, a hydroxy group, C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-10 Cycloalkyl groups, 4-10 membered heterocyclic groups, C 6-12 aryl, or 5-12 membered heteroaryl, and R4 is optionally selected from the group consisting of one or more R e may be substituted with a substituent, where R e is hydrogen, halogen, hydroxyl group, carboxylic acid, amino group, C 1-6 Alkyl group, one or more R e1 C replaced with 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, C 3-8 cycloalkyl groups, 4-7 membered heterocyclic groups, phenyl groups, and 5-7 membered heteroaryl groups, where Re1 is a halogen, hydroxyl group, P(O)(OR e2 ) 2.

[0016] In another preferred embodiment, R4 is hydrogen, C 1-12 Alkyl group, C 1-12 An alkoxy group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, [ka] wherein any position in the ring is missing an H atom to provide a linking site, and R4 is optionally selected from the group consisting of one or more R e It may be substituted with a substituent.

[0017] In another preferred embodiment, R5 is a halogen, a hydroxyl group, a cyano group, an amino group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 It is selected from the group consisting of cycloalkyl groups. In another preferred embodiment, R5 is halogen, C 1-4 Alkyl group, C 1-4 The alkoxy group is selected from the group consisting of alkoxy groups. In a second aspect of the invention there is provided a pharmaceutical composition comprising one or more of the compounds of formula I as defined in the first aspect of the invention, a medicament salt, racemate, R-isomer, S-isomer or mixtures thereof, and one or more medicament carriers, excipients, adjuvants, auxiliary agents and / or diluents.

[0018] In a third aspect of the present invention, there is provided the use of a compound of formula I as defined in the first aspect of the present invention, a medicament salt, racemate, R-isomer, S-isomer or mixtures thereof, for the manufacture of a pharmaceutical composition for treating or preventing tumours or viral infections. In another aspect, the present invention provides conjugates in which a compound according to the present invention is linked via a chemical bond to a small biological molecule or a monoclonal antibody. Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations.

[0019] Specific embodiments After extensive research, the present inventors have found small molecule compounds with TLR7 and / or TLR8 agonistic activity, which have novel structures and have comparable or superior agonistic activity to the same compounds in existing technology. Based on the above findings, the present inventors have completed the present invention.

[0020] term In the present invention, the halogen is F, Cl, Br or I. In the present invention, unless otherwise specified, the terms used have the ordinary meanings known to those skilled in the art. In the present invention, the term "alkyl group" refers to a straight or branched chain alkyl group, preferably having 1 to 6 carbon atoms. In the present invention, examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and hexyl groups, preferably ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups, but are not limited thereto. The term "alkylene group" refers to a divalent group formed by losing one additional hydrogen atom from an alkyl group.

[0021] The term "heteroalkyl group" refers to a group in which one or more carbon atoms (optionally including one or more H atoms) in an alkane chain are replaced by a heteroatom selected from the group consisting of NH, N, O and S. In particular, when a carbon atom is replaced by NH and the heteroalkyl group may carry a substituent, the hydrogen atom in the NH may be similarly substituted. In the present invention, the term "alkoxy group" refers to a straight or branched chain alkoxy group, preferably having 1 to 6 carbon atoms. In the present invention, examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, and butoxy groups. In the present invention, the term "cycloalkyl group" refers to a cyclic alkyl group, preferably having 3 to 12 (e.g., 3 to 7) carbon atoms in the ring, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. The terms "C5-C6 cycloalkyl group" and "C3-C6 cycloalkyl group" have similar meanings.

[0022] In the present invention, the terms "aromatic ring" and "aryl group" have the same meaning, and preferably, an "aryl group" is a "C6-C 12 Aryl group" or "C6-C 10 The term "C6-C aryl group" is used. 12 The term "aryl group" refers to an aromatic ring group having 6 to 12 carbon atoms without heteroatoms in the ring, such as phenyl and naphthyl groups. 10 "Aryl group" has an analogous meaning. In the present invention, the terms "aromatic heterocycle" or "heteroaryl group" have the same meaning and refer to a heteroaromatic group containing one or more heteroatoms. The heteroatoms in this context include oxygen, sulfur and nitrogen. Examples include furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring may be fused to an aryl group, a heterocyclic group or a cycloalkyl ring, where the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group may be optionally substituted or unsubstituted.

[0023] In the present invention, the term "carbocyclic group" refers to a saturated or unsaturated (non-aromatic ring, including monocyclic, fused, spiro, bridged, etc.) cyclic group, the ring structure of which contains only carbon atoms, preferably said carbocyclic group having 3-12 members, e.g., 4-9 members, 5-6 members, etc. Typical examples are, for example, cyclopentyl, cyclohexyl, etc. In the present invention, the term "heterocyclic group" refers to a saturated or unsaturated (non-aromatic ring, including monocyclic, fused, spiro, bridged, etc.) cyclic group containing 1 to 3 heteroatoms selected from oxygen, sulfur, and nitrogen in the ring, and preferably the heterocyclic group is 3-12 membered, for example, 4-9 membered, 3-7 membered, 5-6 membered, etc. A typical example is a dioxolanyl group.

[0024] In the present invention, the term "substituted" refers to the replacement of one or more hydrogen atoms in a particular group with a specified substituent. The specified substituents are the corresponding substituents described above or in the individual examples. Unless otherwise stated, a substituted group may have one substituent selected from a specified group at any substitutable position of the group, and the substituents may be the same or different at each position. A cyclic substituent, such as a heterocycloalkyl group, may be combined with another ring, such as a cycloalkyl group, to form a spiro-bicyclic system, for example, the two rings share a common carbon atom. As will be appreciated by those skilled in the art, the combinations of substituents contemplated by the present invention are stable combinations or chemically feasible combinations. The substituents may be, for example, deuterium, C 1-8 Alkyl group, C 2-8 Alkenyl group, C 2-8 Alkynyl group, C 3-8 Cycloalkyl groups, 3-12 membered heterocyclic groups, aryl groups, heteroaryl groups, halogens, hydroxyl groups, carboxyl groups (-COOH), C 1-8 Aldehyde group, C 2-10 Acyl group, C 2-10 Ester group, amino group, alkoxy group, C 1-10 Such as, but not limited to, a sulfonyl group.

[0025] Compounds of Formula I Having TLR7 and / or TLR8 Modulating Activity The present invention provides a compound represented by Formula I, a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof. [ka] (however, L1 is selected from the group consisting of -O-, -NH-, -S-, -S(=O)- or -S(=O)2-. R1 is H, C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 cycloalkyl or 4-12 membered heterocycloalkyl groups, wherein R1 may further comprise one or more R a may be substituted with a substituent, and R a is hydrogen, halogen, hydroxyl group, cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 Cycloalkyl groups, -NR a1 R a2 , -NHC(=O)-R a3 , one or more R a4 5-6 membered heteroaryl groups substituted with

[0026] R a1 , R a2 , R a3 or R a4 is C 1-6 Alkyl group, C 1-6 Haloalkyl group, C 3-6 It is selected from the group consisting of cycloalkyl groups. The R2 and R3 are each independently hydrogen, halogen, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6A cycloalkyl group or a 4-6 membered heterocycloalkyl group or a 5-8 membered heterocyclic aryl group or a 5-8 membered aryl group, wherein R2 and R3 may be further substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, or amino groups. k is 0 or 1. m is 0, 1, 2, 3, 4, 5, 6, 7 or 8. [ka] represents a single bond or a double bond.

[0027] B does not exist or C 3-12 Cycloalkyl groups, 4-12 membered heterocycloalkyl groups, C 6-12 an aryl group, a 5-12 membered heteroaryl group, or [ka] wherein each A is selected from C, CH, or N, and R6 and R7 together with the carbon atom adjacent thereto are selected from the group consisting of C 4-7 Cycloalkylene group or C 4-7 A heterocycloalkylene group is formed, 4-7 Any one or more methylene groups in the cycloalkylene group or the 4- to 7-membered heterocycloalkylene group may be independently replaced with a carbonyl group or S(=O)2. In the 4- to 7-membered heterocycloalkylene group, the heteroatom is selected from N, O, and S, and the number of heteroatoms is 1 to 3. L2 is -(CR b R c ) p -(NR d ) q -, -O-, -S-, -(CR b R c ) p -C(=O)-, -(CR b R c ) p -C(=O)NH-, -(CR b R c )p -NHC(=O)-, -S(=O)- or -S(=O)-, where R b , R c is hydrogen, halogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl group, 4-6 membered heterocycloalkyl group or C 1-6 haloalkyl groups; R d is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups, C 1-6 Haloalkyl or hydroxy substituted C 1-6 alkyl groups, p is 0, 1, 2, 3, 4, 5 or 6, and q is 0 or 1.

[0028] R4 is hydrogen, halogen, cyano group, amino group, hydroxyl group, C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 Cycloalkyl groups, 4-12 membered heterocyclic groups, C 6-12 aryl or 5-12 membered heteroaryl; and R4 is optionally selected from the group consisting of one or more R e may be substituted with a substituent, where R e is hydrogen, halogen, hydroxyl group, carboxylic acid, amino group, C 1-6 Alkyl group, one or more R e1 C replaced with 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, C 3-12 Cycloalkyl groups, 4-12 membered heterocycloalkyl groups, C 6-12 Aryl groups, 5-12 membered heteroaryl groups, -N(R e2 R e3 R e4 ), -C(=O)OR e2 , -C(=O)NH-R e2 , -S(=O)2-R e2 is selected from the group consisting of: R e1 is selected from the group consisting of halogen and hydroxyl groups. R e2 , R e3 is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, C 1-6 Haloalkyl or hydroxy substituted C 1-6 The alkyl group is selected from the group consisting of alkyl groups.

[0029] R e4 does not exist or C 1-6 Alkyl group, C 3-6 Cycloalkyl group or C 1-6 It is selected from the group consisting of haloalkyl groups. R5 is a halogen, a hydroxyl group, a cyano group, an amino group, or C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups, C 1-6 Haloalkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, -C(=O)OR f , -C(=O)NH-R f , -S(=O)2-R f where R f is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl group or C 1-6 It is selected from the group consisting of haloalkyl groups. n is 1, 2, 3, 4, 5 or 6. wherein each of said heterocyclic groups may be saturated or partially unsaturated (but without aromatic structures), and in said heterocyclic groups, the heteroatoms are selected from N, O, S, and the number of heteroatoms is 1, 2, 3 or 4 (preferably 1 or 2); in said heteroaryl groups, the heteroatoms are selected from N, O, S, and the number of heteroatoms is 1, 2 or 3.

[0030] Methods for preparing compounds of formula I The present invention also provides a method for producing the compound represented by the above formula I. Specifically, the compound of the present invention is produced according to the following scheme 1 or 2. Scheme 1 [ka]

[0031] In Scheme 1, starting compound II-1 undergoes a substitution reaction to obtain compound II. Compound II further undergoes a substitution reaction to obtain compound III. Compound III undergoes a ring-closing reaction to obtain compound IV. Compound IV undergoes a substitution reaction or a copper-catalyzed reaction to obtain compound V. Compound V undergoes a reduction reaction to close the ring to obtain compound VI. Compound VI undergoes a substitution reaction to obtain compound VII. Compound VII undergoes a substitution reaction with a different amine to obtain compound VIII. Compound VIII is deprotected to obtain compound I.

[0032] Q1 and Q2 are chlorine, bromine, iodine, OMs or OTf. [ka] In Scheme 2, compound V undergoes hydrolysis to give compound VI-a, which undergoes condensation to give compound VIII-a, which undergoes deprotection to give compound I.

[0033] Pharmaceutical composition containing an active ingredient Since the compound of the present invention has excellent Toll-like receptor activation activity, the compound of the present invention and various crystal forms thereof, pharma- ceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and pharmaceutical compositions containing the compound of the present invention as a main active ingredient are useful for preventing and / or treating (stabilizing, alleviating or curing) diseases or conditions associated with abnormal expression or activation of Toll-like receptors (particularly TLR7 and 8), such as tumors or infections caused by viruses. Preferably, the virus is one or more of HBV, HCV, HIV and influenza virus, and the tumor is preferably lung cancer, pancreatic cancer, kidney cancer, head and neck cancer, breast cancer, lymphoma, skin cancer, urothelial cancer, gastric cancer, hepatocellular carcinoma and colorectal cancer. The pharmaceutical composition of the present invention comprises the compound of the present invention in a safe and effective amount and a pharma- ceutically acceptable excipient or carrier. Here, the term "safe and effective amount" refers to the amount of the compound that is sufficient to significantly improve the disease condition and does not cause severe side effects. Usually, the pharmaceutical composition contains the compound of the present invention in a weight percentage of 0.01-99.99% / formulation, preferably 0.1-99.9% / formulation. Preferably, the "formulation" is a capsule or tablet.

[0034] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that can be applied to humans and must have sufficient purity and sufficiently low toxicity. "Compatible" refers to the ability of each component in the composition to be mixed with and among the compounds of the present invention without significantly reducing the effect of the compound. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyhydric alcohols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium dodecyl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free distilled water, etc.

[0035] The mode of administration of the compound or pharmaceutical composition of the present invention is not particularly limited, but representative modes of administration include, but are not limited to, oral administration, parenteral (intravenous, intramuscular, or subcutaneous) administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is usually mixed with at least one inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or may contain (a) a filler or compatibilizer, such as starch, lactose, sucrose, glucose, mannitol, or silicic acid; (b) a binder, such as hydromethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, or gum arabic; (c) a humectant, such as glycerin; and (d) a disintegrant, such as agar or calcium carbonate. , potato starch, tapioca starch, alginic acid, certain complex silicates, sodium carbonate, (e) dissolution retarders, such as paraffin, (f) absorption promoters, such as ammonium compounds, (g) wetting agents, such as cetanol, glycerin monostearate, (h) adsorbents, such as kaolin, and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. In capsules, tablets, and pills, the dosage form may contain a buffering agent.

[0036] Solid dosage forms, such as tablets, pills, capsules, pills, and granules, can be prepared with coatings or shells, such as enteric coatings and other materials known in the art. Opacifying agents may be included, and in such compositions, the release of the active or compound may be delayed in a certain part of the digestive tract. Examples of embedding materials that can be used include polymeric and wax-based materials. If necessary, the active compound may also be formed into a microcapsule with one or more of the above excipients. Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, compatibilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn oil, olive oil, castor oil, or sesame oil, or mixtures of these substances.

[0037] Besides these inert diluents, the composition may also include adjuvants, such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, and perfumes. In addition to the active compound, suspensions may contain suspending agents such as ethoxylated isooctadecanol, polyoxyethylene sorbitol or sorbitan esters, microcrystalline cellulose, aluminum methoxyl or agar, or mixtures of these substances. Compositions for parenteral injection include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous or non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols, and suitable mixtures thereof. The compounds of the present invention may be administered alone or in combination with other pharma- ceutically acceptable compounds (eg, anti-HBV agents).

[0038] When administered in combination, the pharmaceutical composition further comprises one or more (two, three, four or more) other pharma- ceutically acceptable compounds, which can be used simultaneously, separately or sequentially with the compounds of the present invention for the prevention and / or treatment of diseases or conditions associated with abnormal expression or activation of Toll-like receptors (especially TLR7, 8). When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (e.g., human) in need of treatment, and the dosage is a pharmacologic effective dosage. Of course, the specific dosage should be determined by considering factors such as the mode of administration and the health condition of the patient, all of which are within the skill of a skilled physician.

[0039] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to explain the present invention and do not limit the scope of the present invention. In the following examples, experimental methods for which no specific conditions are described were usually carried out under normal conditions or conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight.

[0040] In the following examples, the structures of the compounds were confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The NMR shifts (δ) were 10 -6 The NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetic resonance spectrometer, with the solvents being deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS).

[0041] SHIMADZU LC system (chromatography column: Xselect® CSH TM Prep-C18, 19 × 150 mm, liquid handler LH-40, pump LC-20AP, detector SPD-20A, system controller CBM-20A, solvent system: acetonitrile and 0.05% trifluoromethylacetic acid in water). The LC / MS spectrum of the compound was obtained by LC / MS (Agilent Technologies 1200 Series). The LC / MS conditions were as follows (run time 10 min): Acidic conditions: A: 0.05% trifluoromethylacetic acid in water; B: 0.05% trifluoromethylacetic acid in acetonitrile; Basic conditions: A: 0.05% NH3·H2O in water; B: acetonitrile Neutral conditions: A: 10 mM NH4OAC in water; B: acetonitrile Unless otherwise stated, in the following examples, intermediates and final compounds were purified by silica gel column chromatography or purified using Xselect® CSH TM Prep-C18 (5 μm, OBD TM 19×150mm) chromatography column or XBridgeTM Prep Phenyl (5μm, OBD TM The product was purified by preparative HPLC on a reversed-phase chromatography column (30×100 mm).

[0042] Silica gel chromatography is a column chromatography method, and Yantai Yellow Sea silica gel 200-300 mesh silica gel is usually used as the carrier. The CombiFlash rapid production equipment used was Combiflash Rf200 (TELEDYNE ISCO). Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plates were used for thin-layer chromatography (TLC), and the specifications of the silica gel plates used for product detection by thin-layer chromatography were 0.15 mm to 0.2 mm, and those used for product separation and purification by thin-layer chromatography were 0.4 mm to 0.5 mm.

[0043] Known starting materials of the present invention may be synthesized by methods known in the art or may be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Shaoyuan Chemical Technology (Accela ChemBio Inc.), and Darui Chemicals.

[0044] Abbreviations: MeOH: methanol; DIEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DCM: dichloromethane; Dioxane: 1,4-dioxane; EA: ethyl acetate; Conc.HCl: concentrated hydrochloric acid;DMF: dimethylformamide;AcOH: acetic acid;DMA: dimethylacetamide;Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene;DCE: 1,2-dichloroethane;BH3: borane;Boc2O: tert-butoxycarbonyl tert-butyl carbonate;t-BuLi: tert-butyllithium;DMF-DMA: 1,1-dimethoxy-N,N-dimethyl-methylamine;PPA: polyphosphoric acid;NaHMDS: sodium bis(trimethylsilyl)amino;POCl3: phosphorus oxychloride;Pd / C: palladium on carbon;CAN: acetonitrile;EtOH: ethanol;t-butyl nitrite: tert-butyl nitrite;Pyrrolidine: pyrrolidine;Toluene: toluene;TsOH: p-toluenesulfonic acid;Acrylamide: prop-2-enamide;THF: tetrahydrofuran;LDA: lithium diisopropylamide;LAH: lithium aluminum hydride;Pd2(dba)3: tris(dibenzylideneacetone)dipalladium;PMB: p-methoxybenzyl;Xphos: 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl;H2: hydrogen gas;Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium;t -BuOK: potassium tert-butoxide; K2CO3: potassium carbonate; HCOONH4: ammonium formate; LiHMDS: lithium bis(trimethylsilyl)amide; Urea: urea; n-BuLi: n-butyllithium; MsCl: methanesulfonyl chloride; Dppf: bis(diphenylphosphino)ferrocene; Et3N: triethylamine; AcCl: acetyl chloride; NaH: sodium hydride; TFA: trifluoroacetic acid; SOCl2: thionyl chloride; NBS: N-bromosuccinimide; NCS: N-chlorosuccinimide; 1,4-Dioxane: 1,4-dioxane; K3PO4: potassium phosphate; RuPhos Pd G2: chloro(2-dicyclohexylphosphino-2,6-diisopropoxy-1,1-biphenyl)(2-amino-1,1-biphenyl-2-yl)palladium(II); MTBE: methyl t-butyl ether. .

[0045] Intermediate Int.A 2-(Bis(4-methoxybenzyl)amino)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0046] Step 1: Preparation of methyl 4-(butylamino)-2-chloro-6-methylpyrimidine-5-carboxylate (Int. A-1) Methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate (10 g, 45.2 mmol) and n-butylamine (3.6 g, 49.8 mmol) were dissolved in DCM (100 mL), and DIEA (8.8 g, 67.9 mmol) was added with stirring at 0°C. The reaction mixture was reacted for 3 hours with continued stirring at 0°C. The reaction mixture was poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain the crude product, which was purified by silica gel column chromatography to obtain colorless oily methyl 4-(butylamino)-2-chloro-6-methylpyrimidine-5-carboxylate (11.0 g, 95%). MS: 258.1 [M+H] +

[0047] Step 2: Preparation of methyl 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-methylpyrimidine-5-carboxylate (Int. A-2) Methyl 4-(butylamino)-2-chloro-6-methylpyrimidine-5-carboxylate (11.0 g, 42.8 mmol) and bis(4-methoxybenzyl)amine (13.2 g, 51.4 mmol) were dissolved in acetonitrile (100 mL), and K2CO3 (8.9 g, 64.2 mmol) was added with stirring at 0°C. The reaction mixture was reacted at 70°C for 13 hours with continued stirring. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain the crude product, which was purified by silica gel column chromatography to obtain a yellow solid methyl 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-methylpyrimidine-5-carboxylate (18.4 g, 90%). MS: 479.3 [M+H] +

[0048] Step 3: Preparation of 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one (Int. A) 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-methylpyrimidine-5-methyl carboxylate (23 g, 48.1 mmol) and 1,3,5-triazine (4.68 g, 57.7 mmol) were dissolved in DMSO (150 mL), and potassium-tert-butoxide (8.09 g, 72.1 mmol) was added with stirring at 0°C. The reaction mixture was reacted for 2 hours with continued stirring at 80°C. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain the crude product, which was purified by silica gel column chromatography to obtain a yellow solid 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one (17.0 g, 74.7%). MS: 474.2 [M+H] +

[0049] Intermediate Int.B 2-((4-Methoxybenzyl)amino)-4-((2-methoxyethyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.B, refer to the synthesis of intermediate Int.A, and use 2-methoxyethane-1-amine instead of n-butylamine and 4-methoxybenzylamine instead of bis(4-methoxybenzyl)amine to prepare intermediate Int.B. MS: 356.2 [M+H] +

[0050] Intermediate Int.C 2-(Bis(4-methoxybenzyl)amino)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.C, refer to the synthesis of intermediate Int.A, and use pentan-2-amine instead of n-butylamine to prepare intermediate Int.C. MS: 488.2 [M+H] +

[0051] Intermediate Int.D 2-(Bis(4-methoxybenzyl)amino)-4-((2-cyclopropylethyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.D, refer to the synthesis of intermediate Int.A, and use 2-cyclopropan-1-amine instead of n-butylamine to prepare intermediate Int.D. MS: 486.2 [M+H] +

[0052] Intermediate Int.E 2-(Bis(4-methoxybenzyl)amino)-4-((2-ethoxyethyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.E, refer to the synthesis of intermediate Int.A, and use 2-ethoxyethan-1-amine instead of n-butylamine to prepare intermediate Int.E. MS: 490.2 [M+H] +

[0053] Intermediate Int.F 2-(bis(4-methoxybenzyl)amino)-4-((1-hydroxyhexan-3-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.F, refer to the synthesis of intermediate Int.A, and use 3-aminohexan-1-ol instead of n-butylamine to prepare intermediate Int.F. MS: 518.2 [M+H] +

[0054] Intermediate Int.G 2-(Bis(4-methoxybenzyl)amino)-4-(2-(ethylamino)ethyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.G, refer to the synthesis of intermediate Int.A, and use N-butylamine instead of n-butylamine. 1 Intermediate Int.G was prepared using -ethylethane-1,2-diamine. MS: 489.2 [M+H] +

[0055] Intermediate Int.H 2-(Bis(4-methoxybenzyl)amino)-4-((4-fluorobutyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.H, refer to the synthesis of intermediate Int.A, and use 4-fluorobutan-1-amine instead of n-butylamine to prepare intermediate Int.H. MS: 489.2 [M+H] +

[0056] Intermediate Int. J(R)-Pentan-2-amine hydrochloride [ka] Step 1: Preparation of (R,E)-2-methyl-N-(2-pentylene)propane-2-sulfoxide amide (Intermediate Int. J-1) Pentan-2-one (10 grams, 116 mmol) was dissolved in EtOAc (200 mL), and (R)-2-methylpropane-2-sulfoxide amide (14 grams, 116 mmol) and tetraisopropyl titanate (66 grams, 233 mmol) were added to the reaction mixture in order with stirring at 10 degrees, and the reaction mixture was reacted for 15 hours with continued stirring at 10 degrees. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with water and saturated saline respectively, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a colorless oil intermediate Int.J-1 (7.0 grams, 32%). MS: 190.2 [M+H] +

[0057] Step 2: Preparation of (R)-2-methyl-N-((R)-pentan-2-yl)propane-2-sulfoxide amide (Intermediate Int. J-2) Intermediate Int.J-1 (7.0 grams, 37 mmol) was dissolved in THF (100 mL), sodium borohydride (2.1 grams, 55.6 mmol) was added to the reaction mixture with stirring at -70°C, and the reaction mixture was reacted for 2 hours with continued stirring at 20°C. Ice water was added to the reaction mixture to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was washed with water and saturated saline respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain colorless oil intermediate Int.J-2 (3.5 grams, 49%). MS: 192.2 [M+H] +

[0058] Step 3: Preparation of (R)-Pentan-2-amine hydrochloride (Intermediate Int. J) Intermediate Int.J-2 (3.5 grams, 18.3 mmol) in 4N 1,4-dioxane hydrochloric acid solution (20 milliliters) was reacted for 12 hours with stirring at 20° C. The reaction mixture was concentrated and evaporated to dryness to give the crude product, which was washed with ethyl ether to give white solid intermediate Int.J (2.0 grams, 90%).

[0059] Intermediate Int.K (S)-Pentan-2-amine hydrochloride [ka] For the synthesis of intermediate Int.K, the synthesis of intermediate Int.J was referred to, and intermediate Int.K was prepared by using (S)-2-methylpropane-2-sulfoxide amide instead of (R)-2-methylpropane-2-sulfoxide amide.

[0060] Intermediate Int.L (R)-2-(Bis(4-methoxybenzyl)amino)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.L, refer to the synthesis of intermediate Int.A, and use Int.J instead of n-butylamine to prepare intermediate Int.L. MS: 502.2 [M+H] +

[0061] Intermediate Int.M (S)-2-(bis(4-methoxybenzyl)amino)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.M, refer to the synthesis of intermediate Int.A, and use Int.K instead of n-butylamine to prepare intermediate Int.M. MS: 502.2 [M+H] +

[0062] Intermediate Int.N (R)-2-(bis(4-methoxybenzyl)amino)-4-(1-hydroxy-2-methylhexan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.N, refer to the synthesis of intermediate Int.A, and prepare intermediate Int.N by using (R)-2-amino-2-methylhexan-1-ol instead of n-butylamine. MS: 532.2 [M+H] +

[0063] Intermediate Int.P 6-Amino-8-(butylamino)-4-fluoro-2,7-naphthyridin-1(2H)-one [ka]

[0064] Step 1: Preparation of intermediate Int.P-1 2-Chloro-5-fluoropyridin-4-amine (6.00 g, 40.9 mmol) and p-toluenesulfonic acid (0.389 g, 2.047 mmol) were dissolved in ACN (60 mL), and NIS (10.13 g, 45.0 mmol) was added with stirring. The reaction mixture was reacted at 70° C. for 2 hours with stirring, and the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow solid intermediate Int.P-1 (8.8 g, 79%). MS: 272.1&274.2[M+H] +

[0065] Step 2: Preparation of intermediate Int.P-2 A solution of intermediate Int.P-1 (9.5 grams, 34.9 mmol), hexacarbonylmolybdenum (13.81 grams, 52.3 mmol), Et3N (17.64 grams, 174 mmol), Xantphos (1.009 grams, 1.743 mmol) and Pd(OAc)2 (0.391 grams, 1.743 mmol) in MeOH (200 mL) was reacted at 60°C for 4 hours with stirring. The reaction mixture was then poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain white solid intermediate Int.P-2 (4.44 grams, 62%). MS: 205.1 & 207.2 [M+H] +

[0066] Step 3: Preparation of intermediate Int.P-3 For the synthesis of intermediate Int.P-3, the synthesis of intermediate I-14-1 was referred to, and intermediate Int.P-2 was used instead of intermediate I-11-1 to prepare intermediate Int.P-3. MS: 191.1 & 193.1 [M + H] + . Step 4: Preparation of intermediate Int.P-4 A solution of intermediate Int.P-3 (3.92 grams, 20.57 mmol) in POCl3 (20 mL) was reacted with stirring at 70°C for 2 hours and concentrated to obtain a crude product. The crude product was dissolved in THF (30 mL) and ammonium thiocyanate (3.13 grams, 41.1 mmol) was added with stirring. The reaction mixture was reacted with stirring at 20°C for 12 hours, the reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow solid intermediate Int.P-4 (2.7 grams, 57%). MS: 231.1 & 233.2 [M+H] +

[0067] Step 5: Preparation of intermediate Int.P-5 A solution of intermediate Int.P-4 (2.72 grams, 11.74 mmol), sodium methoxide (0.634 grams, 11.74 mmol) and methyl iodide (1.667 grams, 11.74 mmol) in DMF (20 mL) was reacted for 4 hours with stirring at 20 degrees. The reaction mixture was then poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a white solid intermediate Int.P-5 (1.8 grams, 62%). MS: 246.1 & 248.2 [M + H] +

[0068] Step 6: Preparation of intermediate Int.P-6 A solution of intermediate Int.P-5 (0.362 g, 1.474 mmol) and m-CPBA (0.381 g, 2.210 mmol) in toluene (10 mL) was reacted for 2 hours with stirring at 40°C. Then, DIEA (0.571 g, 4.42 mmol) and bis(4-methoxybenzyl)amine (0.758 g, 2.95 mmol) were added to the reaction solution, and the reaction mixture was reacted for 2 hours with stirring at 70°C. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a white solid intermediate Int.P-6 (188 mg, 27%). MS: 455.1 & 457.2 [M+H] +

[0069] Step 7: Preparation of intermediate Int.P-7 A solution of intermediate Int.P-6 (0.3 g, 0.660 mmol) and sodium methoxide (0.381 g, 2.210 mmol) in methanol (5 mL) was reacted at 100° C. for 1 hour in a microwave. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow oil intermediate Int.P-7 (200 mg, 67%). MS: 451.2 [M+H] +

[0070] Step 8: Preparation of intermediate Int.P-8 A solution of intermediate Int.P-7 (0.211 g, 0.468 mmol), BOP (0.414 g, 0.937 mmol), DBU (0.214 g, 1.405 mmol) and butylamine (0.103 g, 1.405 mmol) in DMF (5 mL) was reacted for 2 hours with stirring at 20°C. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain white solid intermediate Int.P-8 (100 mg, 42%). MS: 506.2 [M+H] +

[0071] Step 9: Preparation of intermediate Int.P-9 For the synthesis of intermediate Int.P-9, the synthesis of compound I-1 was referred to, and intermediate Int.P-8 was used instead of intermediate I-1-3 to prepare intermediate Int.P-9. MS: 266.1 [M+H] + . Step 10: Preparation of intermediate Int.P A reaction mixture of intermediate Int.P-9 (40 mg, 0.151 mmol) and boron tribromide (0.754 mmol) in DCM (6 mL) was reacted with stirring at -70°C for 2 hours, the reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain intermediate Int.P. MS: 252.2 [M+H] +

[0072] Intermediate Int.Q 2-(Bis(4-methoxybenzyl)amino)-4-(heptan-4-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.Q, refer to the synthesis of intermediate Int.A, and use heptan-4-amine instead of n-butylamine to prepare intermediate Int.Q. MS: 516.2 [M+H]+

[0073] Intermediate Int. R(S)-2-(bis(4-methoxybenzyl)amino)-4-((1-hydroxyhexan-3-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of intermediate Int.R was prepared by referring to the synthesis of intermediate Int.A, and using (S)-3-aminohexan-1-ol instead of n-butylamine. MS: 518.2 [M+H] +

[0074] Intermediate Int.S 2-(Bis(4-methoxybenzyl)amino)-4-butoxypyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.S, refer to the synthesis of intermediate Int.A, and use n-butanol instead of n-butylamine to prepare intermediate Int.S. MS: 475.2 [M+H] +

[0075] Intermediate Int.T 2-(Bis(4-methoxybenzyl)amino)-4-(pentan-2-oxy)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T, refer to the synthesis of intermediate Int.A, and use pentan-2-ol instead of n-butylamine to prepare intermediate Int.T. MS: 489.2 [M+H] +

[0076] Intermediate Int.T1 (S)-2-(bis(4-methoxybenzyl)amino)-4-(1-hydroxypentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T1, refer to the synthesis of intermediate Int.A, and use (S)-2-aminopentan-1-ol instead of n-butylamine to prepare intermediate Int.T1. MS: 504.2 [M+H] +

[0077] Intermediate Int.T2 (R)-2-(bis(4-methoxybenzyl)amino)-4-(hexan-3-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T2, refer to the synthesis of intermediate Int.A, and use (R)-n-hexane-3-amine instead of n-butylamine to prepare intermediate Int.T2. MS: 502.2 [M+H] + Intermediate Int.T3 N-(2-((2-(bis(4-methoxybenzyl)amino)-5-oxo-5,6-dihydropyrido[4,3-d]pyrimidin-4-yl)amino)pentyl)acetamide [ka] For the synthesis of intermediate Int.T3, refer to the synthesis of intermediate Int.A, and use N-(2-aminopentyl)acetamide instead of n-butylamine to prepare intermediate Int.T3. MS: 545.2 [M+H] +

[0078] Intermediate Int.T4 2-(Bis(4-methoxybenzyl)amino)-4-(butyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T4, refer to the synthesis of intermediate Int.A, and use butane-1-thiol instead of n-butylamine to prepare intermediate Int.T4. MS: 491.2 [M+H] +

[0079] Intermediate Int.T5 (R)-2-(bis(4-methoxybenzyl)amino)-4-(1-hydroxypentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T5, refer to the synthesis of intermediate Int.A, and use (R)-2-aminopentan-1-ol instead of n-butylamine to prepare intermediate Int.T5. MS: 504.2 [M+H] +

[0080] Intermediate Int.T6 (S)-2-(bis(4-methoxybenzyl)amino)-4-(1-methoxypentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T6, refer to the synthesis of intermediate Int.A, and use (S)-1-methoxypentan-2-amine instead of n-butylamine to prepare intermediate Int.T6. MS: 518.2 [M+H] +

[0081] Intermediate Int.T7 (S)-2-(bis(4-methoxybenzyl)amino)-4-(1-hydroxyhexan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T7, refer to the synthesis of intermediate Int.A, and use (S)-1-methoxyhexan-2-amine instead of n-butylamine to prepare intermediate Int.T7. MS: 518.2 [M+H] +

[0082] Intermediate Int.T8 4-((5-(butylamino)-7-((4-methoxybenzyl)amino)-4-oxopyrido[4,5-d]pyrimidin-3(4H)-yl)methyl)benzoic acid methyl ester [ka] For the synthesis of intermediate Int.T8-1, the synthesis of intermediate Int.T7 was referred to, and intermediate Int.T8-1 was prepared by using ethyl 4-amino-6-(butylamino)-2-(methylthio)pyrimidine-5-carboxylate instead of intermediate Int.T7-2. MS: 266.2 [M+H] + For the synthesis of intermediate Int.T8-2, the synthesis of intermediate I-11-1 was referred to, and intermediate Int.T8-2 was prepared using intermediate Int.T8-1 instead of intermediate Int.A. MS: 414.2 [M+H] + For the synthesis of intermediate Int.T8, refer to the synthesis of intermediate I-6-8, and use intermediate Int.T8-2 instead of intermediate Int.I-6-6 to prepare intermediate Int.T8. MS: 503.2 [M+H] +

[0083] Intermediate Int.T9 [ka] For the synthesis of intermediate Int.T9, refer to the synthesis of intermediate Int.A, and use 1-((t-butyldiphenylsilyl)oxy)hexan-3-ol instead of n-butylamine to prepare intermediate Int.T9. MS: 758.2 [M+H] +

[0084] Intermediate Int.T10 4-(Butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T10, refer to the synthesis of intermediate Int.A, and use 4-chloro-6-methylpyrimidine-5-carboxylate methyl instead of 2,4-dichloro-6-methylpyrimidine-5-carboxylate to prepare intermediate Int.T10. MS: 219.2 [M+H] + Intermediate Int.T11 4-(Butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0085] Step 1: Preparation of intermediate Int.T11-1 For the synthesis of intermediate Int.T11-1, refer to the synthesis of intermediate Int.A-1, and use 4,6-dichloro-2-(methylthio)pyrimidine-5-carbonitrile instead of methyl 2,4-dichloro-6-methylpyrimidine-5-carboxylate to prepare intermediate Int.T11-1. MS: 257.2 [M+H] + Step 2: Preparation of intermediate Int.T11-2 A reaction mixture of intermediate Int.T11-1 (5.0 grams, 19.47 mmol), Pd(Ph3P)4 (1.125 grams, 0.974 mmol), DIEA (3.78 grams, 29.2 mmol) and tributylpropynylstannane (9.61 grams, 29.2 mmol) in DMF (50 mL) was reacted at 80 degrees with stirring for 3 hours, the reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a white solid intermediate Int.T11-2 (2.2 grams, 43%). MS: 261.2 [M+H] +

[0086] Step 3: Preparation of intermediate Int.T11-3 A reaction mixture of intermediate Int.T11-2 (2.0 grams, 7.68 mmol) and sodium methoxide (0.830 grams, 15.36 mmol) in methanol (20 mL) was reacted with stirring at 40 degrees for 2 hours, the reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a white solid intermediate Int.T11-3 (1.1 grams, 49%). MS: 293.2 [M+H] +

[0087] Step 4: Preparation of intermediate Int.T11-4 A reaction mixture of intermediate Int.T11-3 (1.0 g, 3.42 mmol), 48% HBr aqueous solution (5 mL) and water (5 mL) was reacted for 3 hours with stirring at 50 degrees, the reaction mixture was poured into aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain white solid intermediate Int.T11-4 (0.7 g, 74%). MS: 279.2 [M+H] +

[0088] Step 5: Preparation of intermediate Int.T11-5 A reaction mixture of intermediate Int.T11-4 (700 mg, 2.51 mmol), metachloroperbenzoic acid (1276 mg, 6.29 mmol) in DCM (15 mL) was stirred at 20°C for 3 hours, and the reaction mixture was poured into aqueous sodium bicarbonate and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to give crude intermediate Int.T11-5 (0.71 g, 91%). MS: 311.2 [M+H] +

[0089] Step 6: Preparation of intermediate Int.T11 A reaction mixture of intermediate Int.T11-5 (0.71 grams, 2.288 millimoles), 4-methoxybenzylamine (0.471 grams, 3.43 millimoles) and potassium carbonate (0.474 grams, 3.43 millimoles) in DMF (10 milliliters) was reacted at 50 degrees with stirring for 3 hours, the reaction mixture was poured into aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a white solid intermediate Int.T11 (0.6 grams, 71%). MS: 368.2 [M+H] +

[0090] Intermediate Int.T12 4-(Butylamino)-2-(4-methoxybenzyl)amino)-7-phenylpyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of intermediate Int.T12, the synthesis of intermediate Int.T11 was referred to, and intermediate Int.T12 was prepared by using tributyl(phenylethynyl)stannane instead of tributylpropynylstannane. MS: 430.2 [M+H] +

[0091] Intermediate Int.T13 [ka] For the synthesis of intermediate Int.T13-2, the synthesis of intermediate Int.B was referred to, and intermediate Int.T2-1 was used instead of intermediate Int.B-1 to prepare intermediate Int.T13-2. MS: 384.3 [M+H] + . The synthesis of intermediate Int.T13 was carried out by referring to the synthesis of intermediate I-11-1, using 4-(chloromethyl)-3-methoxybenzaldehyde instead of methyl 4-(bromomethyl)benzoate, and intermediate Int.T13-2 instead of intermediate Int.A. MS: 532.3 [M+H] + .

[0092] Example Compound I-1 2-Amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0093] Step 1: 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-1-3) The synthesis of intermediate I-1-3 was carried out by referring to the synthesis of compound I-11, except that intermediate I-11-1 was used instead of intermediate I-11-4 to prepare compound I-1-3.

[0094] Step 2: 2-amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-1) The synthesis of compound I-1 was carried out by referring to the synthesis of compound I-11-2, and using intermediate I-1-3 instead of intermediate I-11-1 to prepare compound I-1. MS: 407.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(s,1H),9.98(s,1H),8.11(d,J=7.4Hz,1H),7.99-7.77(m,2H),7.51( d,J=7.8Hz,2H),7.37(d,J=7.7Hz,2H),6.38(d,J=7.4Hz,1H),5.19(s,2H), 4.33(s,2H),3.51(q,J=6.6Hz,4H),3.08(s,2H),2.02(s,2H),1.87(s,2H), 1.57(q,J=7.3Hz,2H),1.34(dt,J=14.8,7.5Hz,2H),0.92(t,J=7.3Hz,3H).

[0095] Example Compound I-2 2-Amino-4-(butylamino)-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0096] Compound I-2 was prepared by referring to the synthesis of compound I-1, except that methyl 4-(bromomethyl)-3-methoxybenzoate was used instead of methyl 4-(bromomethyl)benzoate. MS: 437.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.60(s,1H),10.42(s,1H),10.10(t,J=5.8Hz,1H),8.42(s,2H),8.08(d,J=7.4Hz,1H),7.22( s,1H),7.09(d,J=7.7Hz,1H),7.03(d,J=7.7Hz,1H),6.40(d,J=7.4Hz,1H),5.08(s,2H),4.31(d ,J=5.1Hz,2H),3.84(s,3H),3.51(q,J=6.7Hz,2H),3.35(s,2H),3.06(s,2H),2.00(d,J=7.5Hz, 2H),1.84(d,J=5.4Hz,2H),1.55(p,J=7.2Hz,2H),1.32(h,J=7.4Hz,2H),0.89(t,J=7.3Hz,3H).

[0097] Example Compound I-3 2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] Compound I-3 was prepared by referring to the synthesis of compound I-1, and using intermediate Int.F instead of intermediate Int.A. MS: 451.3 [M+H] + .

[0098] Example Compound I-4 2-Amino-4-(butylamino)-6-(piperidin-4-ylmethyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-4 was carried out by referring to the synthesis of compound I-1, except that tert-butyl 4-((methanesulfonyl)oxy)methyl)piperidine-1-carboxylate was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-4. MS: 331.2 [M+H] + .

[0099] Example Compound I-5 2-Amino-4-(butylamino)-6-(3-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0100] The synthesis of compound I-5 was carried out by referring to the synthesis of compound I-2, except that methyl 4-(bromomethyl)-2-methoxybenzoate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-5. MS: 437.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.57(s,1H),10.11(t,J=5.8Hz,1H),9.83(s,1H),8.40(s,2H),8.19(d,J=7.4Hz,1H),7.40(d, J=7.7Hz,1H),7.11(d,J=1.5Hz,1H),6.84(dd,J=7.8,1.5Hz,1H),6.41(d,J=7.4Hz,1H),5.19(s ,2H),4.26(d,J=4.6Hz,2H),3.82(s,3H),3.52(q,J=6.7Hz,2H),3.36(d,J=11.7Hz,2H),3.07(s ,2H),1.99(s,2H),1.84(s,2H),1.62-1.51(m,2H),1.33(q,J=7.4Hz,2H),0.90(t,J=7.3Hz,3H).

[0101] Example Compound I-6 2-Amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one [ka]

[0102] Step 1: Preparation of ethyl 2-(bis(methylthio)methylene)-3-oxobutyrate (I-6-1) Carbon disulfide (3.80 g, 49.9 mmol) and ethyl 3-oxobutyrate (6.5 g, 49.9 mmol) were dissolved in DMF (100 mL), and potassium tert-butoxide (11.21 g, 100 mmol) was added in batches at 0° C. with stirring. The reaction mixture was reacted at 20° C. for 1 hour with continued stirring. Then, methyl iodide (14.18 g, 100 mmol) was slowly added to the reaction solution, and the reaction was carried out at 20° C. for 1 hour with continued stirring. The reaction mixture was poured into ice water and extracted with MTBE. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain ethyl 2-(bis(methylthio)methylene)-3-oxobutyrate (6.25 g, 53.4%). MS: 235.2 [M+H] +

[0103] Step 2: Preparation of ethyl 4-(butylamino)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (I-6-2) Ethyl 2-(bis(methylthio)methylene)-3-oxobutyrate (6.25 g, 26.7 mmol) and DIEA (6.89 g, 53.3 mmol) were dissolved in DMF (100 mL), and n-butylamine (11.21 g, 100 mmol) was added with stirring at 0°C. The reaction mixture was reacted for 16 hours at 20°C with continued stirring. Then, K2CO3 (11.06 g, 80 mmol) and methyl carbamoylthioformate hemisulfate (7.42 g, 26.7 mmol) were slowly added to the reaction solution, and the reaction was continued for 1 hour at 80°C with continued stirring. The reaction mixture was poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give ethyl 4-(butylamino)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (8.5 grams, 73%). MS: 284.2 [M+H] +

[0104] Step 3: Preparation of ethyl 4-(butylamino)-6-formyl-2-(methylthio)pyrimidine-5-carboxylate (I-6-3) A solution of selenium dioxide (2.232 grams, 20.11 mmol) and ethyl 4-(butylamino)-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (1.9 grams, 6.70 mmol) in dioxane was reacted for 16 hours with stirring at 100 degrees. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain ethyl 4-(butylamino)-6-formyl-2-(methylthio)pyrimidine-5-carboxylate (2.0 grams, 99%). MS: 298.2 [M+H] +

[0105] Step 4: Preparation of methyl 4-((4-(butylamino)-2-(methylthio)-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)methyl)benzoate (I-6-4) Ethyl 4-(butylamino)-6-formyl-2-(methylthio)pyrimidine-5-carboxylate (3.8 g, 12.8 mmol), methyl 4-(aminomethyl)benzoate (2.11 g, 12.8 mmol) and AcOH (0.08 g, 1.3 mmol) were dissolved in DCM (100 mL) and reacted at 20° C. with stirring for 1 hour, and then sodium cyanoborohydride (11.21 g, 100 mmol) was added to the reaction solution and reacted at 20° C. with stirring for 1 hour. The reaction mixture was concentrated and evaporated to dryness, and the obtained crude product and potassium carbonate (1.532 g, 11.08 mmol) were dissolved in DMF (80 mL). Then the reaction mixture was reacted at 80° C. with continued stirring for 1 hour. The reaction mixture was poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give methyl 4-((4-(butylamino)-2-(methylthio)-5-oxo-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)methyl)benzoate (0.465 grams, 9%). MS: 401.2 [M+H] +

[0106] Step 5: Preparation of 4-(butylamino)-6-(4-(hydroxymethyl)benzyl)-2-(methylthio)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (I-6-5) For the synthesis of intermediate I-6-5, refer to the synthesis of intermediate I-1-1, and use intermediate I-6-4 instead of intermediate I-11-2 to prepare intermediate I-6-5. MS: 373.2 [M+H] +

[0107] Step 6: Preparation of 4-(butylamino)-2-(methylthio)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (I-6-6) A solution of 4-(butylamino)-6-(4-(hydroxymethyl)benzyl)-2-(methylthio)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (200 mg, 0.537 mmol) and Dess-Martin (342 mg, 0.8 mmol) in DCM (20 mL) was reacted for 1 hour with stirring at 20°C. The reaction mixture was concentrated and evaporated to dryness, and the resulting crude product, acetic acid (1 mL) and pyrrolidine (71 mg, 1 mmol) were dissolved in DCM (10 mL), the reaction mixture was reacted for 0.5 hours with stirring at 20°C, and sodium cyanoborohydride (63 mg, 1 mmol) was added to the reaction mixture and reacted for 1 hour with stirring at 20°C. The reaction mixture was poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give 4-(butylamino)-2-(methylthio)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (300 milligrams, 99%). MS: 426.2 [M+H] +

[0108] Step 7: Preparation of 4-(butylamino)-2-(methylsulfinyl)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (I-6-7) A mixture of 4-(butylamino)-2-(methylthio)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (300 mg, 0.705 mmol) and potassium peroxymonosulfonate (1.75 g, 2.82 mmol) in THF (10 mL) and water (10 mL) was reacted for 1 hour with stirring at 20° C. The reaction mixture was then poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give 4-(butylamino)-2-(methylsulfinyl)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (300 milligrams, 96%). MS: 442.2 [M+H] +

[0109] Step 8: Preparation of 4-(butylamino)-2-((4-methoxybenzyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (I-6-8) A solution of 4-(butylamino)-2-(methylsulfinyl)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (300 mg, 0.679 mmol), potassium carbonate (282 mg, 2.04 mmol) and 4-methoxybenzylamine (186 mg, 1.36 mmol) in DMF (5 mL) was reacted for 1 hour with stirring at 100° C. The reaction mixture was then poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give 4-(butylamino)-2-((4-methoxybenzyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (300 milligrams, 86%). MS: 515.2 [M+H] +

[0110] Step 9: Preparation of 2-amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (I-6) A solution of 4-(butylamino)-2-((4-methoxybenzyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (300 mg, 0.583 mmol) and methyl phenyl ether (2 mL) in trifluoroacetic acid (5 mL) was reacted at 100° C. for 1 hour with stirring. The reaction mixture was then poured into 10% potassium bicarbonate ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by prep-HPLC to obtain 2-amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (10.2 mg). MS: 395.4 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.19(s,1H),7.98(s,2H),7.78(s,1H),7.49(d,J=8.0Hz,2H),7.34(d,J=8.0Hz,2H),4.62(s,2H),4.33(d,J=8.0Hz,2H),4.28(s,2H),3. 46(q,J=5.0Hz,2H),3.34(s,2H),3.05(m,2H),2.01(s,2H),1.92-1.72(m,2H),1.55(m,2H),1.30(p,J=7.4Hz,2H),0.90(t,J=8.0Hz,3H).

[0111] Example Compound I-7 2-Amino-4-(butylamino)-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one [ka]

[0112] Compound I-7 was prepared by referring to the synthesis of compound I-6, except that methyl 4-(aminomethyl)-3-methoxybenzoate was used instead of methyl 4-(aminomethyl)benzoate. MS: 425.4 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.92(s,1H),7.21(s,1H),7.16(s,1H),7.05(s,1H),4.56(s,2H),4.33(d,J=5.5Hz,2H),4.25(s,2H) ,3.87(s,3H),3.48-3.41(m,2H),3.38-3.34(m,2H),3.14-3.06(m,2H),2.07-2.00(m,2H),1.90-1.85 (m,2H),1.57-1.53(m,2H),1.35-1.29(m,2H),0.91(t,J=6.0Hz,3H).

[0113] Example Compound I-8 4-((2-amino-4-((2-methoxyethyl)amino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid methyl ester [ka] Compound I-8 was prepared by referring to the synthesis of compound I-11-2, and using intermediate I-21-1 instead of intermediate I-11-1. MS: 384.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(s,1H),8.18(d,J=7.3Hz,1H),7.96(d,J=7.8Hz,2H),7.42(d,J=7.9Hz,2H),6.47(d, J=7.3Hz,1H),5.27(s,2H),3.85(s,3H),3.72-3.68(m,2H),3.55-3.53(m,2H),3.29(s,3H).

[0114] Example Compound I-9 2-Amino-8-bromo-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] Compound I-9 was prepared by referring to the synthesis of compound I-11, and using intermediate I-11-3 instead of intermediate I-11-4. MS: 485.2 & 487.2 [M + H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.49-9.47(m,1H),8.21(s,1H),7.28-7.20(m,4H),6.95-6.78(br,2H),5.02(s,2H),3.52(s,2H),3.41(q,J=6 .6Hz,2H),2.41-2.37(m,4H),1.69-1.62(m,4H),1.56-1.47(m,2H),1.37-1.28(m,2H),0.89(t,J=7.3Hz,3H).

[0115] Example Compound I-10 2-Amino-4-(butylamino)-8-chloro-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0116] Step 1: Preparation of methyl 4-((2-amino-4-(butylamino)-8-chloro-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (I-10-1) Intermediate I-10-1 was prepared by referring to the synthesis of intermediate I-11-3, and using NCS instead of NBS. MS: 416.2 [M+H]+. Step 2: Preparation of 2-amino-4-(butylamino)-8-chloro-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-10) The synthesis of compound I-10 was carried out by referring to the synthesis of compound I-11, and using intermediate I-10-1 instead of intermediate I-11-4 to prepare compound I-10. MS: 441.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.49-9.47(m,1H),8.17-8.12(m,1H),7.30-7.21(m,4H),7.02-6.78(br,2H),5.02(s,2H),3.56(s,2H),3.41(q, J=6.6Hz,2H),2.46-2.37(m,4H),1.69-1.62(m,4H),1.56-1.47(m,2H),1.37-1.28(m,2H),0.89(t,J=7.3Hz,3H).

[0117] Example Compound I-11 2-Amino-4-(butylamino)-8-methyl-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0118] Step 1: Preparation of methyl 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (I-11-1) 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one (4.0 grams, 8.45 mmol), methyl 4-(bromomethyl)benzoate (3.87 grams, 16.89 mmol), and K2CO3 (2.335 grams, 16.89 mmol) were dissolved in DMF (40 mL), and the reaction mixture was reacted for 12 hours with stirring at 60 degrees. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with water and saturated saline respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow solid 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (4.6 grams, 88%). MS:662.2[M+H] +

[0119] Step 2: Preparation of methyl 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (I-11-2) Methyl 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (3.0 grams, 4.83 millimoles) was dissolved in trifluoroacetic acid (20 milliliters) and the reaction mixture was stirred at 70 degrees for 2 hours. The reaction mixture was concentrated, evaporated to dryness, and extracted with ethyl acetate. The organic phase was washed with saturated sodium bicarbonate solution and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow solid methyl 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (1.6 grams, 87%). MS: 382.2 [M+H] +

[0120] Step 3: Preparation of 4-((2-amino-8-bromo-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid ester (I-11-3) Methyl 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (500 mg, 1.311 mmol) was dissolved in DMF (5 mL) and NBS (280 mg, 1.573 mmol) was added with stirring at 0° C. The reaction mixture was warmed to room temperature and reacted for 1 hour with continued stirring. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow solid 4-((2-amino-8-bromo-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (450 mg, 74.6%). MS:460.1&462.1[M+H] +

[0121] Step 4: Preparation of methyl 4-((2-amino-4-(butylamino)-8-methyl-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (I-11-4) 4-((2-amino-8-bromo-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid ester (300 mg, 0.652 mmol) and methylboronic acid (195 mg, 3.26 mmol) were dissolved in 1,4-dioxane (2 mL) and water (0.400 mL), and K3PO4 (414 mg, 1.955 mmol) and RuPhos Pd G2 (50.6 mg, 0.065 mmol) were added while stirring at 0°C. The reaction mixture was heated to 80°C and reacted for 2 hours while continuing to stir. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give a yellow solid methyl 4-((2-amino-4-(butylamino)-8-methyl-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (140 mg, 54.3%). MS: 396.2 [M+H] +

[0122] Step 5: Preparation of 2-amino-4-(butylamino)-6-(4-(hydroxymethyl)benzyl)-8-methylpyrido[4,3-d]pyrimidin-5(6H)-one (I-11-5) Methyl 4-((2-amino-4-(butylamino)-8-methyl-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (140 mg, 0.354 mmol) was dissolved in THF (2 mL) and 1.0 M LAH (0.35 mL, 0.354 mmol) in tetrahydrofuran was added with stirring at 0°C. The reaction mixture was warmed to 20°C and reacted for 1 hour with continued stirring. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a white solid 2-amino-4-(butylamino)-6-(4-(hydroxymethyl)benzyl)-8-methylpyrido[4,3-d]pyrimidin-5(6H)-one (100 mg, 77%). MS:368.2[M+H] +

[0123] Step 6: Preparation of 2-amino-4-(butylamino)-6-(4-(chloromethyl)benzyl)-8-methylpyrido[4,3-d]pyrimidin-5(6H)-one (I-11-6) 2-Amino-4-(butylamino)-6-(4-(hydroxymethyl)benzyl)-8-methylpyrido[4,3-d]pyrimidin-5(6H)-one (100 mg, 0.272 mmol) was dissolved in DCM (1 mL) and thionyl chloride (48.6 mg, 0.408 mmol) was added with stirring at 0° C. The reaction mixture was then reacted at 20° C. for 1 hour with continued stirring. The reaction mixture was concentrated to give a white solid 2-amino-4-(butylamino)-6-(4-(chloromethyl)benzyl)-8-methylpyrido[4,3-d]pyrimidin-5(6H)-one (100 mg, 95%). MS: 386.2 [M+H] +

[0124] Step 7: Preparation of 2-amino-4-(butylamino)-8-methyl-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-11) 2-Amino-4-(butylamino)-6-(4-(chloromethyl)benzyl)-8-methylpyrido[4,3-d]pyrimidin-5(6H)-one (100 mg, 0.259 mmol) and pyrrolidine (36.9 mg, 0.518 mmol) were dissolved in EtOH (1 mL) and K2CO3 (71.6 mg, 0.518 mmol) was added with stirring at 20°C. The reaction mixture was reacted at 75°C for 2 hours with continued stirring. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified by Prep-HPLC to give a white solid 2-amino-4-(butylamino)-8-methyl-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (70 mg, 64.2%). MS: 421.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 8.19(s,1H),7.55(s,1H),7.29(d,J=7.8Hz,2H),7.22(d,J=7.9Hz,2H),6.59(s,2H),4.99(s,2H),3.67(s,2H),3.40(q,J=6 .6Hz,2H),2.57-2.52(m,4H),1.98(s,3H),1.73-1.64(m,4H),1.56-1.47(m,2H),1.36-1.29(m,2H),0.89(t,J=7.3Hz,3H).

[0125] Example Compound I-12 2-Amino-4-(pentan-2-ylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0126] The synthesis of compound I-12 was carried out by referring to the synthesis of compound I-1, and compound I-12 was prepared by using intermediate Int.C instead of intermediate Int.A. MS: 421.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.18(s,1H),10.04-10.02(d,J=8.0Hz,1H),8.42(br,1H),8.20-8.18(d,J=8.0Hz, 1H),7.50-7.48(d,J=8.0Hz,2H),7.38-7.34(m,2H),6.44-6.42(d,J=8.0Hz,1H),5. 25-5.14(m,2H),4.32-4.25(m,5H),3.05(br,2H),2.00(br,2H),1.85-1.82(m,2H), 1.56-1.51(m,2H),1.34-1.27(m,2H),1.20(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0127] Example Compound I-13 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)-N-(2-(methylamino)ethyl)benzamide [ka]

[0128] Compound I-13 was prepared by referring to the synthesis of compound I-14, except that t-butyl (2-aminoethyl)(methyl)carbamate was used instead of t-butyl piperazine-1-carboxylate. MS: 424.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.06(t,J=5.7Hz,1H),8.68(t,J=5.7Hz,1H),8.56(s,2H),8.18(d,J=7.4Hz,3H),7.88-7.81(m,2H),7.37(d,J=8.1Hz,2H),6.41(d ,J=7.5Hz,1H),5.22(s,2H),3.07(s,2H),2.48(p,J=1.9Hz,3H),1.55(p,J=7.1Hz,2H),1.32(q,J=7.5Hz,2H),0.89(t,J=7.3Hz,3H).

[0129] Example Compound I-14 2-Amino-4-(butylamino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0130] Step 1: Preparation of 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid (I-14-1) Methyl 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoate (1.0 g, 1.61 mmol) was dissolved in MeOH (20 mL) and H2O (10 mL) and sodium hydroxide (193 mg, 4.83 mmol) was added with stirring at 0°C. The reaction mixture was reacted at 70°C for 14 hours with continued stirring. The reaction mixture was cooled, poured into ice water, and the pH value was adjusted to 4 with 1N hydrochloric acid, and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give a yellow oily substance 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid (928 mg, 95%). MS: 608.7 [M+H] +

[0131] Step 2: Preparation of 4-(4-(2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoyl)piperazine-1-carboxylate-t-butyl (I-14-2) A mixture of 4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid (100 mg, 0.164 mmol), HATU (87.6 mg, 0.23 mmol), DIEA (42.3 mg, 0.328 mmol) and piperazine-1-carboxylate-t-butyl (45.7 mg, 0.246 mmol) in DMF (2 mL) was reacted at 50° C. for 2 hours with continuous stirring. The reaction mixture was then poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give a yellow oily product 4-(4-(2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoyl)piperazine-1-carboxylate-t-butyl (130 mg, 100%). MS: 776.9 [M+H] +

[0132] Step 3: Preparation of 2-amino-4-(butylamino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-14) The synthesis of compound I-14 was carried out by referring to the synthesis of compound I-1, and using intermediate I-14-2 instead of intermediate I-1-3 to prepare compound I-14. MS: 436.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.07(t,J=6.0Hz,1H),9.07(s,1H),8.18(d,J=7.4Hz,3H),7.44(d,J=8.2Hz,2H),7.36(d,J=8.2Hz,2H),6.41( d,J=7.5Hz,1H),5.21(s,2H),3.85-3.01(m,10H),1.60-1.51(m,2H),1.37-1.28(m,2H),0.89(t,J=7.4Hz,3H).

[0133] Example Compound I-15 2-Amino-4-(butylamino)-6-(4-(morpholine-4-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0134] The synthesis of compound I-15 was carried out by referring to the synthesis of compound I-14, and compound I-13 was prepared by using morpholine instead of piperazine-1-carboxylate-t-butyl. MS: 437.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(t,J=5.8Hz,1H),8.20(d,J=7.4Hz,3H),7.40-7.33(m,4H),6.43(d,J=7.4Hz,1H),5. 20(s,2H),3.54-3.29(m,10H),1.58-1.54(m,2H),1.35-1.30(m,2H),0.89(t,J=7.3Hz,3H).

[0135] Example Compound I-16 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)-N,N-dimethylbenzamide [ka]

[0136] Compound I-16 was prepared by referring to the synthesis of compound I-14, except that dimethylamine hydrochloride was used instead of piperazine-1-carboxylate-t-butyl. MS: 395.4 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.13(t,J=5.8Hz,1H),8.52-8.02(m,3H),7.38-7.31(m,4H),6.43-6.41(d,J=7.4Hz,1H),5.20(s,2H),3 .69-3.23(m,2H),2.94(s,3H),2.86(s,3H),1.60-1.52(m,2H),1.37-1.28(m,2H),0.89(t,J=7.3Hz,3H).

[0137] Example Compound I-17 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)-N-(2-(pyrrolidin-2-yl)ethyl)benzamide [ka]

[0138] The synthesis of compound I-17 was carried out by referring to the synthesis of compound I-14, except that tert-butyl 2-(2-aminoethyl)pyrrolidine-1-carboxylate was used instead of tert-butyl piperazine-1-carboxylate to prepare compound I-17. MS: 464.6 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.09(t,J=5.9Hz,1H),8.95(s,1H),8.62-8.14(m,5H),7.80(d,J=8.1Hz,2 H),7.36(d,J=8.1Hz,2H),6.42(d,J=7.5Hz,1H),5.22(s,2H),3.51(m,2H), 3.46-3.38(m,1H),3.32(m,2H),3.21-3.07(m,2H),2.15-2.10(m,1H),1.96 -1.77(m,4H),1.59-1.49(m,3H),1.35-1.29(m,2H),0.89(t,J=7.4Hz,3H).

[0139] Example Compound I-18 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)benzamide [ka]

[0140] The synthesis of compound I-18 was carried out by referring to the synthesis of compound I-14, and using 2-(1-methylpyrrolidin-2-yl)ethan-1-amine instead of piperazine-1-carboxylate-t-butyl to prepare compound I-18. MS: 478.6 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.09(t,J=5.8Hz,1H),9.75(s,1H),8.65-8.12(m,3H),7.81(d,J=8.0Hz ,2H),7.36(d,J=8.2Hz,2H),6.42(d,J=7.4Hz,1H),5.21(s,2H),3.51(m,4 H),3.36-3.21(m,3H),3.07-2.96(m,1H),2.79(m,2H),2.31-2.10(m,2H), 2.02-1.78(m,2H),1.78-1.50(m,4H),1.31(m,2H),0.89(t,J=7.3Hz,3H).

[0141] Example Compound I-19 6-(4-(3,6-diazacyclo[3.1.1]heptane-3-carbonyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0142] The synthesis of compound I-19 was carried out by referring to the synthesis of compound I-14, except that 3,6-diazadicyclo[3.1.1]heptane-6-formate-t-butyl was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-19. MS: 448.5 [M+H] + was prepared. 1H NMR(400MHz,DMSO-d6) δ 10.11(t,J=5.8Hz,1H),9.63(s,1H),8.50-8.14(m,3H),7.45(d,J=7.9Hz,2H),7.38( d,J=8.1Hz,2H),6.43(d,J=7.4Hz,1H),5.22(s,2H),4.40(s,1H),4.21(s,1H),4.05-4 .01(m,1H),3.90-3.80(m,2H),3.72-3.69(m,1H),3.51(q,J=6.7Hz,2H),2.85-2.74(m ,1H),1.83-1.79(m,1H),1.58-1.53(m,2H),1.38-1.20(m,3H),0.90(t,J=7.3Hz,3H).

[0143] Example Compound I-20 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzoic acid [ka]

[0144] Compound I-20 was prepared by referring to the synthesis of compound I-1, and using intermediate I-14-1 instead of intermediate I-1-3. MS: 368.4 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.00(s,1H),8.12(d,J=7.4Hz,1H),7.90(d,J=8.2Hz,2H),7.37(d,J=8.1Hz,2H),6.40(d,J=7.4Hz, 1H),5.22(s,2H),3.49(q,J=6.6Hz,2H),1.59-1.51(m,2H),1.37-1.27(m,2H),0.89(t,J=7.3Hz,3H).

[0145] Example Compound I-21 2-Amino-4-((2-methoxyethyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0146] The synthesis of compound I-21 was carried out by referring to the synthesis of compound I-2, using intermediate Int.B instead of intermediate Int.A, and using methyl 4-(bromomethyl)benzoate instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-21. MS: 409.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.17-10.14(m,1H),10.10-10.05(m,1H),8.58-8.25(m,2H),8.19(d,J=7.4Hz,1H),7.4 8(d,J=7.8Hz,2H),7.35(d,J=7.9Hz,2H),6.42(d,J=7.4Hz,1H),5.20(s,2H),4.62-4.46 (m,1H),4.31(d,J=5.3Hz,2H),3.68(q,J=5.4Hz,2H),3.52(t,J=5.3Hz,2H),3.37-3.30( m,2H),3.27(s,3H),3.16-2.95(m,2H),2.05-1.95(d,J=18.5Hz,2H),1.92-1.75(m,2H).

[0147] Example Compound I-22 2-Amino-4-(butylamino)-6-((1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0148] The synthesis of compound I-22 was carried out by referring to the synthesis of compound I-1, except that tert-butyl 7-(bromomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-22. MS: 379.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.03(s,1H),9.15(s,2H),8.12(d,J=7.4Hz,3H),7.20-7.10(m,3H),6.36(d,J=7.4Hz,1H),5.11(s,2H),4.23(s,2H),3.50(q, J=6.6Hz,2H),3.36-3.34(m,2H),2.93(t,J=6.2Hz,2H),1.61-1.48(m,2H),1.32(dt,J=14.5,7.4Hz,2H),0.89(t,J=7.3Hz,3H).

[0149] Example Compound I-23 2-Amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0150] Step 1: Preparation of 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (I-23-1) 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (320 mg, 0.5 mmol) was dissolved in methanol (5 mL) and 1.0 sodium borohydride (0.5 mmol) was added while stirring at 0°C. The reaction mixture was warmed to 0°C and reacted for 1 hour while continuing to stir. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (160 mg, 49%). MS:649.1[M+H] +

[0151] Step 2: Preparation of 2-amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (I-23) The synthesis of compound I-23 was carried out by referring to the synthesis of compound I-11-2, and using intermediate I-23-1 instead of intermediate I-11-1 to prepare compound I-23. MS: 409.3 [M+H] +

[0152] Example Compound I-24 2-Amino-4-(butylamino)-6-(3-(diethylamino)propyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0153] Step 1: Preparation of methyl 3-((methanesulfonyl)oxy)propionate (I-24-1) Methyl 3-hydroxypropionate (500 mg, 4.80 mmol) and TEA (729 mg, 7.20 mmol) were dissolved in DCM (10 mL) and MsCl (660 mg, 5.76 mmol) was added with stirring at 0° C. The reaction mixture was reacted for 1 h at 0° C. with continued stirring. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a yellow solid methyl 3-((methanesulfonyl)oxy)propionate (750 mg, 86%).

[0154] Step 2: Preparation of 2-amino-4-(butylamino)-6-(3-(diethylamino)propyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-24) The synthesis of compound I-24 was carried out by referring to the synthesis of compound I-1, using I-24-1 instead of methyl 4-(bromomethyl)benzoate, using methanesulfonyl chloride instead of thionyl chloride, and using diethylamine instead of pyrrolidine to prepare compound I-24. MS: 347.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.44(t,J=5.6Hz,1H),8.19(s,1H),7.55(d,J=7.5Hz,1H),6.59(s,2H),6.03(d,J=7.5Hz,1H),3.83(t,J=7.1Hz,2H),3.42-3.38(m,2H),2.64( q,J=7.1Hz,4H),2.57(t,J=7.4Hz,2H),1.84-1.77(m,2H),1.57-1.49(m,2H),1.40-1.29(m,2H),0.98(t,J=7.1Hz,6H),0.90(t,J=7.3Hz,3H).

[0155] Example Compound I-25 2-Amino-4-(butylamino)-6-(5-(diethylamino)pentyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0156] The synthesis of compound I-25 was carried out by referring to the synthesis of compound I-24, except that methyl 5-hydroxypentanoate was used instead of methyl 3-hydroxypropionate. MS: 375.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.46(t,J=5.5Hz,1H),8.24(s,1H),7.55(d,J=7.5Hz,1H),6.02(d,J=7.5Hz,1H),3.80(t,J=7.2Hz,2H),3.42-3.38(m,2H),2.65(q,J=7.1Hz,4H ),2.57-2.52(m,2H),1.63-1.58(m,2H),1.55-1.42(m,4H),1.39-1.30( m,2H),1.28-1.20(m,2H),0.99(t,J=7.1Hz,6H),0.90(t,J=7.3Hz,3H).

[0157] Example Compound I-26 2-Amino-6-(4-(aminomethyl)benzyl)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0158] The synthesis of compound I-26 was carried out by referring to the synthesis of compound I-2, except that tert-butyl (4-(bromomethyl)benzyl)carbamate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-26. MS: 353.3 [M+H] + was prepared. 1H NMR(400MHz,DMSO-d6) δ 10.08(s,1H),8.5-7.9(m,6H),7.41(d,J=8.2Hz,2H),7.33(d,J=8.2Hz,2H),6.41(d,J= 7.4Hz,1H),5.17(s,2H),4.05-3.95(m,2H),3.55-3.46(m,3H),1.62-1.50(m,2H),1.38- 1.26(m,2H),0.90(t,J=7.4Hz,3H).

[0159] Example Compound I-27 2-Amino-4-(butylamino)-6-(3-fluoro-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0160] The synthesis of compound I-27 was carried out by referring to the synthesis of compound I-2, except that 4-(bromomethyl)-2-fluorobenzoic acid methyl was used instead of 4-(bromomethyl)-3-methoxybenzoic acid methyl. MS: 425.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.20-10.12(m,1H),10.07(t,J=5.8Hz,1H),8.50-8.30(m,1H),8.18(d,J=7.4Hz,2H),7.58(t ,J=7.8Hz,1H),7.26(d,J=10.5Hz,1H),7.20(dd,J=7.9,1.7Hz,1H),6.43(d,J=7.4Hz,1H),5.2 1(s,2H),4.38(s,2H),3.54-3.49(q,J=6.7Hz,3H),3.45-3.35(m,2H),3.15-3.00(m,2H),2.07 -1.93(m,2H),1.88-1.76(m,2H),1.63-1.51(m,2H),1.37-1.28(m,2H),0.89(t,J=7.3Hz,3H).

[0161] Example Compound I-28 2-Amino-4-(butylamino)-6-(4-(hydroxymethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0162] For the synthesis of compound I-28, the synthesis of intermediate I-11-5 was referred to, and intermediate I-11-2 was used instead of intermediate I-11-4 to prepare compound I-28. MS: 354.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 12.72(s,1H),10.13(s,1H),8.33(s,1H),8.14(d,J=7.4Hz,1H),7.80(s,1H),7.32-7.20(m,4H),6.40(d,J=7.4H z,1H),5.13(s,3H),4.44(s,2H),3.55-3.47(m,2H),1.63-1.50(m,2H),1.39-1.24(m,2H),0.89(t,J=7.3Hz,3H).

[0163] Example Compound I-29 2-Amino-4-(butylamino)-6-(4-((hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0164] The synthesis of compound I-29 was carried out by referring to the synthesis of compound I-1, except that hexahydropyrrolo[3,4-c]pyrrole-2(1H)-t-butyl formate was used instead of pyrrolidine to prepare compound I-29. MS: 448.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.34(s,5H),8.47(s,2H),8.19(d,J=7.5Hz,1H),7.42(s,2H),7.35(d,J=7.9Hz,2H),6.39(d,J=7.4Hz,1H),5.19(s,2H),4.27 (s,2H),3.36(s,4H),3.10(s,4H),2.87(s,1H),2.71(s,1H),1.63-1.49(m,2H),1.32(h,J=7.3Hz,2H),0.89(t,J=7.3Hz,3H).

[0165] Example Compound I-30 2-Amino-4-(butylamino)-6-(4-((4-cyclohexylpiperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0166] The synthesis of compound I-30 was carried out by referring to the synthesis of compound I-1, except that 1-cyclohexylpiperazine was used instead of pyrrolidine to prepare compound I-30. MS: 504.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.33(s,1H),8.49(s,1H),8.18(d,J=7.4Hz,1H),7.30(q,J=8.1Hz,4H),6. 42(d,J=7.5Hz,1H),5.16(s,2H),3.67(s,3H),3.51(q,J=6.7Hz,3H),3.39( s,3H),3.00(s,5H),1.97(s,2H),1.79(d,J=12.1Hz,2H),1.56(h,J=7.1,6. 7Hz,3H),1.40-1.14(m,6H),1.07(t,J=12.2Hz,1H),0.89(t,J=7.3Hz,3H).

[0167] Example Compound I-31 (S)-N-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)pyrrolidine-2-formamide [ka]

[0168] Step 1: Preparation of 6-(4-(aminomethyl)benzyl)-4-(butylamino)-2-((4-methoxybenzyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one (I-31-1) A solution of (4-((2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl) t-butylcarbamate (0.45 g, 0.649 mmol) in a mixture of DCM (10 mL) and TFA (3 mL) was diluted with 20 mL of water. o The reaction was stirred at 4°C for 1 hour. The reaction mixture was then concentrated to give a crude product, which was purified by silica gel column chromatography to give 6-(4-(aminomethyl)benzyl)-4-(butylamino)-2-((4-methoxybenzyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one (290 milligrams, 94%). MS: 473.2 [M+H] +

[0169] Step 2: Preparation of t-butyl (S)-2-((4-((4-(butylamino)-2-((4-methoxybenzyl)amino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)carbamoyl)pyrrolidine-1-carboxylate (I-31-2) A mixture of (tert-butoxycarbonyl)-L-proline (0.034 g, 0.159 mmol), DIEA (0.068 g, 0.529 mmol) and HATU (0.060 g, 0.159 mmol) in DMF (3 mL) was added to 20 mL of the mixture. oC and reacted for 1 hour with stirring. Then, 6-(4-(aminomethyl)benzyl)-4-(butylamino)-2-((4-methoxybenzyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one (0.05 grams, 0.106 millimoles) was added to the reaction solution, and the reaction mixture was reacted for 2 hours with continued stirring at 20 degrees. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain t-butyl (S)-2-((4-((4-(butylamino)-2-((4-methoxybenzyl)amino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)carbamoyl)pyrrolidine-1-carboxylate (50 milligrams, 70.4%). MS:670.2[M+H] +

[0170] Step 3: (S)—N-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)pyrrolidine-2-formamide (I-31) The synthesis of compound I-31 was carried out by referring to the synthesis of compound I-11-2, and compound I-31 was prepared by using intermediate I-31-2 instead of intermediate I-11-1. MS: 450.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.09(s,1H),9.23(s,1H),8.97(t,J=5.8Hz,1H),8.55(s,1H),8.14(d,J=7.4Hz,1H ),7.30-7.17(m,4H),6.40(d,J=7.4Hz,1H),5.13(s,2H),4.40-4.20(m,2H),4.15(br s,1H),3.55-3.45(m,3H),3.20(s,2H),1.97-1.75(m,3H),1.61-1.48(m,2H),1.40-1.22(m,2H),0.89(t,J=7.3Hz,3H).

[0171] Example Compound I-32 2-Amino-6-(4-(azetidin-1-ylmethyl)benzyl)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0172] The synthesis of compound I-32 was carried out by referring to the synthesis of compound I-1, except that azetidine was used instead of pyrrolidine to prepare compound I-32. MS: 393.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.36(t,J=5.5Hz,1H),8.25(s,2H),7.67(d,J=7.5Hz,1H),7.36-7.15(m,4H), 6.63(s,2H),6.06(d,J=7.5Hz,1H),5.00(s,2H),3.90(t,J=8.2Hz,1H),3.65(d ,J=3.1Hz,2H),3.38(q,J=6.8Hz,2H),3.34-3.22(m,2H),2.40-2.26(m,1H),2 .05-1.98(m,2H),1.55-1.48(m,2H),1.37-1.28(m,2H),0.88(t,J=7.3Hz,2H).

[0173] Example Compound I-33 2-Amino-4-(butylamino)-6-(4-(piperidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0174] The synthesis of compound I-33 was carried out by referring to the synthesis of compound I-1, except that piperidine was used instead of pyrrolidine to prepare compound I-33. MS: 421.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.38(t,J=5.4Hz,1H),7.69(s,1H),7.32(d,J=7.9Hz,2H),7.25(d,J=7.7Hz, 2H),6.80-6.50(s,2H),6.25-6.00(s,2H),5.03(s,2H),3.73(s,2H),3.39(q ,J=6.6Hz,2H),3.09-2.90(m,2H),2.65-2.52(m,2H),1.70-1.58(m,2H),1.5 7-1.47(m,4H),1.43-1.37(m,2H),1.35-1.28(m,2H),0.88(t,J=7.3Hz,3H).

[0175] Example Compound I-34 2-Amino-4-(butylamino)-6-(4-((2-hydroxyethyl)amino)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0176] The synthesis of compound I-34 was carried out by referring to the synthesis of compound I-1, except that ethanolamine was used instead of pyrrolidine to prepare compound I-34. MS: 397.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.07(s,1H),8.86(s,2H),8.16(d,J=7.4Hz,1H),7.46(d,J=8.0Hz,2H),7.33(d,J=8.0Hz,2H),6.41(d,J=7.4Hz,1H), 5.17(s,2H),3.62(s,2H),3.55-3.42(m,3H),2.92(s,2H),1.61-1.48(m,2H),1.39-1.25(m,2H),0.89(t,J=7.3Hz,3H).

[0177] Example Compound I-35 2-Amino-4-(butylamino)-6-(4-((dimethylamino)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0178] Compound I-35 was synthesized by referring to the synthesis of compound I-1, except that dimethylamine hydrochloride was used instead of pyrrolidine. MS: 381.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.37(t,J=5.5Hz,1H),8.16(s,1H),7.68(d,J=7.5Hz,1H),7.33-7.20(m,4H),6.65(s,2H),6.07(d,J=7.5Hz,1H),5. 03(s,2H),3.60(s,2H),3.41-3.36(m,2H),2.27(s,6H),1.53-1.48(m,2H),1.38-1.27(m,2H),0.89(t,J=7.3Hz,3H).

[0179] Example Compound I-36 2-Amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)phenyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0180] Step 1: Preparation of methyl 4-(2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)benzoate (I-36-1) A reaction mixture of 2-(bis(4-methoxybenzyl)amino)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one (200 mg, 0.422 mmol), dimethylglycine (65.3 mg, 0.633 mmol), Cs2CO3 (413 mg, 1.267 mmol), methyl 4-iodobenzoate (166 mg, 0.633 mmol) and CuI (16.09 mg, 0.084 mmol) in DMF (15 mL) was reacted with stirring at 100° C. for 1 hour. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, filtered and concentrated to give a crude product, which was purified by silica gel column chromatography to give a yellow solid methyl 4-(2-(bis(4-methoxybenzyl)amino)-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)benzoate (200 milligrams, 78%). MS: 608.1 [M+H] +

[0181] Step 2: Preparation of 2-amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)phenyl)pyrido[4,3-d]pyrimidin-5(6H)-one (I-36) The synthesis of compound I-36 was carried out by referring to the synthesis of compound I-1, and using intermediate I-36-1 instead of intermediate I-11-1 to prepare compound I-36. MS: 393.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.48-10.23(s,1H),10.06-10.04(m,1H),8.68-8.22(m,2H),8.01(d,J=7.5Hz,1 H),7.68(d,J=8.1Hz,2H),7.55(d,J=8.0Hz,2H),6.47(d,J=7.5Hz,1H),4.43(s,2 H),3.53(q,J=6.6Hz,3H),3.44-3.31(m,2H),3.16-3.03(m,2H),1.99-2.10(m,2H) ),1.95-1.80(m,2H),1.59-1.52(m,2H),1.35-1.29(m,2H),0.89(t,J=7.3Hz,3H).

[0182] Example Compound I-37 2-Amino-4-(butylamino)-6-(4-(morpholinomethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0183] Compound I-37 was synthesized by referring to the synthesis of compound I-1, except that morpholine was used instead of pyrrolidine to prepare compound I-37. MS: 423.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.51-10.19(m,1H),10.12-10.10(m,1H),8.56-8.09(m,2 H),8.18(d,J=7.4Hz,1H),7.46(d,J=8.2Hz,2H),7.37(d,J=8.1Hz,2H),6.42(d,J=7.4Hz,1H),5.20(s,2H),4.30(s,2H) ,4.03-3.56(m,4H),3.53-3.49(m,2H),3.28-2.95(m,4H),1.59-1.52(m,2H),1.38-1.27(m,2H),0.89(t,J=7.4Hz,3H).

[0184] Example Compound I-38 2-Amino-4-(butylamino)-6-(4-((cyclopropylamino)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0185] The synthesis of compound I-38 was carried out by referring to the synthesis of compound I-1, except that cyclopropylamine was used instead of pyrrolidine to prepare compound I-38. MS: 393.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.11(t,J=5.8Hz,1H),9.40(s,2H),8.59-8.51(m,2H),8.21(d,J=7.4Hz,1H),8 .15(s,1H),7.46(d,J=8.1Hz,2H),7.33(d,J=7.8Hz,2H),6.38(d,J=7.4Hz,1H), 5.18(s,2H),4.19(s,2H),3.50(q,J=6.7Hz,2H),2.63(s,1H),1.59-1.51(m,2H) ,1.36-1.27(m,2H),0.88(t,J=7.3Hz,3H),0.84-0.79(m,2H),0.72-0.67(m,2H).

[0186] Example Compound I-39 6-(4-((5-azaspiro[2.4]heptan-5-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0187] The synthesis of compound I-39 was carried out by referring to the synthesis of compound I-1, except that 5-azaspiro[2.4]heptane was used instead of pyrrolidine to prepare compound I-39. MS: 433.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.39(s,1H),10.56(s,1H),10.11(t,J=5.8Hz,1H),8.39(d,J=39.3Hz,2H),8.19(d,J=7.5Hz,1H),7.54- 7.44(m,2H),7.39-7.30(m,2H),6.42(d,J=7.4Hz,1H),5.19(s,2H),4.44-4.26(m,2H),3.51(q,J=6.7Hz, 3H),3.29(s,1H),3.16(d,J=6.8Hz,1H),3.12-3.01(m,1H),2.09-1.96(m,1H),1.91-1.79(m,1H),1.61-1 .49(m,2H),1.36-1.26(m,2H),0.89(t,J=7.3Hz,3H),0.65(dd,J=17.3,6.4Hz,3H),0.55(d,J=6.1Hz,1H).

[0188] Example Compound I-40 6-(4-((3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0189] The synthesis of compound I-40 was carried out by referring to the synthesis of compound I-29, except that 3,6-diazabicyclo[3.1.1]heptane-6-t-butyl formate was used instead of hexahydropyrrolo[3,4-c]pyrrole-2(1H)-t-butyl formate to prepare compound I-40. MS: 434.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.41(s,1H),10.14(t,J=5.8Hz,1H),9.51(s,1H),8.39(d,J=51.1Hz,2H),8.19(d,J=7.4Hz,1 H),7.99(s,1H),7.36(d,J=7.8Hz,2H),7.30(d,J=7.9Hz,2H),6.41(d,J=7.4Hz,1H),5.17(s,2 H),4.25(d,J=5.9Hz,2H),3.91(s,2H),3.51(q,J=6.7Hz,2H),3.21(d,J=44.1Hz,4H),2.67(s, 1H),2.12(dd,J=10.1,5.5Hz,1H),1.62-1.49(m,2H),1.40-1.23(m,2H),0.89(t,J=7.3Hz,3H).

[0190] Example Compound I-41 6-(4-((3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0191] The synthesis of compound I-41 was carried out by referring to the synthesis of compound I-29, except that tert-butyl 3,6-diazabicyclo[3.1.1]heptane-3-carboxylate was used instead of tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-formate to prepare compound I-41. MS: 434.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.26-9.62(m,3H),8.41(s,2H),8.19(d,J=7.4Hz,1H),7.46(s,2H),7.34(d,J=7.8Hz,2H),6.41(d,J=7.4Hz,1H), 5.18(s,2H),4.27-3.44(m,11H),2.07(s,1H),1.55(p,J=7.2Hz,2H),1.32(h,J=7.4Hz,2H),0.89(t,J=7.3Hz,3H).

[0192] Example Compound I-42 6-(4-((2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0193] The synthesis of compound I-42 was carried out by referring to the synthesis of compound I-29, except that tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate was used instead of tert-butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-formate to prepare compound I-42. MS: 434.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.33(s,1H),10.12(t,J=5.8Hz,1H),9.37(m,2H),8.39(m,2H),8.19(d,J=7.5Hz,1H),7.45(s,2H),7.33(d,J=7.7Hz,2H),6.41(d,J=7.4Hz, 1H),5.18(s,2H),4.29(m,5H),3.51(q,J=6.7Hz,3H),3.28(m,3H),1.9 4(s,1H),1.62-1.49(m,2H),1.40-1.25(m,2H),0.89(t,J=7.3Hz,3H).

[0194] Example Compound I-43 6-(4-((2,7-diazaspiro[4.4]nonan-2-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0195] The synthesis of compound I-43 was carried out by referring to the synthesis of compound I-29, except that 2,7-diazaspiro[4.4]nonane-2-t-butyl formate was used instead of hexahydropyrrolo[3,4-c]pyrrole-2(1H)-t-butyl formate to prepare compound I-43. MS: 462.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.58(s,1H),10.84(s,1H),10.09(t,J=5.8Hz,1H),9.19(s,2H),8.38(s,2H ),8.18(d,J=7.4Hz,1H),7.48(d,J=7.9Hz,2H),7.35(d,J=7.9Hz,2H),6.40( d,J=7.4Hz,1H),5.19(s,2H),4.35(d,J=28.4Hz,2H),3.59-3.19(m,11H),2. 21-1.81(m,5H),1.62-1.49(m,2H),1.40-1.25(m,2H),0.89(t,J=7.3Hz,3H).

[0196] Example Compound I-44 6-(4-((2,6-diazaspiro[3.4]octan-6-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0197] The synthesis of compound I-44 was carried out by referring to the synthesis of compound I-29, except that 2,6-diazaspiro[3.4]octane-2-t-butyl formate was used instead of hexahydropyrrolo[3,4-c]pyrrole-2(1H)-t-butyl formate to prepare compound I-44. MS: 448.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.51(s,1H),10.67(s,1H),10.09(t,J=5.7Hz,1H),9.03(s,1H),8.80(s,1H),8.34(s,2H),8.18(d ,J=7.4Hz,1H),7.46(d,J=8.2Hz,2H),7.36(d,J=8.1Hz,2H),6.41(d,J=7.4Hz,1H),5.19(s,2H),4.3 1(d,J=15.4Hz,2H),4.01(s,3H),3.82(s,1H),3.62(s,1H),3.51(q,J=6.7Hz,3H),3.37(s,2H),3.1 5(s,1H),2.41(s,1H),2.19(s,1H),1.61-1.50(m,2H),1.32(h,J=7.4Hz,2H),0.89(t,J=7.3Hz,3H).

[0198] Example Compound I-45 (4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)proline [ka]

[0199] The synthesis of compound I-45 was carried out by referring to the synthesis of compound I-29, except that tert-butyl pyrrolidine-2-carboxylate was used instead of hexahydropyrrolo[3,4-c]pyrrole-2(1H)-t-butyl formate to prepare compound I-45. MS: 451.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.05(t,J=5.7Hz,1H),8.34(s,2H),8.16(d,J=7.5Hz,1H),7.46(d,J=8.0Hz,2H),7.33(d,J=7.9Hz,2H ),6.38(d,J=7.4Hz,1H),5.17(s,2H),4.36(d,J=12.9Hz,1H),4.16(d,J=12.9Hz,1H),4.05(t,J=8.3Hz ,1H),3.50(q,J=6.7Hz,2H),3.31(d,J=11.3Hz,1H),3.09(q,J=8.8Hz,1H),2.33(q,J=9.1,7.5Hz,1H), 2.03-1.89(m,2H),1.80(d,J=12.1Hz,1H),1.61-1.49(m,2H),1.39-1.26(m,2H),0.89(t,J=7.3Hz,3H).

[0200] Example Compound I-46 6-(4-((1H-imidazol-1-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0201] The synthesis of compound I-46 was carried out by referring to the synthesis of compound I-1, except that imidazole was used instead of pyrrolidine to prepare compound I-46. MS: 404.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 14.01(s,1H),10.08(t,J=5.8Hz,1H),9.17(s,1H),8.32(d,J=65.0Hz,2H),8.1 7(d,J=7.4Hz,1H),7.77-7.69(m,1H),7.63(d,J=2.0Hz,1H),7.38(d,J=8.3Hz,2 H),7.32(d,J=8.3Hz,2H),6.39(d,J=7.4Hz,1H),5.38(s,2H),5.16(s,2H),3.5 0(q,J=6.7Hz,2H),1.60-1.49(m,2H),1.37-1.25(m,2H),0.89(t,J=7.3Hz,3H).

[0202] Example Compound I-47 2-Amino-4-(butylamino)-6-(4-(ethoxymethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0203] The synthesis of compound I-47 was carried out by referring to the synthesis of compound I-1, except that sodium ethoxide was used instead of pyrrolidine to prepare compound I-47. MS: 382.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.00(s,1H),8.07(d,J=7.3Hz,1H),7.44-7.23(m,4H),6.35(dd,J=7.5,2.0Hz,1H),5.13(d,J=5.7Hz,2H),4.39(s,2H), 3.46(dq,J=22.7,6.8Hz,4H),1.55(p,J=7.2Hz,2H),1.32(h,J=7.4Hz,2H),1.11(t,J=7.0Hz,2H),0.89(t,J=7.3Hz,3H).

[0204] Example Compound I-48 2-Amino-4-((2-cyclopropylethyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0205] For the synthesis of compound I-48, the synthesis of intermediate I-1 was referred to, and intermediate Int.B was used instead of intermediate Int.A to prepare compound I-48. MS: 419.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 11.39(d,J=4.4Hz,1H),10.39(s,1H),8.47(s,2H),8.09(d,J=7.5Hz,1H),7.51-7.44(m,2H),7.3 9-7.32(m,2H),6.26(d,J=7.5Hz,1H),5.20-5.11(m,2H),4.43(d,J=10.0Hz,1H),4.31(d,J=5.6H z,3H),3.32(d,J=8.9Hz,2H),3.06(d,J=7.7Hz,2H),2.22(d,J=14.2Hz,1H),1.99(d,J=7.5Hz,3H ),1.83(p,J=5.3Hz,3H),1.71(dt,J=13.5,6.5Hz,1H),1.62-1.52(m,1H),0.92(t,J=7.3Hz,3H).

[0206] Example Compound I-49 2-Amino-4-(butylamino)-6-(4-((3-fluoropyrrolidin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0207] The synthesis of compound I-49 was carried out by referring to the synthesis of compound I-1, except that 3-fluoropyrrolidine was used instead of pyrrolidine to prepare compound I-49. MS: 425.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.47(s,1H),10.88(s,1H),10.11(t,J=5.7Hz,1H),8.42(s,2H),8.19(d,J=7 .5Hz,1H),7.50(d,J=7.7Hz,2H),7.35(d,J=8.1Hz,2H),6.41(d,J=7.4Hz,1H) ,5.43(d,J=53.3Hz,1H),5.20(s,2H),4.37(s,2H),3.64-3.21(m,6H),2.25(d ,J=50.7Hz,2H),1.62-1.50(m,2H),1.38-1.26(m,2H),0.89(t,J=7.4Hz,3H).

[0208] Example Compound I-50 2-Amino-6-(4-((bis(2-hydroxyethyl)amino)methyl)benzyl)-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0209] The synthesis of compound I-50 was carried out by referring to the synthesis of compound I-1, except that diethanolamine was used instead of pyrrolidine to prepare compound I-50. MS: 441.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.07(s,1H),9.37(s,1H),8.16(d,J=7.4Hz,1H),8.00(s,1H),7.52(d,J=8.0Hz,2H),7.35(d,J=8.0Hz,2H),6.42(d,J=7.4Hz,1H),5.32(s ,2H),5.19(s,2H),4.38(s,2H),3.57-3.42(m,3H),3.19(s,2H),3.11(s,2H),1.63-1.48(m,2H),1.39-1.25(m,2H),0.89(t,J=7.4Hz,3H).

[0210] Example Compound I-51 2-Amino-4-(butylamino)-6-(2-fluoro-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0211] The synthesis of compound I-51 was carried out by referring to the synthesis of compound I-2, except that 4-(bromomethyl)-3-fluorobenzoic acid methyl was used instead of 4-(bromomethyl)-3-methoxybenzoic acid methyl. MS: 425.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.98(s,2H),8.40(s,1H),8.12(d,J=7.4Hz,1H),7.46-7.38(m,1H),7.30(s,2H),6.45(d,J=7.4Hz,1H),5.22(s,2H),4.38-4.28(m,2H) ),3.58-3.45(m,3H),3.34(s,2H),3.06(s,2H),2.01(s,2H),1.84(s,2H),1.60-1.48(m,2H),1.38-1.25(m,2H),0.88(t,J=7.4Hz,3H).

[0212] Example Compound I-52 6-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0213] The synthesis of compound I-52 was carried out by referring to the synthesis of compound I-1, except that 2-oxa-6-azaspiro[3.3]heptane was used instead of pyrrolidine to prepare compound I-52. MS: 435.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.37(t,J=5.5Hz,1H),8.21(s,1H),7.66(d,J=7.5Hz,1H),7.18(s,4H),6.62(s,2H),6.06(d,J=7.5Hz,1H),4.99( s,2H),4.56(s,4H),3.42-3.34(m,2H),3.25(s,4H),1.57-1.46(m,2H),1.39-1.26(m,2H),0.89(t,J=7.4Hz,3H).

[0214] Example Compound I-53 2-Amino-4-(butylamino)-6-(4-(4-isopropylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0215] The synthesis of compound I-53 was carried out by referring to the synthesis of compound I-14, except that 1-isopropylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-53. MS: 478.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.15-9.96(m,2H),8.19(d,J=7.4Hz,3H),7.62-7.44(m,2H),7.42-7.29(m,2H),6.42(d,J=7.4Hz,1 H),5.21(s,2H),3.79-3.00(m,10H),1.58-1.54(m,2H),1.37-1.29(m,2H),1.24(s,3H),1.22(s,3H) 0.89(t,J=7.3Hz,3H).

[0216] Example Compound I-54 2-Amino-4-((2-ethoxyethyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-54 was carried out by referring to the synthesis of compound I-1, and using intermediate Int.E instead of intermediate Int.A to prepare compound I-54. MS: 423.1 [M+H] + .

[0217] Example Compound I-55 2-Amino-4-(butylamino)-6-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0218] The synthesis of compound I-55 was carried out by referring to the synthesis of compound I-1, except that 2-(piperazin-1-yl)ethan-1-ol was used instead of pyrrolidine to prepare compound I-55. MS: 466.6 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(t,J=5.8Hz,1H),8.45(s,2H),8.19(d,J=7.4Hz,1H),7.40-7.25(m,4H),6.40(d,J=7.4Hz,1H),5.17(s,2H) ,3.90-3.68(m,4H),3.57-3.49(m,2H),3.13(m,11H),1.58-1.54(m,2H),1.38-1.27(m,2H),0.89(t,J=7.3Hz,3H).

[0219] Example Compound I-56 2-Amino-4-(butylamino)-6-(4-((4-cyclopentylpiperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0220] The synthesis of compound I-56 was carried out by referring to the synthesis of compound I-1, except that 1-cyclopentylpiperazine was used instead of pyrrolidine to prepare compound I-56. MS: 490.6 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(t,J=5.8Hz,1H),8.38(s,2H),8.18(d,J=7.4Hz,1H),7.29(t,J=7.1Hz,4H),6.40(d,J=7.4Hz,1H),5.16(s,2H),3.64(s,2 H),3.54-3.43(m,6H),2.96(s,4H),2.42(s,1H),1.95-1.93(m,2H),1.64-1.50(m,8H),1.38-1.28(m,2H),0.90(t,J=7.3Hz,3H).

[0221] Example Compound I-57 2-Amino-4-(butylamino)-6-(4-(piperazin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0222] The synthesis of compound I-57 was carried out by referring to the synthesis of compound I-1, except that piperazine-1-carboxylate-t-butyl was used instead of pyrrolidine to prepare compound I-57. MS: 422.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(t,J=5.8Hz,1H),8.98(s,2H),8.55-8.23(m,2H),8.19(d,J=7.5Hz,1H),7.38(d,J=8.0Hz,1H),7.31(d,J=8.0Hz,1H),6.41(d,J=7.4Hz) ,1H),5.17(s,2H),3.89(s,2H),3.51(q,J=6.7Hz,2H),3.19(s,4H),2. 88(s,4H),1.63-1.50(m,2H),1.37-1.28(m,2H),0.89(t,J=7.3Hz,3H).

[0223] Example Compound I-58 1-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)phenyl)-N,N,N-trimethylformamide iodonium [ka]

[0224] A reaction mixture of 2-amino-4-(butylamino)-6-(4-((dimethylamino)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one (10 mg, 0.026 mmol) and methyl iodide (3.73 mg, 0.026 mmol) in acetonitrile (10 mL) was reacted at 20°C for 1 hour with stirring. The reaction mixture was concentrated to give a crude product, which was purified by pre-HPLC to give 1-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)phenyl)-N,N,N-trimethylformamide iodonium. MS: 523.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.34(t,J=5.5Hz,1H),8.32(s,2H),7.69(d,J=7.5Hz,1H),7.49(d,J=7.9Hz,2H),7.38(d,J=7.8Hz,2H),6.63(s,2H),6.09(d,J=7 .5Hz,1H),5.10(s,2H),4.47(s,2H),3.47-3.35(m,2H),2.98(s,9H),1.58-1.46(m,2H),1.39-1.27(m,2H),0.89(t,J=7.3Hz,3H).

[0225] Example Compound I-59 2-Amino-4-(butylamino)-6-(1-(4-(pyrrolidin-1-ylmethyl)phenyl)ethyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0226] Compound I-59 was prepared by referring to the synthesis of compound I-1, except that 4-(1-chloroethyl)benzoic acid methyl was used instead of 4-(bromomethyl)benzoic acid methyl. MS: 421.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.19(t,J=5.8Hz,1H),8.55-8.17(m,2H),8.06(d,J=7.7Hz,1H),7.50(d,J=8.0Hz,2H),7 .39(d,J=8.0Hz,2H),6.40(d,J=7.6Hz,1H),6.13(q,J=7.1Hz,1H),4.32(d,J=5.3Hz,2H), 3.58-3.47(m,2H),3.39-3.28(m,2H),3.12-3.00(m,2H),2.06-1.94(m,2H),1.89-1.78(m ,2H),1.72(d,J=7.2Hz,3H),1.63-1.50(m,2H),1.42-1.27(m,2H),0.90(t,J=7.3Hz,3H).

[0227] Example Compound I-60 2-Amino-4-(butylamino)-6-(4-(2-(pyrrolidin-1-yl)ethoxy)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0228] The synthesis of compound I-60 was carried out by referring to the synthesis of compound I-1, except that methyl 2-(4-(chloromethyl)phenoxy)acetate was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-60. MS: 437.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.15(t,J=5.9Hz,1H),9.92(s,1H),8.50-8.03(m,2H),8.17(d,J=7.4Hz,1H), 7.36-7.24(m,2H),7.01-6.92(m,2H),6.39(d,J=7.4Hz,1H),5.10(s,2H),4.25 (t,J=4.9Hz,2H),3.59-3.47(m,J=6H),3.16-3.03(m,2H),2.07-1.94(m,2H),1 .92-1.78(m,2H),1.63-1.50(m,2H),1.38-1.29(m,2H),0.90(t,J=7.3Hz,3H).

[0229] Example Compound I-61 2-Amino-4-(butylamino)-6-(4-((4-methylpiperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-61 was carried out by referring to the synthesis of compound I-1, except that 1-methylpiperazine was used instead of pyrrolidine to prepare compound I-61. MS: 436.6 [M+H] + .

[0230] Example Compound I-62 2-Amino-4-(butylamino)-6-(4-((4-cyclobutylpiperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0231] The synthesis of compound I-62 was carried out by referring to the synthesis of compound I-1, except that 1-cyclobutylpiperazine was used instead of pyrrolidine to prepare compound I-62. MS: 476.6 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.13(t,J=5.8Hz,1H),8.57-8.13(m,3H),7.32(q,J=8.0Hz,4H),6.41(d,J=7.4Hz,1H),5.16(s,2H) ,4.51-2.58(m,13H),2.20-2.03(m,4H),1.73-1.52(m,4H),1.35-1.30(m,2H),0.89(t,J=7.3Hz,3H).

[0232] Example Compound I-63 2-Amino-4-(butylamino)-6-(4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0233] The synthesis of compound I-63 was carried out by referring to the synthesis of compound I-14, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-63. MS: 449.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.08(t,J=5.7Hz,1H),8.18(d,J=7.5Hz,3H),7.76-7.35(m,4H),6.42(d,J=7.4Hz,1H),5.21(s, 2H),3.90-2.90(m,10H),2.79(s,3H),1.62-1.52(m,2H),1.39-1.28(m,2H),0.90(t,J=7.4,3H).

[0234] Example Compound I-64 2-Amino-4-(butylamino)-6-((2-methoxy-6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0235] The synthesis of compound I-64 was carried out by referring to the synthesis of compound I-2, except that 5-(chloromethyl)-6-methoxypyridineformate was used instead of 4-(bromomethyl)-3-methoxybenzoate. MS: 438.5 [M+H] + 1H NMR (400MHz, DMSO-d6) δ 9.35(t,J=5.6Hz,1H),8.14(s,1H),7.68(d,J=7.6Hz,1H),7.35(d,J=7.4Hz ,1H),7.04(d,J=7.5Hz,1H),6.81(s,2H),6.12(d,J=7.4Hz,1H),4.96(s,2H) ),4.33(s,2H),3.97(s,3H),3.39(td,J=6.9,5.4Hz,2H),3.26(s,4H),1.97 -1.87(m,4H),1.56-1.45(m,2H),1.37-1.25(m,2H),0.88(t,J=7.3Hz,3H).

[0236] Example Compound I-65 6-(4-(3,6-diazacyclo[3.1.1]heptane-6-carbonyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0237] The synthesis of compound I-65 was carried out by referring to the synthesis of compound I-14, except that tert-butyl 3,6-diazabicyclo[3.1.1]heptane-3-carboxylate was used instead of tert-butyl piperazine-1-carboxylate to prepare compound I-65. MS: 448.5 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.08(s,1H),9.62(s,1H),8.50-7.98(m,3H),7.50-7.34(m,4H),6.42(d,J=7.4Hz,1H),5.22(d,J=5.0Hz,2H),4.6 9-3.08(m,8H),2.82-2.78(m,1H),1.87-1.80(m,1H),1.60-1.53(m,2H),1.38-1.30(m,2H),0.90(t,J=7.4Hz,3H).

[0238] Example Compound I-66 6-(4-(2,5-diazacyclo[2.2.1]heptane-2-carbonyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0239] The synthesis of compound I-66 was carried out by referring to the synthesis of compound I-14, except that tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate was used instead of tert-butyl piperazine-1-carboxylate to prepare compound I-66. MS: 448.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.05(s,1H),9.28(m,1H),8.89-8.16(m,3H),7.54-7.35(m,4H),6.41(d,J=7.4Hz,1H),5.22(d,J=5.1Hz,2H),4.86-4.28(m ,2H),3.77-3.18(m,6H),2.11-2.02(m,1H),1.90-1.73(m,1H),1.60-1.52(m,2H),1.37-1.30(m,2H),0.90(t,J=7.3Hz,3H).

[0240] Example Compound I-67 2-Amino-4-(butylamino)-6-(4-(2-hydroxyethyl)piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-67 was carried out by referring to the synthesis of compound I-14, except that 2-(piperazin-1-yl)ethan-1-ol was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-67. MS: 480.1 [M+H] + .

[0241] Example Compound I-68 2-Amino-4-(butylamino)-6-(3-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0242] The synthesis of compound I-68 was carried out by referring to the synthesis of compound I-2, except that methyl 3-(bromomethyl)benzoate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-68. MS: 407.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.08(s,1H),9.96(s,1H),8.35(s,1H),8.13(d,J=7.4Hz,1H),7.49-7.38(m,3H),6.43(d,J=7.4Hz,1H),5.20(s,2H),4.32 (d,J=5.2Hz,2H),3.55-3.47(m,3H),3.38-3.27(m,2H),3.12-2.97(m,2H),2.07-1.93(m,2H),1.90-1.75(m,2H),1.61-1.50 (m,2H),1.39-1.27(m,2H),0.90(t,J=7.4Hz,3H).

[0243] Example Compound I-69 2-Amino-4-(butylamino)-6-(4-(pyrrolidin-1-ylmethyl)phenylethyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0244] Compound I-69 was prepared by referring to the synthesis of compound I-2, except that 4-(2-bromoethyl)benzoic acid methyl was used instead of 4-(bromomethyl)-3-methoxybenzoic acid methyl. MS: 421.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.22(s,1H),10.20(s,1H),9.99(s,1H),8.50-8.00(m,2H),7.84(d,J=7.4Hz,1H),7.43(d,J=7.8Hz ,2H),7.30(d,J=7.8Hz,2H),6.26(d,J=7.4Hz,1H),4.30(d,J=4.8Hz,2H),4.17(t,J=7.4Hz,2H),3.58 - 3.50(m,2H),3.31(s,2) H),3.15-3.02(m,2H),2.99(t,J=7.4Hz,2H),2.07-1.92(m,2H),1.92-1 .75(m,2H),1.66-1.53(m,2H),1.42-1.28(m,2H),0.92(t,J=7.4Hz,3H).

[0245] Example Compound I-70 2-Amino-4-(butylamino)-6-(3-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0246] The synthesis of compound I-70 was carried out by referring to the synthesis of compound I-14, and using intermediate I-68-1 instead of intermediate I-11-1 to prepare compound I-70. MS: 436.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.13(s,1H),10.07(s,1H),8.98(s,1H),8.49-7.88(m,3H),7.49-7.36(m,6H),6.41(d,J=7.4Hz,1H),5 .20(s,2H),3.93-3.26(m,7H),3.14(s,2H),1.60-1.50(m,2H),1.40-1.26(m,2H),0.90(t,J=7.4Hz,3H).

[0247] Example Compound I-71 (S)-2,6-Diamino-N-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)caproamide [ka] The synthesis of compound I-71 was carried out by referring to the synthesis of compound I-14, except that intermediate I-26-1 was used instead of t-butyl piperazine-1-carboxylate, and N 2 ,N 6 Compound I-71 was prepared using bis(tert-butoxycarbonyl)-L-lysine. MS: 481.1 [M+H] + .

[0248] Example Compound I-72 2-Amino-4-(butylamino)-6-(2-methoxy-4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0249] The synthesis of compound I-72 was carried out by referring to the synthesis of compound I-14, and using intermediate I-2-1 instead of intermediate I-11-1 to prepare compound I-72. MS: 466.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.05(s,1H),10.12(s,1H),8.94(s,2H),8.45(s,1H),8.09(d,J=7.5Hz,1H),7.14-7.06(m,2H),6.98(dd,J=7.6,1.4Hz,1H),6.43(d,J= 7.5Hz,1H),5.11(s,2H),3.96-3.66(m,7H),3.57-3.47(m,3H),3.14(s,4H),1.62-1.49(m,2H),1.39-1.28(m,2H),0.89(t,J=7.4Hz,3H).

[0250] Example Compound I-73 2-Amino-4-(butylamino)-6-(2-methoxy-4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0251] The synthesis of compound I-73 was carried out by referring to the synthesis of compound I-72, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-73. MS: 480.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.30(s,1H),10.18-10.08(m,1H),8.61-8.20(m,2H),8.10(d,J=7.5Hz,1H),7.12(d,J=7.8H z,1H),7.07(d,J=1.4Hz,1H),6.97(dd,J=7.6,1.6Hz,1H),6.42(d,J=7.6Hz,1H),5.11(s,2H), 3.85(s,3H),3.56-3.47(m,2H),3.07(s,2H),2.88(s,2H),2.81(s,3H),2.72(d,J=0.6Hz,1H) ,2.67(s,2H),1.61-1.50(m,2H),1.38-1.28(m,2H),1.28-1.20(m,2H),0.89(t,J=7.3Hz,3H).

[0252] Example Compound I-74 2-Amino-4-((2-methoxyethyl)amino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0253] The synthesis of compound I-74 was carried out by referring to the synthesis of compound I-14, and using intermediate I-21-1 instead of intermediate I-11-1 to prepare compound I-74. MS: 438.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.00(s,1H),9.07(s,2H),8.10(d,J=7.4Hz,1H),8.01(s,1H),7.40(d,J=8.2Hz,2H),7.35(d,J=8.2Hz,2H),6.35(d,J=7 .4Hz,1H),5.19(s,2H),3.66(q,J=5.4Hz,3H),3.52(t,J=5.4Hz,3H),3.86-3.22(m,4H),3.28(s,3H),3.20-3.07(m,4H).

[0254] Example Compound I-75 2-Amino-4-((2-methoxyethyl)amino)-6-(4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0255] The synthesis of compound I-75 was carried out by referring to the synthesis of compound I-74, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-75. MS: 452.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.14(t,J=5.5Hz,1H),8.53-8.22(m,2H),8.19(d,J=7.4Hz,1H),7.44(d,J=8.2Hz,2H),7.37(d,J=8.2Hz,2H),6.42(d ,J=7.4Hz,1H),5.22(s,2H),3.68(q,J=5.4Hz,3H),3.53(t,J=5.4Hz,3H),3.85-2.95(m,8H),3.28(s,3H),2.79(s,3H).

[0256] Example Compound I-76 2-Amino-4-((2-(ethylamino)ethyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0257] The synthesis of compound I-76 was carried out by referring to the synthesis of compound I-1, and using intermediate Int.G instead of intermediate Int.A to prepare compound I-76. MS: 422.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.94(s,1H),10.74(s,1H),10.10(t,J=6.1Hz,1H),9.02(s,1H),8.81(s,2H),8.59(d,J=48.3Hz,2 H),8.26(d,J=7.5Hz,1H),7.50(d,J=8.0Hz,2H),7.36(d,J=7.9Hz,2H),6.41(d,J=7.4Hz,1H),5.20 (s,2H),4.32(d,J=4.8Hz,2H),3.80(q,J=5.8Hz,2H),3.41-3.27(m,2H),3.20(q,J=5.8Hz,2H),3.1 5-2.94(m,4H),1.99(q,J=7.0,6.3Hz,2H),1.83(td,J=8.4,7.1,4.7Hz,2H),1.15(t,J=7.2Hz,3H).

[0258] Example Compound I-77 2-Amino-4-(butylamino)-6-(3-methoxy-4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0259] The synthesis of compound I-77 was carried out by referring to the synthesis of compound I-14, and using intermediate I-5-1 instead of intermediate I-11-1 to prepare compound I-77. MS: 466.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.42(s,1H),10.11(t,J=5.8Hz,1H),9.15(s,2H),8.34(s,2H),8.19(d,J=7.4Hz,1H ),7.22(d,J=7.7Hz,1H),7.11(d,J=1.5Hz,1H),6.86(dd,J=7.8,1.4Hz,1H),6.41(d, J=7.4Hz,1H),5.19(s,2H),3.79(s,5H),3.52(q,J=6.7Hz,2H),3.38-3.23(m,2H),3. 15(s,2H),3.02(s,2H),1.62-1.52(m,2H),1.40-1.28(m,2H),0.90(t,J=7.3Hz,3H).

[0260] Example Compound I-78 2-Amino-4-(butylamino)-6-((4-(pyrrolidin-1-ylmethyl)naphthalen-1-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0261] The synthesis of compound I-78 was carried out by referring to the synthesis of compound I-2, except that 4-(bromomethyl)-1-naphthoic acid methyl was used instead of 4-(bromomethyl)-3-methoxybenzoic acid methyl. MS: 457.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.64(s,1H),10.19-10.03(m,2H),8.57-8.32(m,3H),8.22(dt,J=8.0,2.8Hz,1H),8.08(d,J=7. 4Hz,1H),7.72(ddd,J=12.6,8.7,6.1Hz,3H),7.11(d,J=7.4Hz,1H),6.47(d,J=7.4Hz,1H),5.73( s,2H),4.87(d,J=5.0Hz,2H),3.53(q,J=6.7Hz,2H),3.40(d,J=9.2Hz,2H),3.21(d,J=9.7Hz,2H) ,2.04(s,2H),1.85(d,J=9.8Hz,2H),1.63-1.48(m,2H),1.38-1.28(m,2H),0.89(t,J=7.4Hz,3H).

[0262] Example Compound I-79 2-Amino-4-(butylamino)-6-(3-methoxy-4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0263] The synthesis of compound I-79 was carried out by referring to the synthesis of compound I-77, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-79. MS: 480.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.50(s,1H),10.48(s,1H),10.14(t,J=5.8Hz,1H),8.45(s,2H),8.21(d,J=7.4H z,1H),7.21(d,J=7.7Hz,1H),7.11(d,J=1.5Hz,1H),6.92-6.84(m,1H),6.42(d,J =7.5Hz,1H),5.20(s,2H),4.52(s,1H),3.80(s,3H),3.53(q,J=6.7Hz,2H),3.38( m,7H),2.82(s,3H),1.63-1.52(m,2H),1.40-1.28(m,2H),0.90(t,J=7.4Hz,3H).

[0264] Example Compound I-80 2-Amino-4-((4-fluorobutyl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0265] The synthesis of compound I-80 was carried out by referring to the synthesis of compound I-1, and using intermediate Int.H instead of intermediate Int.A to prepare compound I-80. MS: 425.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.55(s,1H),10.38(s,1H),10.11(s,1H),8.37(m,2H),8.19(d,J=7.5Hz,1H),7.4 9(d,J=7.9Hz,2H),7.35(d,J=7.9Hz,2H),6.41(dd,J=7.4,3.9Hz,1H),5.22(d,J=16 .5Hz,2H),4.53(q,J=5.5Hz,2H),4.45-4.37(m,2H),4.31(s,2H),3.60-3.49(m,2H) ),3.33(m,2H),3.05(m,2H),2.00(m,2H),1.83(d,J=8.4Hz,2H),1.75-1.57(m,4H).

[0266] Example Compound I-81 2-Amino-4-butoxy-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0267] The synthesis of compound I-81 was carried out by referring to the synthesis of compound I-1, and compound I-81 was prepared by using intermediate Int.S instead of intermediate Int.A. MS: 408.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.10(s,1H),7.94(d,J=7.5Hz,1H),7.89-7.44(m,3H),7.34(d,J=8.0Hz,2H),6.21(s,1H),5.08(s,2H),4.43-4.18 (m,4H),3.33(m,2H),3.06(m,2H),2.01(m,2H),1.83(m,2H),1.70(m,2H),1.50-1.39(m,2H),0.92(t,J=7.4Hz,3H).

[0268] Example Compound I-82 4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)-N-(2-(pyrrolidin-1-yl)ethyl)benzamide [ka]

[0269] The synthesis of compound I-82 was carried out by referring to the synthesis of compound I-14, except that 2-(pyrrolidin-1-yl)ethan-1-amine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-82. MS: 464.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.23-9.86(m,2H),8.78(d,J=5.6Hz,1H),8.19(d,J=7.4Hz,3H),7.90-7.79(m,2H),7.38(d,J=8.0Hz,2H),6.42(d,J=7.4Hz ,1H),5.23(s,2H),3.78-2.99(m,9H),2.00(s,2H),1.85(s,2H),1.61-1.52(m,2H),1.34(p,J=7.5Hz,2H),0.95-0.87(m,3H).

[0270] Example Compound I-83 2-Amino-4-(butylamino)-6-(4-(4-methylpiperazin-1-yl)-4-oxobutyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0271] The synthesis of compound I-83 was carried out by referring to the synthesis of compound I-14, except that 4-bromobutyric acid methyl was used instead of 4-(bromomethyl)benzoic acid methyl, and 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl, to prepare compound I-83. MS: 402.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.20(t,J=5.8Hz,1H),8.44-8.06(m,2H),7.99(d,J=7.4Hz,1H),6.35(d,J=7.4Hz,1H),4.24-3.07(m,13H) ),2.78(s,3H),2.40(t,J=7.2Hz,2H),1.89(m,2H),1.59(m,2H),1.42-1.31(m,2H),0.92(t,J=7.3Hz,3H).

[0272] Example Compound I-84 2-Amino-4-(butylamino)-6-(4-oxo-4-(piperazin-1-yl)butyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-84 was carried out by referring to the synthesis of compound I-83, except that t-butyl piperazine-1-carboxylate was used instead of 1-methylpiperazine. MS: 388.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.25(t,J=5.7Hz,1H),8.38(s,2H),8.02(d,J=7.4Hz,1H),6.36(d,J=7.4Hz,1H),3.96(t,J=7.1Hz,2H),3.69-3.47(m,6H),3.11( s,2H),3.05(s,2H),2.68(s,1H),2.40(t,J=7.2Hz,2H),1.95-1.81(m,2H),1.58(m,2H),1.42-1.29(m,2H),0.92(t,J=7.3Hz,3H).

[0273] Example Compound I-86 2-Amino-4-(butylamino)-6-((3-(piperazine-1-carbonyl)bicyclo[1.1.1]pentan-1-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-86 was carried out by referring to the synthesis of compound I-14, except that methyl 3-(bromomethyl)bicyclo[1.1.1]pentane-1-carboxylate was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-86. MS: 426.2 [M+H] + .

[0274] Example Compound I-88 (R)-2-Amino-4-((1-hydroxy-2-methylhexan-2-yl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-88, the synthesis of compound I-1 was referred to, and intermediate Int.N was used instead of intermediate Int.A to prepare compound I-88. MS: 465.2 [M+H] + .

[0275] Example Compound I-90 2-Amino-4-(butylamino)-6-(4-(2-(dimethylamino)ethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-90 was carried out by referring to the synthesis of compound I-2, except that 2-(4-(bromomethyl)phenyl)acetate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate, and dimethylamine hydrochloride was used instead of pyrrolidine. MS: 395.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.11(s,1H),9.66(s,1H),8.23-7.90(m,2H),7.39-7.15(m,4H),5.14(s,2H),3.55-3.48(m,2H),3.28-3 .21(m,2H),2.97-2.88(m,2H),2.81(s,6H),1.64-1.50(m,2H),1.40-1.25(m,2H),0.90(t,J=7.3Hz,3H).

[0276] Example Compound I-91 (R)-2-Amino-4-((1-hydroxy-2-methylhexan-2-yl)amino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0277] The synthesis of compound I-91 was carried out by referring to the synthesis of compound I-83, except that intermediate I-88-1 was used instead of intermediate I-83-1, and piperazine-1-carboxylate-t-butyl was used instead of 1-methylpiperazine to prepare compound I-91. MS: 494.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.23(s,2H),8.45-8.14(m,3H),7.55-7.44(m,2H),7.35(d,J=8.2Hz,2H),6.41(d,J=7.4Hz,1H),5.20(s,2H),4.32(d, J=4.8Hz,2H),3.68-3.06(m,3H),2.00(s,2H),1.93-1.70(m,4H),1.36(s,3H),1.31-1.16(m,4H),0.85(t,J=6.9Hz,3H).

[0278] Example Compound I-93 2-Amino-4-(butylamino)-6-((4-(pyrrolidin-1-ylmethyl)cyclohexyl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-93 was carried out by referring to the synthesis of compound I-2, except that methyl 4-(bromomethyl)cyclohexane-1-carboxylate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate. MS: 413.1 [M+H] + .

[0279] Example Compound I-94 2-Amino-4-(butylamino)-6-(4-(piperazin-1-yl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0280] Intermediate I-94-1 was prepared by referring to the synthesis of intermediate I-2-1, except that 4-(bromomethyl)bromobenzene was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate. For the synthesis of intermediate I-94-2, the synthesis of intermediate I-36-1 was referred to, and intermediate I-94-2 was prepared by using piperazine-1-carboxylate-t-butyl instead of intermediate A and intermediate I-94-1 instead of methyl 4-iodobenzoate. The synthesis of compound I-94 was carried out by referring to the synthesis of compound I-1, and using intermediate I-94-2 instead of intermediate I-1-3 to prepare compound I-94. MS: 408.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.99(s,1H),8.71(s,2H),8.04(s,1H),7.23(d,J=8.4Hz,2H),6.95(d,J=8.4Hz,2H),6.31(s,1H),5.03(s,2H),3.5 6-3.45(m,2H),3.29-3.17(m,9H),2.97-2.85(m,1H),1.62-1.50(m,2H),1.41-1.28(m,2H),0.90(t,J=7.3Hz,3H).

[0281] Example Compound I-95 2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0282] For the synthesis of compound I-95, the synthesis of intermediate I-1 was referred to, and intermediate Int.F was used instead of intermediate Int.A to prepare compound I-95. MS: 451.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.34(s,1H),10.08(d,J=9.2Hz,1H),8.51-8.06(m,3H),7.50(d,J=8.2Hz,2H),7.36(d,J=8.1Hz, 2H),6.43(d,J=7.4Hz,1H),5.20(s,2H),4.40(d,J=6.3Hz,1H),4.32(d,J=5.2Hz,2H),3.45(t,J=6. 5Hz,2H),3.34(dd,J=10.2,6.4Hz,2H),3.15-2.98(m,2H),1.99(dt,J=12.7,6.6Hz,2H),1.84(dd,J =16.4,8.1Hz,2H),1.78-1.63(m,2H),1.63-1.48(m,2H),1.37-1.20(m,2H),0.87(t,J=7.3Hz,3H).

[0283] Example Compound I-96 3-((2-amino-5-oxo-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6-dihydropyrido[4,3-d]pyrimidin-4-yl)amino)hexyl 2,2,2-trifluoroacetate [ka]

[0284] For the synthesis of compound I-96, the synthesis of intermediate I-1 was referred to, and intermediate Int.F was used instead of intermediate Int.A to prepare compound I-96. MS: 547.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.33(s,1H),10.07(d,J=9.0Hz,1H),8.54-8.10(m,3H),7.55-7.46(m,2H),7.42-7.33(m ,2H),6.43(d,J=7.4Hz,1H),5.20(s,2H),4.40(d,J=7.1Hz,1H),4.32(d,J=5.0Hz,2H),3.4 5(t,J=6.4Hz,2H),3.33(d,J=9.4Hz,2H),3.07(m,2H),2.01(m,2H),1.83(d,J=5.9Hz,2H), 1.78-1.63(m,2H),1.56(dt,J=13.4,8.8Hz,2H),1.38-1.21(m,2H),0.87(t,J=7.3Hz,3H).

[0285] Example Compound I-97 2-Amino-4-(butylamino)-6-(4-(piperazin-1-ylsulfonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-97 was carried out by referring to the synthesis of compound I-1, except that 4-(4-(chloromethyl)phenyl)sulfonyl)piperazine-1-carboxylate-t-butyl was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-97. MS: 472.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.35(t,J=5.7Hz,1H),8.18-8.09(m,2H),7.76(m,3H),7.53(d,J=8.3Hz,2H),6.78(s,2H),6.15(d,J=7.5Hz,1H),5.18(s,2H),3.4 5-3.38(m,2H),3.13(d,J=5.6Hz,4H),3.07(d,J=5.6Hz,4H),2.88(m,2H),1.57-1.46(m,2H),1.40-1.25(m,2H),0.94-0.84(m,3H).

[0286] Example Compound I-98 2-Amino-4-(butylamino)-6-(4-((2-hydroxyethyl)(propyl)amino)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-98 was carried out by referring to the synthesis of compound I-1, except that 2-(propylamino)ethan-1-ol was used instead of pyrrolidine to prepare compound I-98. MS: 439.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.07(s,1H),9.51(s,1H),8.40-8.03(m,2H),7.51(d,J=8.0Hz,2H),7.36(d, J=8.0Hz,2H),6.42(d,J=7.4Hz,1H),5.38(s,1H),5.20(s,2H),4.32(s,2H),3. 76-3.66(m,2H),3.56-3.47(m,2H),3.15-2.92(m,4H),1.80-1.62(m,2H),1.62 -1.50(m,2H),1.39-1.25(m,2H),0.90(t,J=7.3Hz,3H),0.85(t,J=7.3Hz,3H).

[0287] Example Compound I-99 2-Amino-4-(butylamino)-6-(4-(4,5-dihydro-1H-imidazol-2-yl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-99 was carried out by referring to the synthesis of compound I-1, except that 2-(4-(chloromethyl)phenyl)-4,5-dihydro-1H-imidazole was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-99. MS: 392.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.60(s,2H),10.06(t,J=5.6Hz,1H),8.62-8.16(m,2H),8.22(d,J=7.4Hz,1H),7.89(d,J=8.0Hz,2H),7.51(d,J=8.0Hz,2H),6.45(d ,J=7.4Hz,1H),5.29(s,2H),3.99(s,4H),3.51(q,J=6.7Hz,2H),1.55(p,J=7.2Hz,2H),1.32(h,J=7.3Hz,2H),0.89(t,J=7.4Hz,3H).

[0288] Example Compound I-100 2-Amino-4-(butylamino)-6-(4-(4-(2,3-dihydroxypropyl)piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka]

[0289] The synthesis of compound I-100 was carried out by referring to the synthesis of compound I-14, except that 1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)piperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-100. MS: 510.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.09(s,1H),9.70(s,1H),8.18(d,1H),7.45(d,J=8.1Hz,2H),7.38(d ,J=8.1Hz,2H),6.44(d,J=7.5Hz,1H),5.59(s,1H),5.22(s,2H),4.99(s ,1H),3.88(s,1H),3.75-3.47(m,7H),3.35-3.23(m,4H),3.23-2.98(m ,4H),1.65-1.49(m,2H),1.43-1.27(m,2H),0.91(t,J=7.4,4.1Hz,3H).

[0290] Example Compound I-101 (R)-2-Amino-4-((1-hydroxy-2-methylhexan-2-yl)amino)-6-(4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-101 was carried out by referring to the synthesis of compound I-91, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-101. MS: 508.2 [M+H] + .

[0291] Example Compound I-102 2-Amino-4-(butylamino)-6-((4-(pyrrolidin-1-ylmethyl)thiazol-2-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-102 was carried out by referring to the synthesis of compound I-1, except that methyl 2-(bromomethyl)thiazole-4-carboxylate was used instead of methyl 4-(bromomethyl)benzoate to prepare compound I-102. MS: 414.2 [M+H] + .

[0292] Example Compound I-103 (R)-2-Amino-4-(pentan-2-ylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-103 was carried out by referring to the synthesis of compound I-1, and using intermediate Int.L instead of intermediate Int.A to prepare compound I-103. MS: 421.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.18(s,1H),10.04-10.02(d,J=8.0Hz,1H),8.42(br,1H),8.20-8.18(d,J=8.0Hz, 1H),7.50-7.48(d,J=8.0Hz,2H),7.38-7.34(m,2H),6.44-6.42(d,J=8.0Hz,1H),5. 25-5.14(m,2H),4.32-4.25(m,5H),3.05(br,2H),2.00(br,2H),1.85-1.82(m,2H), 1.56-1.51(m,2H),1.34-1.27(m,2H),1.20(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0293] Example Compound I-104 (S)-2-Amino-4-(pentan-2-ylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-104 was carried out by referring to the synthesis of compound I-1, and compound I-104 was prepared by using intermediate Int.M instead of intermediate Int.A. MS: 435.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.18(s,1H),10.04-10.02(d,J=8.0Hz,1H),8.42(br,1H),8.20-8.18(d,J=8.0Hz, 1H),7.50-7.48(d,J=8.0Hz,2H),7.38-7.34(m,2H),6.44-6.42(d,J=8.0Hz,1H),5. 25-5.14(m,2H),4.32-4.25(m,5H),3.05(br,2H),2.00(br,2H),1.85-1.82(m,2H), 1.56-1.51(m,2H),1.34-1.27(m,2H),1.20(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0294] Example Compound I-105 4-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)phenyl)piperazine-1-carboxylate methyl [ka] Compound I-105 was prepared by referring to the synthesis of compound I-94, except that piperazine-1-carboxylate methyl was used instead of piperazine-1-carboxylate-t-butyl. MS: 466.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.19(s,1H),8.39-7.76(m,2H),7.21(d,J=8.6Hz,2H),6.92(d,J=8.6Hz,2H),6.40(d,J=7.5Hz,1H),5.05(s,2H) ,3.60(s,3H),3.56-3.43(m,7H),3.13-3.02(m,4H),1.63-1.52(m,2H),1.41-1.26(m,2H),0.91(t,J=7.3Hz,3H).

[0295] Example Compound I-107 2-Amino-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)-4-((2-methoxyethyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] Compound I-107 was prepared by referring to the synthesis of compound I-21, except that methyl 4-(bromomethyl)-3-methoxybenzoate was used instead of methyl 4-(bromomethyl)benzoate. MS: 439.2 [M+H] + .

[0296] Example Compound I-109 4-(4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)piperazine-1-carboxylate methyl [ka] The synthesis of compound I-109 was carried out by referring to the synthesis of compound I-1, except that methyl piperazine-1-carboxylate was used instead of pyrrolidine. MS: 480.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.12(s,1H),8.45(s,1H),8.19(d,J=7.4Hz,1H),7.98(s,1H),7.45(d,J=7.9Hz,2H),7.37(d,J=7.8Hz,2H),6.45(d,J=7.4Hz,1H),5.20(s,2 H),4.29(s,2H),4.04(s,2H),3.61(s,2H),3.57-3.49(m,6H),3.21-2. 93(m,4H),1.64-1.49(m,2H),1.40-1.26(m,2H),0.90(t,J=7.3Hz,3H).

[0297] Example Compound I-110 2-Amino-4-(butylamino)-8-fluoro-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-110 was carried out by referring to the synthesis of compound I-1, and intermediate Int.P was used instead of intermediate Int.A to prepare compound I-110. MS: 425.1 [M+H] + .

[0298] Example Compound I-112 2-Amino-4-(heptan-4-ylamino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-112 was carried out by referring to the synthesis of compound I-91, and intermediate I-113-1 was used instead of intermediate I-88-1 to prepare compound I-112. MS: 478.2 [M+H]+ . 1 H NMR(400MHz,DMSO-d6) δ 9.99(d,J=9.0Hz,1H),9.12(s,1H),8.18(d,J=7.4Hz,2H),7.46(d,J=8.2Hz,2H),7.37(d,J=8.1Hz,2H),6.43(d,J= 7.4Hz,1H),5.22(s,2H),4.30(d,J=7.6Hz,1H),3.34(m,9H),1.52(m,4H),1.37-1.19(m,4H),0.87(t,J=7.3Hz,6H).

[0299] Example Compound I-113 2-Amino-4-(heptan-4-ylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-113 was carried out by referring to the synthesis of compound I-1, and intermediate Int.Q was used instead of intermediate Int.A to prepare compound I-113. MS: 449.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.43-9.98(m,1H),8.48-8.14(m,2H),7.51(d,J=8.2Hz,2H),7.36(d,J=8.1Hz,2H),6.43(d,J=7.4Hz,1H),5.20(s,2H),4.32(d,J=5 .3Hz,3H),3.33(s,2H),3.05(s,2H),2.00(s,2H),1.85(d,J=7.9Hz,2H),1.62-1.44(m,4H),1.37-1.20(m,4H),0.87(t,J=7.3Hz,6H).

[0300] Example Compound I-114 2-Amino-4-(heptan-4-ylamino)-6-(4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-114 was carried out by referring to the synthesis of compound I-112, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-114. MS: 492.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.99(m,1H),8.18(d,J=7.5Hz,2H),7.45(d,J=8.2Hz,2H),7.38(d,J=8.3Hz,2H),6.43(d,J=7.4Hz,1H),5.22(s,2H),3.44-2.98(m,10H) 2.79(s,3H),1.52(m,4H),1.28(m,4H),0.87(t,J=7.3Hz,6H).

[0301] Example Compound I-115 2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-115 was carried out by referring to the synthesis of compound I-91, and using intermediate I-95-1 instead of intermediate I-88-1 to prepare compound I-115. MS: 480.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.39(s,1H),9.91(s,1H),9.20(s,2H),8.09(d,J=7.5Hz,1H),7.99-7.89(m,2H),7 .45(d,J=8.0Hz,2H),7.36(d,J=8.0Hz,2H),6.36(d,J=7.4Hz,1H),5.25-5.12(m,2H) ,4.37(d,J=6.7Hz,1H),3.65-3.59(m,2H),3.40-3.32(m,8H),1.79-1.61(m,2H),1. 55(td,J=16.0,7.9Hz,2H),1.28(tq,J=13.3,6.7,6.2Hz,2H),0.87(t,J=7.3Hz,3H).

[0302] Example Compound I-116 2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-116 was carried out by referring to the synthesis of compound I-115, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-116. MS: 494.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.36(s,1H),9.93(s,1H),9.18(s,2H),8.19(d,J=7.5Hz,1H),7.99-7.88(m,2H ),7.45(d,J=8.0Hz,2H),7.35(d,J=8.0Hz,2H),6.33(d,J=7.4Hz,1H),5.26-5.15 (m,2H),4.37(d,J=6.7Hz,1H),3.65-3.59(m,2H),3.40-3.32(m,8H),2.75(s,3H) ,1.79-1.61(m,2H),1.57-1.53(m,2H),1.30-1.26(m,2H),0.87(t,J=7.2Hz,3H).

[0303] Example Compound I-117 (R)-2-Amino-4-(pentan-2-ylamino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-117, the synthesis of compound I-115 was referred to, and intermediate I-103-1 was used instead of intermediate I-95-1 to prepare compound I-117. MS: 450.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.61(s,1H),9.98(d,J=8.3Hz,1H),9.24(s,2H),8.35(s,2H),8.18(d,J=7. 4Hz,1H),7.45(d,J=8.0Hz,2H),7.37(d,J=8.0Hz,2H),6.40(d,J=7.4Hz,1H), 5.21(q,J=15.0Hz,2H),4.27(p,J=6.9Hz,1H),3.93-3.35(m,8H),1.59-1.47( m,2H),1.39-1.26(m,2H),1.20(dd,J=6.6,3.3Hz,3H),0.88(t,J=7.3Hz,3H).

[0304] Example Compound I-118 (S)-2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-118, the synthesis of intermediate I-1 was referred to, and intermediate Int.R was used instead of intermediate Int.A to prepare compound I-118. MS: 451.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.19(s,1H),9.35(d,J=8.9Hz,1H),8.25(s,2H),7.68(d,J=7.5Hz,1H),7.34(s,1H),7.33(d,J=7.8Hz,2H),7.23(d,J=7.8Hz,2H),6.08(d,J =7.5Hz,1H),5.10-4.96(m,2H),4.29(q,J=6.4,5.9Hz,1H),3.77(d,J=13.6Hz,3H),3.41(tq,J=7.5,4.0Hz,2H),2.66-2.62(m,3H),1.75-1.71 m,5H),1.62-1.40(m,3H),1.37-1.22(m,2H),0.85(t,J=7.2Hz,3H).

[0305] Example Compound I-119 2-Amino-4-(butylamino)-6-((5-methoxy-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-119 was carried out by referring to the synthesis of compound I-2, except that tert-butyl 7-(bromomethyl)-5-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-119. MS: 409.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.13(s,1H),9.04(s,2H),8.43(s,1H),8.16(d,J=7.5Hz,2H),6.95(s,1H),6.65(s,1H),6.42(d,J=7.4Hz,1H),5.13(s,2H),4.18( s,2H),3.79(s,3H),3.56-3.49(m,2H),3.34(s,2H),2.79-2.71(m,2H),1.61-1.51(m,2H),1.39-1.29(m,2H),0.91(t,J=7.3Hz,3H).

[0306] Example Compound I-120 2-Amino-4-(butylamino)-6-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2-methoxybenzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-120 was carried out by referring to the synthesis of compound I-72, except that 2-(piperazin-1-yl)ethan-1-ol was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-120. MS: 510.1 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.33(s,1H),10.09(s,1H),9.96(s,1H),8.50-8.12(m,2H),8.08(d,J=7.5Hz,1 H),7.12(d,J=7.7Hz,1H),7.08(s,1H),6.98(d,J=7.8Hz,1H),6.41(d,J=7.4Hz,1 H),5.42(s,1H),5.11(s,2H),3.86(s,3H),3.77-3.70(m,2H),3.56-3.45(m,3H) ,3.45-2.95(m,7H),1.65-1.50(m,2H),1.44-1.25(m,2H),0.90(t,J=7.3Hz,3H).

[0307] Example Compound I-121 2-Amino-4-(butylamino)-8-fluoro-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-121, the synthesis of compound I-115 was followed, and intermediate I-110-1 was used instead of intermediate I-95-1 to prepare compound I-121. MS: 454.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.86(s,1H),8.91(s,2H),8.43(d,J=5.6Hz,1H),7.89(s,1H),7.44(d,J=8.0Hz,2H),7.39(d,J=8.1Hz,2H) ,5.12(s,2H),3.60-3.45(m,5H),3.14(s,5H),1.61-1.49(m,2H),1.39-1.27(m,2H),0.90(t,J=7.3Hz,3H).

[0308] Example Compound I-122 2-Amino-4-(butylamino)-6-(4-(piperidin-4-yl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-122 was carried out by referring to the synthesis of compound I-2, except that tert-butyl 4-(4-(bromomethyl)phenyl)piperidine-1-carboxylate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-122. MS: 407.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.21(s,1H),10.12(d,J=6.2Hz,1H),8.67(s,1H),8.44(s,2H),8.18(d,J=7.4Hz,1H),7.2 7(d,J=8.1Hz,2H),7.20(d,J=8.1Hz,2H),6.41(d,J=7.4Hz,1H),5.14(s,2H),3.51(q,J=6.8 Hz,2H),3.35(d,J=12.5Hz,2H),2.98(q,J=12.2Hz,2H),2.81(t,J=12.0Hz,1H),1.88(d,J=1 3.7Hz,2H),1.82-1.67(m,2H),1.63-1.51(m,2H),1.41-1.26(m,2H),0.90(t,J=7.3Hz,3H).

[0309] Example Compound I-123 (R)-2-Amino-6-(4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2-methoxybenzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-123 was carried out by referring to the synthesis of compound I-117, except that 4-(bromomethyl)-3-methoxybenzoic acid methyl was used instead of 4-(bromomethyl)benzoic acid methyl, and 2-(piperazin-1-yl)ethan-1-ol was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-123. MS: 524.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.43(s,1H),10.03(d,J=8.3Hz,1H),8.40(d,J=57.9Hz,2H),8.09(d,J=7.5Hz,1H),7.15-7 .06(m,2H),6.99(d,J=7.7Hz,1H),6.43(d,J=7.4Hz,1H),5.43(s,1H),5.18-5.03(m,2H),4. 48(s,1H),4.33-4.21(m,1H),3.86(s,3H),3.73(t,J=5.0Hz,2H),3.19(t,J=5.1Hz,2H),3.1 2(s,2H),1.60-1.44(m,2H),1.38-1.21(m,2H),1.19(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0310] Example Compound I-124 2-Amino-4-(pentan-2-oxy)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-124 was carried out by referring to the synthesis of compound I-1, and compound I-124 was prepared by using intermediate Int.T instead of intermediate Int.A. MS: 422.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.86(s,1H),8.18-7.85(m,2H),7.48(d,J=8.1Hz,2H),7.35(d,J=7.9Hz,2H) ,6.24(d,J=7.5Hz,1H),5.41-5.33(m,1H),5.18-4.98(m,2H),4.32(d,J=5.6 Hz,2H),3.34(s,2H),3.06(s,2H),2.07-1.92(m,2H),1.90-1.76(m,2H),1.7 4-1.49(m,2H),1.45-1.33(m,2H),1.32-1.21(m,3H),0.87(t,J=7.3Hz,3H).

[0311] Example Compound I-126 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-126 was carried out by referring to the synthesis of compound I-115, and using intermediate I-127-1 instead of intermediate I-95-1 to prepare compound I-126. MS: 466.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.38(d,J=8.6Hz,1H),8.17(s,1H),7.71(d,J=7.5Hz,1H),7.42-7.29(m,4H),6.59(br,2H),6.09(d,J=7.5Hz,1H),5.17-4.97(m,2H),4.23 -4.13(m,1H),3.50-3.35(m,4H),2.98-2.79(m,6H),1.63-1.52(m,1H),1.50-1.38(m,1H),1.35-1.23(m,2H),0.88(td,J=7.3,3.1Hz,3H).

[0312] Example Compound I-127 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-127, the synthesis of intermediate I-1 was referred to, and intermediate Int.T1 was used instead of intermediate Int.A to prepare compound I-127. MS: 437.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.40(d,J=8.5Hz,1H),8.23(s,1H),7.67(d,J=7.5Hz,1H),7.29-7.16(m,4H ),6.56(br,2H),6.06(d,J=7.5Hz,1H),5.10-4.90(m,2H),4.23-4.14(m,1H) ,3.54(s,2H),3.49-3.38(m,2H),2.45-2.35(m,4H),1.70-1.63(m,4H),1.6 3-1.53(m,1H),1.50-1.38(m,1H),1.35-1.25(m,2H),0.87(t,J=7.3Hz,3H).

[0313] Example Compound I-128 2-Amino-4-(butylamino)-6-((5-(pyrrolidin-1-ylmethyl)pyridin-2-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-128 was carried out by referring to the synthesis of compound I-2, except that methyl 6-(bromomethyl)nicotinate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-128. MS: 408.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.23(s,1H),10.24(s,1H),10.06(t,J=5.8Hz,1H),8.59(d,J=2.1Hz,1H),8.49(s,1H),8. 41(s,1H),8.17(d,J=7.4Hz,1H),7.95(dd,J=8.1,2.3Hz,1H),7.46(d,J=8.0Hz,1H),6.46( d,J=7.4Hz,1H),5.32(s,2H),4.38(d,J=5.2Hz,2H),3.50(q,J=6.7Hz,2H),3.09(s,2H),2. 02(s,2H),1.86-1.81(m,2H),1.60-1.48(m,2H),1.38-1.24(m,2H),0.88(t,J=7.3Hz,3H).

[0314] Example Compound I-129 2-Amino-4-(butylamino)-6-((5-(pyrrolidin-1-ylmethyl)pyrazin-2-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-129 was carried out by referring to the synthesis of compound I-2, except that methyl 5-(bromomethyl)pyrazine-2-carboxylate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate. MS: 409.2 [M+H] + . Example Compound I-130 N-(2-((2-amino-5-oxo-6-(4-(piperazine-1-carbonyl)benzyl)-5,6-dihydropyrido[4,3-d]pyrimidin-4-yl)amino)pentyl)acetamide [ka]

[0315] The synthesis of compound I-130 was carried out by referring to the synthesis of compound I-113, and using intermediate Int.T3 instead of intermediate Int.Q to prepare compound I-130. MS: 507.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.28(d,J=8.4Hz,1H),8.21(s,1H),7.88(t,J=5.8Hz,1H),7.71(d,J=7.5Hz,1H), 7.40-7.29(m,4H),6.62(br,2H),6.10(d,J=7.5Hz,1H),5.16-5.00(m,2H),4.28- 4.16(m,1H),3.69-3.50(m,2H),3.36-3.28(m,3H),3.10-3.02(m,1H),2.90-2.72 (m,4H),1.76(s,3H),1.57-1.36(m,2H),1.35-1.22(m,2H),0.86(t,J=7.2Hz,3H).

[0316] Example Compound I-131 N-(2-(2-amino-5-oxo-6-(4-(pyrrolidin-1-ylmethyl)benzyl)-5,6-dihydropyrido[4,3-d]pyrimidin-4-yl)amino)pentyl)acetamide [ka] The synthesis of compound I-131 was carried out by referring to the synthesis of compound I-5, and intermediate I-130-1 was used instead of intermediate I-5-1 to prepare compound I-131. MS: 478.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.31(d,J=8.4Hz,1H),8.17(d,J=1.5Hz,1H),7.88(t,J=5.8Hz,1H),7.68(d,J=7.5Hz,1 H),7.34-7.18(m,4H),6.07(d,J=7.5Hz,1H),6.60(br,2H),5.10-4.95(m,2H),4.28-4. 17(m,1H),3.68(s,2H),3.37-3.30(m,1H),3.10-3.02(m,1H),2.60-2.52(m,4H),1.76( s,3H),1.74-1.65(m,4H),1.55-1.37(m,2H),1.35-1.22(m,2H),0.86(t,J=7.3Hz,3H).

[0317] Example Compound I-132 2-Amino-4-(heptan-4-ylamino)-6-(2-methoxy-4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-132 was carried out by referring to the synthesis of compound I-113, except that 4-(bromomethyl)-3-methoxybenzoic acid methyl was used instead of 4-(bromomethyl)benzoic acid methyl. MS: 508.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.25(d,J=8.8Hz,1H),8.14(d,J=1.5Hz,1H),7.58(d,J=7.6Hz,1H),7.03(s,1H),6.92(s,2H),6.57(br,2H),6.08(d,J=7.5Hz,1H),4.98( s,2H),4.30-4.20(m,1H),3.86(s,3H),3.69-3.48(m,4H),2.92-2.77(m,4H),1.53-1.35(m,4H),1.34-1.18(m,4H),0.85(t,J=7.2Hz,6H).

[0318] Example Compound I-133 2-Amino-4-(heptan-4-ylamino)-6-(2-methoxy-4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-133 was carried out by referring to the synthesis of compound I-132, except that 1-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-133. MS: 522.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.32(d,J=8.8Hz,1H),7.62(d,J=7.5Hz,1H),7.02(d,J=1.3Hz,1H),6.97-6.90(m,2H),6.70(br,2H),6.11(d,J=7.5Hz,1H),4.99(s,2H),4.3 0-4.20(m,1H),3.86(s,3H),3.50-3.35(m,4H),2.68-2.50(m,4H),2.3 6(s,3H),1.54-1.37(m,4H),1.35-1.19(m,4H),0.85(t,J=7.3Hz,6H).

[0319] Example Compound I-134 6-(4-((4-acetylpiperazin-1-yl)methyl)benzyl)-2-amino-4-(butylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-134 was carried out by referring to the synthesis of compound I-1, except that 1-(piperazin-1-yl)ethan-1-one was used instead of pyrrolidine to prepare compound I-134. MS: 464.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.40(s,1H),10.12(t,J=5.8Hz,1H),8.62-8.25(m,2H),8.20(d,J=7.4Hz,1H),7. 46(d,J=7.8Hz,2H),7.37(d,J=7.8Hz,2H),6.43(d,J=7.4Hz,1H),5.21(s,2H),4.6 5-4.35(m,2H),4.30(s,2H),3.97(s,1H),3.52(q,J=6.7Hz,2H),3.45-2.75(m,6H) ,2.01(s,3H),1.56(p,J=7.1Hz,2H),1.33(h,J=7.4Hz,2H),0.90(t,J=7.3Hz,3H).

[0320] Example Compound I-135 7-Amino-5-(butylamino)-3-(4-(piperazine-1-carbonyl)benzyl)pyrimidine[4,5-d]pyrimidin-4(3H)-one [ka] The synthesis of compound I-135 was carried out by referring to the synthesis of compound I-132, and using intermediate Int.T8 instead of intermediate I-132-1. MS: 437.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.41(t,J=5.9Hz,1H),9.14(s,2H),8.96(s,1H),8.57(s,1H),8.28(s,1H),7.45(s,4H),5.21(s,2H) ),3.94-3.36(m,6H),3.14(s,4H),1.62-1.47(m,2H),1.31(q,J=7.5Hz,2H),0.89(t,J=7.3Hz,3H).

[0321] Example Compound I-136 2-Amino-4-(heptan-4-ylamino)-6-(4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-2-methoxybenzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-136 was carried out by referring to the synthesis of compound I-132, except that 2-(piperazin-1-yl)ethan-1-ol was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-136. MS: 552.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.02(d,J=7.3Hz,1H) 8.08(d,J=7.3Hz,1H),7.14(d,J=7.7Hz,1H),7.09(s,1H),7.00(dd,J=7.5,1.5Hz,1H),6.44(d,J=7.2Hz,1H),5.11(s,2H),4.34-4.26(m ,1H),3.86(s,3H),3.75-3.70(m,2H),3.60-3.55(m,4H),3.22-3.06(m,6H),1.60-1.45(m,4H),1.35-1.20(m,4H),0.87(t,J=7.2Hz,6H).

[0322] Example Compound I-137 (R)-2-Amino-4-(hexan-3-ylamino)-6-(4-(piperazine-1-carbonyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-137, the synthesis of compound I-126 was referred to, and intermediate Int.T2 was used instead of intermediate Int.M to prepare compound I-137. MS: 464.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.30(d,J=8.7Hz,1H),8.21(d,J=1.0Hz,1H),7.70(d,J=7.5Hz,1H),7.38-7.29(m,4H),6.60(br,2H),6.09(d,J=7.5Hz,1H),5.08(s,2H), 4.20-4.10(m,1H),3.62-3.48(m,2H),3.28(s,2H),2.82-2.65(m,4H),1.61-1.37(m,4H),1.35-1.20(m,2H),0.86(dt,J=9.2,7.3Hz,6H).

[0323] Example Compound I-138 (R)-2-Amino-4-(hexan-3-ylamino)-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-138 was carried out by referring to the synthesis of compound I-5, and intermediate I-137-1 was used instead of intermediate I-5-1 to prepare compound I-138. MS: 435.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.33(d,J=8.8Hz,1H),8.19(s,1H),7.67(d,J=7.5Hz,1H),7.33-7.19(m,4H),6.59(br,2H),6.07(d,J=7.5Hz,1H),5.03(s,2H),4.20 -4.10(m,1H),3.63(s,2H),2.52-2.46(m,4H),1.74-1.65(m,4H),1.61-1.38(m,4H),1.36-1.23(m,2H),0.86(dt,J=9.0,7.3Hz,6H).

[0324] Example Compound I-139 (R)-2-Amino-6-(4-((2-hydroxyethyl)(methyl)amino)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-139 was carried out by referring to the synthesis of compound I-103, except that 2-(methylamino)ethan-1-ol was used instead of pyrrolidine to prepare compound I-139. MS: 425.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.33(d,J=8.2Hz,1H),7.67(d,J=7.6Hz,1H),7.29-7.17(m,4H),6.60(br ,2H),6.07(d,J=7.5Hz,1H),5.10-4.94(m,2H),4.21(p,J=6.8Hz,1H),3.4 9-3.45(m,2H),3.44(s,2H),2.38(t,J=6.4Hz,2H),2.11(s,3H),1.54-1.4 3(m,2H),1.37-1.25(m,2H),1.14(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).

[0325] Example Compound I-140 (R)-2-Amino-6-(4-((2-hydroxyethyl)(propyl)amino)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-140 was carried out by referring to the synthesis of compound I-103, except that 2-(propylamino)ethan-1-ol was used instead of pyrrolidine to prepare compound I-140. MS: 453.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.34(d,J=8.2Hz,1H),8.18(s,1H),7.68(d,J=7.5Hz,1H),7.31-7.15(m,4H),6.63(b r,2H),6.07(d,J=7.5Hz,1H),5.09-4.93(m,2H),4.21(p,J=6.8Hz,1H),3.55(s,2H), 3.44(t,J=6.6Hz,2H),2.46(t,J=6.6Hz,2H),2.39-2.33(m,2H),1.53-1.38(m,4H),1 .37-1.26(m,2H),1.14(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H),0.79(t,J=7.3Hz,3H).

[0326] Example Compound I-141 (R)-2-Amino-6-(4-((bis(2-hydroxyethyl)amino)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] Compound I-141 was prepared by following the synthesis of compound I-103, except that diethanolamine was used instead of pyrrolidine. MS: 455.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.34(d,J=8.2Hz,1H),8.15(s,1H),7.68(d,J=7.6Hz,1H),7.34-7.16(m,4 H),6.63(br,2H),6.08(d,J=7.5Hz,1H),5.09-4.93(m,2H),4.21(p,J=6.8H z,1H),3.62(s,2H),3.44(t,J=6.3Hz,4H),2.53(t,J=6.3Hz,4H),1.54-1. 42(m,2H),1.38-1.25(m,2H),1.14(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).

[0327] Example Compound I-142 (S)-6-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)benzyl)-2-amino-4-((1-hydroxyhexan-3-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-142 was carried out by referring to the synthesis of compound I-118, except that 2-oxa-6-aza-spiro[3,3]heptane was used instead of pyrrolidine to prepare compound I-142. MS: 479.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.75(s,1H),7.98(s,1H),7.58(s,1H),7.41(d,J=8.2Hz,2H),7.33(d,J=7.9Hz,2H),6.29(d,J=7.4Hz,1H),5.19-5 .08(m,2H),4.70-4.10(m,13H),3.44(t,J=6.6Hz,2H),1.79-1.45(m,4H),1.38-1.21(m,2H),0.87(t,J=7.3Hz,3H).

[0328] Example Compound I-143 (S)-2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-((4-methylpiperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-143 was carried out by referring to the synthesis of compound I-118, except that 1-methylpiperazine was used instead of pyrrolidine to prepare compound I-143. MS: 480.6 [M+H] +

[0329] Example Compound I-144 (S)-2-Amino-4-((1-hydroxyhexan-3-yl)amino)-6-(4-(piperazin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-144 was carried out by referring to the synthesis of compound I-118, except that piperazine-1-carboxylate-t-butyl was used instead of pyrrolidine to prepare compound I-144. MS: 480.6 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.11(d,J=8.8Hz,1H),9.03(s,2H),8.55-8.16(m,3H),7.45-7.27(m,4H),6.43(d,J=7.4Hz,1H),5.18 (s,2H),4.91-3.06(m,10H),2.84(s,3H),1.82-1.48(m,4H),1.39-1.22(m,2H),0.88(t,J=7.3Hz,3H).

[0330] Example Compound I-147 7-Amino-5-(butylamino)-3-(4-(piperazin-1-ylmethyl)benzyl)pyrimidine[4,5-d]pyrimidin-4(3H)-one [ka] The synthesis of compound I-147 was carried out by referring to the synthesis of compound I-107, and compound I-147 was prepared by using intermediate Int.T8 instead of intermediate I-107-1. MS: 423.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.42(s,1H),8.95(s,1H),8.81(s,2H),8.56(s,1H),7.91(s,1H),7.38(s,4H),5.16(s,2H),3.51(q,J=6.7H z,2H),3.17(s,4H),2.78(s,4H),1.55(q,J=7.3Hz,2H),1.30(dt,J=14.6,7.4Hz,2H),0.90(t,J=7.4Hz,3H).

[0331] Example Compound I-148 (R)-2-Amino-6-(4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-148 was carried out by referring to the synthesis of compound I-103, except that 2-(piperazin-1-yl)ethan-1-ol was used instead of pyrrolidine to prepare compound I-148. MS: 480.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.34(d,J=8.2Hz,1H),8.20(s,1H),7.68(d,J=7.5Hz,1H),7.35-7.14(m,4H ),6.68(s,2H),6.08(d,J=7.5Hz,1H),5.09-4.94(m,2H),4.31-4.12(m,1H), 3.50(t,J=6.1Hz,2H),3.43(s,2H),2.67-2.49(m,6H),2.39(s,4H),1.56-1 .40(m,2H),1.39-1.23(m,2H),1.14(d,J=6.5Hz,3H),0.87(t,J=7.2Hz,3H).

[0332] Example Compound I-149 2-Amino-4-(butyl mercaptan)-6-(4-(piperazin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-149 was carried out by referring to the synthesis of compound I-1, and using intermediate Int.T4 instead of intermediate Int.A to prepare compound I-149. MS: 439.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 8.78(d,J=4.3Hz,1H),8.12(d,J=4.3Hz,1H),7.92(d,J=7.6Hz,1H),7.30-7.23(m,4H),6.32(d,J=7.4Hz,1H),5.10(s,2H),3.47( s,2H),3.07(t,J=7.3Hz,2H),3.03-2.90(m,4H),2.50-2.41(m,4H),1.68-1.54(m,2H),1.44-1.37(m,2H),0.90(t,J=7.3Hz,3H).

[0333] Example Compound I-150 (R)-6-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)benzyl)-2-amino-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-150 was carried out by referring to the synthesis of compound I-103, except that 2-(piperazin-1-yl)ethan-1-ol was used instead of pyrrolidine to prepare compound I-150. MS: 449.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.33(d,J=8.2Hz,1H),8.17(s,2H),7.68(d,J=7.5Hz,1H),7.26-7.16( m,4H),6.65(s,2H),6.08(d,J=7.5Hz,1H),5.10-4.93(m,2H),4.58(s,4 H),4.27-4.15(m,1H),3.55(s,2H),2.51(d,J=1.8Hz,1H),1.52-1.42(m,2H),1.39-1.24(m,2H),1.14(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).

[0334] Example Compound I-151 6-(4-(3,6-diazacyclo[3.1.1]heptane-3-carbonyl)benzyl)-2-amino-4-((R)-pentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-151 was carried out by referring to the synthesis of compound I-117, except that 6-(tert-butoxycarbonyl)-3,6-diazadicyclo[3.1.1]heptane was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-151. MS: 462.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.03(d,J=8.3Hz,1H),9.74(s,1H),8.37(s,3H),8.22(d,J=7.4Hz,1H),7.47 (d,J=8.2Hz,2H),7.39(d,J=8.0Hz,2H),6.44(d,J=7.4Hz,1H),5.23(q,J=15.0 Hz,2H),4.48-2.77(m,7H),1.82(dd,J=10.4,4.6Hz,1H),1.63-1.48(m,2H),1. 32(dtd,J=10.4,6.7,3.3Hz,2H),1.21(d,J=6.5Hz,3H),0.89(t,J=7.3Hz,3H).

[0335] Example Compound I-152 (R)-2-Amino-6-(2-chloro-4-(pyrrolidin-1-ylmethyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-152 was carried out by referring to the synthesis of compound I-5, using intermediate Int.L instead of intermediate Int.A, and using 4-(bromomethyl)-3-chlorobenzoic acid methyl instead of 4-(bromomethyl)-2-methoxybenzoic acid methyl to prepare compound I-152. MS: 456.3 [M + H] + . 1H NMR(400MHz,DMSO-d6) δ 9.24(d,J=8.2Hz,1H),8.17(s,1H),7.61(d,J=7.6Hz,1H),7.44(d,J=1.6Hz,1H),7.24 (dd,J=7.9,1.7Hz,1H),6.86(d,J=7.9Hz,1H),6.67(br,2H),6.13(d,J=7.5Hz,1H),5.0 9(q,J=16.0Hz,2H),4.25-4.15(m,1H),3.62(s,2H),2.49-2.44(m,4H),1.73-1.66(m,4 H),1.50-1.42(m,2H),1.36-1.24(m,2H),1.13(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0336] Example Compound I-153 (R)-2-Amino-6-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-153 was carried out by referring to the synthesis of compound I-152, except that 2-((5-(bromomethyl)pyridin-2-yl)oxy)-N-methylethan-1-amine was used instead of methyl 4-(bromomethyl)-3-chlorobenzoate to prepare compound I-153. MS: 412.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.03(d,J= 8.6Hz,1H),8.69(s,1H),8.26-8.13(m 3H),7.76(d,J=8.6Hz,1H),6.85(d,J=8.6Hz,1H),6.42(d,J=7.4Hz,1H),5.13(q,J=14.6Hz,2H),4.45(d,J=5.8Hz,2H),4.32-4 .22(m,1H),3.35-3.26(m,2H),2.61(s,3H),1.61-1.50(m,2H),1.37-1.26(m,2H),1.21(d,J=6.5Hz,3H),0.89(t,J=7.3Hz,3H).

[0337] Example Compound I-154 (R)-2-Amino-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-154, refer to the synthesis of compound I-5, and use intermediate Int.L instead of intermediate Int.A to prepare compound I-154. MS: 451.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.32(d,J=8.2Hz,1H),8.19(s,1H),7.56(d,J=7.5Hz,1H),6.98(s,1H),6.85(d, J=1.5Hz,2H),6.59(br,2H),6.07(d,J=7.5Hz,1H),5.02-4.87(m,2H),4.20(p,J =6.8Hz,1H),3.82(s,3H),3.60(s,2H),2.49-2.45(m,4H),1.73-1.65(m,4H),1. 52-1.43(m,2H),1.38-1.22(m,2H),1.13(d,J=6.5Hz,3H),0.87(t,J=7.2Hz,3H).

[0338] Example Compound I-156 2-Amino-4-(butylamino)-6-((5-(pyrrolidin-1-ylmethyl)pyrimidin-2-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-156 was carried out by referring to the synthesis of compound I-2, except that methyl 2-(bromomethyl)pyrimidine-5-carboxylate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate to prepare compound I-156. MS: 409.2 [M+H] + .

[0339] Example Compound I-157 (R)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-157 was carried out by referring to the synthesis of compound I-5, and using intermediate Int.T5 instead of intermediate Int.A to prepare compound I-157. MS: 467.3 [M+H] + .

[0340] Example Compound I-158 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-158 was carried out by referring to the synthesis of compound I-5, and using intermediate Int.T1 instead of intermediate Int.A to prepare compound I-158. MS: 467.3 [M+H] + .

[0341] Example Compound I-159 (R)-2-Amino-6-(2-methyl-4-(pyrrolidin-1-ylmethyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-159 was carried out by referring to the synthesis of compound I-5, using intermediate Int.L instead of intermediate Int.A, and using 4-(bromomethyl)-3-methylbenzoic acid methyl ester instead of 4-(bromomethyl)-3-methoxybenzoic acid methyl ester to prepare compound I-159. MS: 435.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.33(d,J=8.2Hz,1H),8.19(s,1H),7.51(d,J=7.6Hz,1H),7.18(s,1H),7.10(d,J=7. 8,1H),6.74(d,J=7.8Hz,1H),6.64(br,2H),6.11(d,J=7.5Hz,1H),5.02(q,J=15.7Hz, 2H),4.25-4.15(m,1H),3.62(s,2H),2.55-2.52(m,4H),2.29(s,3H),1.74-1.67(m,4H ),1.51-1.43(m,2H),1.37-1.26(m,2H),1.14(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0342] Example Compound I-160 (R)-2-Amino-6-(4-((2-hydroxyethyl)(methyl)amino)methyl)-2-methoxybenzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-160 was carried out by referring to the synthesis of compound I-154, except that 2-(methylamino)ethan-1-ol was used instead of pyrrolidine to prepare compound I-160. MS: 455.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.32(d,J=8.2Hz,1H),8.17(s,1H),7.57(d,J=7.5Hz,1H),7.01(s,1H),6.87- 6.82(M,2H),6.62(br,2H),6.07(d,J=7.5Hz,1H),5.01-4.87(m,2H),4.25-4.1 5(m,1H),3.82(s,3H),3.54-3.48(m,4H),2.48-2.41(m,2H),2.20(s,3H),1.51 -1.42(m,2H),1.36-1.25(m,2H),1.13(d,J=6.4Hz,3H),0.87(t,J=7.2Hz,3H).

[0343] Example Compound I-161 6-(4-(3,6-diazacyclo[3.1.1]heptane-6-carbonyl)benzyl)-2-amino-4-(((R)-pentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-161 was carried out by referring to the synthesis of compound I-117, except that tert-butyl 3,6-diazadicyclo[3.1.1]heptane-3-carboxylate was used instead of tert-butyl piperazine-1-carboxylate to prepare compound I-161. MS: 462.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.02(t,J=8.4Hz,1H),9.66-9.29(m,2H),8.51-8.15(m,3H),7.70-7.63(m,1H),7 .47(d,J=8.2Hz,1H),7.39(dd,J=8.2,3.7Hz,2H),6.45(d,J=7.4Hz,1H),5.24(qd,J =15.1,5.3Hz,2H),4.71-2.77(m,7H),1.86(d,J=9.7Hz,1H),1.55(dq,J=8.7,6.4H z,2H),1.40-1.26(m,2H),1.21(dd,J=6.5,1.8Hz,3H),0.89(td,J=7.3,1.3Hz,3H).

[0344] Example Compound I-162 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-((4-methylpiperazin-1-yl)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-162 was carried out by referring to the synthesis of compound I-158, except that 1-methylpiperazine was used instead of pyrrolidine to prepare compound I-162. MS: 496.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.77(s,1H),7.80(s,1H),7.36(s,1H),6.97(d,J=8.1Hz,2H),6.86(d,J=7.6Hz,1H),6.23(d,J=7.5Hz,1H),5.08-4.84( m,3H),4.26-4.16(m,1H),3.83(s,3H),3.61-2.59(m,16H),1.60-1.43(m,2H),1.35-1.28(m,2H),0.88(t,J=7.3Hz,3H).

[0345] Example Compound I-163 (S)-2-Amino-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)-4-((1-methoxypentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-163 was carried out by referring to the synthesis of compound I-5, and using intermediate Int.T6 instead of intermediate Int.A to prepare compound I-163. MS: 481.3 [M+H] + .

[0346] Example Compound I-164 (S)-2-Amino-4-((1-hydroxyhexan-2-yl)amino)-6-(2-methoxy-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-164 was carried out by referring to the synthesis of compound I-5, and using intermediate Int.T7 instead of intermediate Int.A to prepare compound I-164. MS: 481.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.39(s,1H),10.22(s,1H),10.17(d,J=8.7Hz,1H),8.30(s,2H),8.09(d,J=7.5Hz,1H),7.23(d,J=1.6H z,1H),7.12(d,J=7.7Hz,1H),7.05(dd,J=7.6,1.5Hz,1H),6.42(d,J=7.5Hz,1H),5.18-5.02(m,2H),4.32 (d,J=5.0Hz,2H),4.23(s,1H),3.91-3.81(m,3H),3.57-3.44(m,2H),3.36(s,2H),3.08(s,2H),2.11-1.9 5(m,2H),1.93-1.77(m,2H),1.72-1.58(m,1H),1.58-1.46(m,1H),1.38-1.18(m,4H),0.89-0.80(m,3H).

[0347] Example Compound I-165 (R)-2-Amino-6-(4-((2-hydroxyethyl)(propyl)amino)methyl)-2-methoxybenzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-165 was carried out by referring to the synthesis of compound I-154, except that 2-(propylamino)ethan-1-ol was used instead of pyrrolidine to prepare compound I-165. MS: 483.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.33(d,J=8.2Hz,1H),8.16(s,1H),7.56(d,J=7.6Hz,1H),7.01(s,1H),6.84(s,2H),6.60(br,2H),6.07(d,J=7.5Hz,1H),5.03- 4.86(m,2H),4.25-4.15(m,1H),3.81(s,3H),3.57(s,2H),3.46(t,J=6.5Hz,2H),2.50-2.47(m,2H),2.42-2.36( m,2H),1.51-1.38(m,4H),1.35-1.25(m,2H),1.14(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H),0.82(t,J=7.3Hz,3H).

[0348] Example Compound I-166 (R)-2-Amino-6-(4-((bis(2-hydroxyethyl)amino)methyl)-2-methoxybenzyl)-4-(pentyl-2-amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-166 was carried out by referring to the synthesis of compound I-154, except that diethanolamine was used instead of pyrrolidine to prepare compound I-166. MS: 485.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.32(d,J=8.2Hz,1H),8.16(s,1H),7.56(d,J=7.5Hz,1H),7.04(s,1H),6.84( s,2H),6.59(br,2H),6.07(d,J=7.5Hz,1H),5.04-4.84(m,2H),4.25-4.15(m, 1H),3.82(s,3H),3.62(s,2H),3.45(t,J=6.3Hz,4H),2.55-2.50(m,4H),1.52 -1.43(m,2H),1.38-1.24(m,2H),1.14(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).

[0349] Example Compound I-168 (S)-2-Amino-6-(2-chloro-4-(pyrrolidin-1-ylmethyl)benzyl)-4-((1-hydroxypentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-168 was carried out by referring to the synthesis of compound I-158, except that methyl 4-(bromomethyl)-3-chlorobenzoate was used instead of methyl 4-(bromomethyl)-3-methoxybenzoate. MS: 472.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.33(d,J=8.5Hz,1H),8.17(s,1H),7.62(d,J=7.5Hz,1H),7.44(s,1H),6.87(d,J=7.9Hz,1H),6.63(s,2H),6.12(d,J=7.5Hz,1H),5.09(q,J=1 6.0Hz,2H),4.24-4.15(m,1H),3.63(s,2H),3.50-3.38(m,2H),1.83-1. 66(m,4H),1.66-1.37(m,2H),1.38-1.22(m,1H),0.87(t,J=7.3Hz,3H).

[0350] Example Compound I-169 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methyl-4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-169 was carried out by referring to the synthesis of compound I-158, except that 4-(bromomethyl)-3-methylbenzoic acid methyl was used instead of 4-(bromomethyl)-3-methoxybenzoic acid methyl. MS: 451.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.42(d,J=8.5Hz,1H),8.20(s,1H),7.51(d,J=7.5Hz,1H),7.18(s,1H),7.10(d,J=6.1Hz,1H), 6.75(d,J=7.8Hz,1H),6.61(s,2H),6.10(d,J=7.5Hz,1H),5.10-4.93(m,2H),4.25-4.15(m,1H) ,3.52-3.37(m,2H),2.54(s,3H),2.51(d,J=1.9Hz,1H),2.49(d,J=1.9Hz,1H),2.30(s,3H),1.7 5-1.67(m,4H),1.65-1.52(m,1H),1.51-1.37(m,1H),1.39-1.23(m,2H),0.87(t,J=7.3Hz,3H).

[0351] Example Compound I-170 2-Amino-4-((1-hydroxyhexan-3-yl)oxy)-6-((6-(2-(methylamino)ethoxy)pyridin-3-yl)methyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-170 was carried out by referring to the synthesis of compound I-158, using intermediate Int.T9 instead of intermediate Int.T1, and using 2-((5-(bromomethyl)pyridin-2-yl)oxy)-N-methylethan-1-amine instead of methyl 4-(bromomethyl)-3-methylbenzoate to prepare compound I-170. MS: 443.3 [M+H] + .

[0352] Example Compound I-171 2-((4-((2-amino-4-(butylamino)-5-oxopyrido[4,3-d]pyrimidin-6(5H)-yl)methyl)benzyl)(methyl)amino)diethylcarbamate ethyl [ka] The synthesis of compound I-171 was carried out by referring to the synthesis of compound I-1, except that 2-(methylamino)ethyl diethyl carbamate was used instead of pyrrolidine to prepare compound I-171. MS: 510.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.12(t,J=5.8Hz,1H),10.10-9.92(brs,1H),8.55-8.25(m,2H),8.20(d,J=7.4H z,1H),7.50(d,J=7.8Hz,2H),7.38(d,J=7.8Hz,2H),6.43(d,J=7.4Hz,1H),5.21(s ,2H),4.44-4.21(m,4H),3.53(q,J=6.7Hz,2H),3.34(s,2H),3.20(q,J=7.1Hz,5H) ,2.74(s,3H),1.56(m,2H),1.34(m,2H),1.08-0.96(m,6H),0.91(t,J=7.3Hz,3H).

[0353] Example Compound I-174 4-(Butylamino)-6-(4-(piperazin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-174 was carried out by referring to the synthesis of compound I-1, using intermediate Int.T10 instead of intermediate Int.A, and using piperazine-1-carboxylate-t-butyl instead of pyrrolidine. MS: 407.3 [M+H] + .

[0354] Example Compound I-175 [ka] The synthesis of compound I-175 was carried out by referring to the synthesis of compound I-1, except that diethyl (4-(piperazin-1-yl)butyl)phosphonate was used instead of pyrrolidine to prepare compound I-175. MS: 614.3 [M+H] + . Example Compound I-176 [ka] Compound I-177 and TMSBr in dichloromethane were reacted for 5 hours with stirring at 25°C. The reaction mixture was then concentrated to obtain a crude product, which was then purified by prep-HPLC to prepare compound I-176. MS: 588.4 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.22(d,J=8.6Hz,1H),8.42(s,1H),8.20(d,J=7.5Hz,1H),7.33(q,J=8.0Hz,4 H),6.44(d,J=7.4Hz,1H),5.25-5.10(m,2H),4.26(s,1H),3.73(s,2H),3.59-3 .46(m,2H),3.40(s,2H),3.02(s,5H),2.50(p,J=1.8Hz,5H),1.67(s,2H),1.63 -1.54(m,1H),1.54-1.43(m,2H),1.32(q,J=7.5Hz,2H),0.89(t,J=7.3Hz,3H).

[0355] Example Compound I-177 [ka] The synthesis of compound I-177 was carried out by referring to the synthesis of compound I-1, except that diethyl (4-(piperazin-1-yl)butyl)phosphonate was used instead of pyrrolidine to prepare compound I-177. MS: 644.3 [M+H] + . Example Compound I-178 [ka] A solution of compound I-175 and TMSBr in dichloromethane was reacted for 5 hours with stirring at 25 degrees. The reaction mixture was then concentrated to give a crude product, which was then purified by prep-HPLC to give compound I-178. MS: 558.4 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 12.46(s,1H),10.17(t,J=5.8Hz,1H),8.53(s,1H),8.26(dd,J=7.5,2.2Hz,1H),7 .54(s,2H),7.38(d,J=7.5Hz,2H),6.51(d,J=7.4Hz,1H),5.23(s,2H),4.38(s,3H) ),3.65(s,2H),3.58-3.48(m,2H),3.17(s,7H),3.16-3.04(m,1H),1.72(s,1H),1 .63-1.49(m,5H),1.41-1.26(m,2H),1.18(t,J=7.3Hz,1H),0.91(t,J=7.3Hz,3H).

[0356] Example Compound I-179 (R)-2-Amino-6-(2-methoxy-4-((4-methylpiperazin-1-yl)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-179 was carried out by referring to the synthesis of compound I-154, except that 4-methylpiperazine was used instead of pyrrolidine to prepare compound I-179. MS: 480.3 [M+H] + .

[0357] Example Compound I-180 (R)-2-Amino-6-(2-methoxy-4-(piperazine-1-carbonyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-180 was carried out by referring to the synthesis of compound I-117, and using intermediate I-154-1 instead of intermediate I-103-1 to prepare compound I-180. MS: 480.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.52(s,1H),8.87(s,2H),7.75(s,1H),7.08(s,1H),6.98(s,2H),6.20(d,J=7.6Hz,1H),5.11-4.92(m,2H),4.11-4.22(m,1H),3.86 (s,4H),3.13(s,5H),2.51(s,1H),2.35(s,2H),1.53-1.42(m,2H),1.21-1.32(m,2H),1.14(d,J=6.5Hz,3H),0.86(t,J=7.3Hz,3H).

[0358] Example Compound I-181 6-(4-(3,6-diazadicyclo[3.1.1]heptane-3-carbonyl)-2-methoxybenzyl)-2-amino-4-((R)-pentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-181 was carried out by referring to the synthesis of compound I-151, and intermediate I-154-1 was used instead of intermediate I-103-1 to prepare compound I-181. MS: 492.2 [M+H] + .

[0359] Example Compound I-182 (R)-2-Amino-6-(2-methoxy-4-(4-methylpiperazine-1-carbonyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-182 was carried out by referring to the synthesis of compound I-180, except that 4-methylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-182. MS: 494.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.57(s,1H),7.78(d,J=7.5Hz,1H),7.27(s,2H),7.07-6.91(m,3H),6.22(d,J=7.5Hz,1H),5.11-4.95(m,2H),4.28-4.16(m,1H),3.8 5(s,3H),3.50(s,3H),2.99(s,5H),2.65(s,3H),1.53-1.43(m,2H),1.34-1.26(m,2H),1.15(d,J=6.5Hz,3H),0.86(t,J=7.2Hz,3H).

[0360] Example Compound I-183 (R)-2-Amino-6-(4-(4-isopropylpiperazine-1-carbonyl)-2-methoxybenzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-183 was carried out by referring to the synthesis of compound I-180, except that 4-isopropylpiperazine was used instead of piperazine-1-carboxylate-t-butyl to prepare compound I-183. MS: 522.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.60(s,1H),7.81(d,J=7.5Hz,1H),7.36(s,2H),7.08(s,1H),7.00(d,J=3.2Hz,2H),6.23(d,J=7.4Hz,1H),5.11-4.96(m,2H),4.22(p ,J=6.8Hz,1H),3.86(s,3H),3.03(s,3H),1.55-1.41(m,2H),1.37-1.25(m,2H),1.17(dd,J=15.5,6.4Hz,10H),0.86(t,J=7.2Hz,3H).

[0361] Example Compound I-184 (R)-2-Amino-6-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-184 was carried out by referring to the synthesis of compound I-154, except that piperazine-1-carboxylate-t-butyl was used instead of pyrrolidine to prepare compound I-184. MS: 466.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.58(s,1H),7.79(d,J=7.5Hz,1H),7.23(s,2H),7.08-6.92(m,3H),6.25(d,J=7.5Hz,1H),5.12-4.91(m,2H),4.27-4.13(m,1 H),3.85(s,3H),2.96(s,5H),2.63(s,3H),1.53-1.44(m,2H),1.34-1.26(m,2H),1.14(d,J=6.5Hz,3H),0.86(t,J=7.2Hz,3H).

[0362] Example Compound I-185 6-(4-(3,6-diazadicyclo[3.1.1]heptan-3-yl)methyl)-2-methoxybenzyl)-2-amino-4-((R)-pentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-185 was carried out by referring to the synthesis of compound I-154, except that 3,6-diazadicyclo[3.1.1]heptane-6-t-butyl formate was used instead of pyrrolidine to prepare compound I-185. MS: 478.2 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 13.50(s,2H),10.06(d,J=8.3Hz,1H),9.53(s,1H),8.38(d,J=42.3Hz,2H),8.06(d,J=7.4Hz,2H),7. 07(d,J=8.4Hz,2H),6.94(d,J=7.7Hz,1H),6.41(d,J=7.4Hz,1H),5.15-5.00(m,2H),4.33-4.18(m,3 H),3.94(s,2H),3.83(s,3H),3.25(d,J=50.4Hz,4H),2.69(s,1H),2.15(dd,J=10.0,5.2Hz,1H),1.5 3(q,J=7.0Hz,2H),1.31(ddt,J=13.4,10.4,4.8Hz,2H),1.20(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).

[0363] Example Compound I-187 2-Amino-4-(butylamino)-7-methyl-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-187, reference was made to the synthesis of compound I-1, and compound I-187 was prepared by using intermediate Int.T11 instead of intermediate Int.A. MS: 421.3 [M+H. 1 H NMR(400MHz,DMSO-d6) δ 9.64,(s,1H),7.32(m,6H),6.15(s,1H),5.29(s,2H),4.29(s,2H),3.45(q,J=6.6Hz,3H),3.17(m,4H), 2.28(d,J=2.2Hz,3H),1.91(s,4H),1.54(p,J=7.3Hz,2H),1.34(p,J=7.4Hz,2H),0.89(t,J=7.3Hz,3H).

[0364] Example Compound I-188 (R)-6-(6-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-2-methoxypyridin-3-yl)methyl)-2-amino-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-188 was carried out by referring to the synthesis of compound I-64, using intermediate Int.L instead of intermediate Int.A, and using 2-oxa-6-azaspiro[3.3]heptane instead of pyrrolidine. MS: 438.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 13.28(s,1H),10.74(s,1H),10.15(s,1H),10.02(d,J=8.3Hz,1H),8.32(d,J=84.0Hz,2H),8.07(d,J=7.4 Hz,1H),7.16(d,J=8.7Hz,1H),7.13-7.06(m,1H),7.01(t,J=9.0Hz,1H),6.42(d,J=7.4Hz,1H),5.16-5.01 (m,2H),4.39(s,1H),4.27(p,J=7.1Hz,3H),4.05(d,J=7.5Hz,4H),3.95-3.77(m,6H),3.45(d,J=26.3Hz,2 H),1.53(dt,J=13.0,6.7Hz,2H),1.31(q,J=7.2,6.7Hz,2H),1.19(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0365] Example Compound I-191 (S)-2-amino-4-(1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-191 was carried out by referring to the synthesis of compound I-158, except that piperazine-1-carboxylate-t-butyl was used instead of pyrrolidine to prepare compound I-191. MS: 482.3 [M+H] + . 1 H NMR(400MHz,Methanol-d4) δ 8.53(s,2H),7.73(d,J=7.6Hz,1H),7.24(d,J=7.7Hz,1H),7.04(s,1H),6.94(d, J=7.7Hz,1H),6.25(d,J=7.6Hz,1H),5.16-5.03(m,2H),4.38(t,J=6.6Hz,1H),3 .91(s,3H),3.74-3.55(m,4H),3.34(d,J=2.1Hz,2H),3.23(t,J=5.1Hz,4H),2.7 0(d,J=5.5Hz,4H),1.77-1.56(m,2H),1.55-1.38(m,2H),0.99(t,J=7.4Hz,3H).

[0366] Example Compound I-192 2-Amino-4-(butylamino)-7-phenyl-6-(4-(pyrrolidin-1-ylmethyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-192, refer to the synthesis of compound I-187, and use intermediate Int.T12 instead of intermediate Int.T11 to prepare compound I-192. MS: 483.3 [M+H. 1 H NMR(400MHz,DMSO-d6) δ 11.19(s,1H),9.62(s,1H),7.45(d,J=8.2Hz,3H),7.31(d,J=7.2Hz,2H),7.23(d,J=7.7Hz,2H),6.99(d,J=7.7Hz,2H),6.55(s,2H),4.0 5(s,2H),3.87(s,2H),3.48(m,2H),2.97(s,4H),1.87(s,4H),1.64-1.54(m,2H),1.46-1.36(m,2H),1.27(s,2H),0.96(t,J=7.4Hz,3H).

[0367] Example Compound I-194 (R)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-((4-methylpiperazin-1-yl)methyl)benzyl)pyrido[4,3d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-194 was carried out by referring to the synthesis of compound I-157, except that methylpiperazine was used instead of pyrrolidine to prepare compound I-194. MS: 496.3 [M+H] + .

[0368] Example Compound I-195 (S)-2-Amino-6-(4-((dimethylamino)methyl)-2-methoxybenzyl)-4-((1-hydroxypentan-2-yl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-195 was carried out by referring to the synthesis of compound I-158, except that dimethylamine hydrochloride was used instead of pyrrolidine to prepare compound I-195. MS: 441.5 [M+H] + .

[0369] Example Compound I-198 (R)-2-Amino-6-(2-methoxy-4-((methylamino)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-198 was carried out by referring to the synthesis of compound I-154, except that methylamine hydrochloride was used instead of pyrrolidine to prepare compound I-198. MS: 411.5 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 8.74(s,2H),7.17(s,1H),6.99(t,J=6.9Hz,2H),6.23(s,1H),5.02(d,J=7.3Hz,2H),4.23(s,1H),4.09(s,2H),3.85 (s,5H),2.55(s,3H),1.48(t,J=7.2Hz,2H),1.30(s,1H),1.23(s,2H),1.15(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0370] Example Compound I-207 (S)-2-Amino-6-(4-((4-(2-aminoethyl)piperazin-1-yl)methyl)-2-methoxybenzyl)-4-((1-hydroxypentan-2-yl)amino)pyrido[4,3d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-207 was carried out by referring to the synthesis of compound I-158, except that tert-butyl (2-(piperazin-1-yl)ethyl)carbamate was used instead of pyrrolidine to prepare compound I-207. MS: 525.32 [M+H] + .

[0371] Example Compound I-208 (S)-2-Amino-6-(4-(((2-aminoethyl)(methyl)amino)methyl)-2-methoxybenzyl)-4-((1-hydroxypentan-2-yl)amino)pyrido[4,3d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-208 was carried out by referring to the synthesis of compound I-158, except that tert-butyl (2-(methylamino)ethyl)carbamate was used instead of pyrrolidine to prepare compound I-208. MS: 470.28 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.23(s,1H),8.11(d,J=7.3Hz,1H),7.14(s,2H),7.02(s,1H),6.48(d,J =7.3Hz,1H),5.13(d,J=6.7Hz,2H),4.30(s,1H),3.90(s,4H),3.55(d,J= 6.6Hz,5H),2.75-2.68(m,2H),2.58(s,3H),2.40-2.33(m,2H),1.70-1.6 2(m,1H),1.60-1.49(m,1H),1.36(q,J=7.6Hz,2H),0.93(d,J=7.4Hz,3H).

[0372] Example Compound I-209 (R)-2-Amino-6-(2-methoxy-4-((4-(methylamino)piperidin-1-yl)methyl)benzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-209 was carried out by referring to the synthesis of compound I-154, and compound I-209 was prepared by using tert-butyl methyl(piperidin-4-yl)carbamate instead of pyrrolidine. MS: 494.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.31(d,J=8.1Hz,1H),8.32(s,2H),7.55(d,J=7.6Hz,1H),6.93(s,1H),6.86(d,J=7.6Hz,1H),6.8 0(d,J=7.7Hz,1H),6.59(s,1H),6.07(d,J=7.6Hz,1H),5.00-4.88(m,2H),4.20(p,J=6.8Hz,2H),4. 02-3.85(m,4H),3.81(s,3H),2.82(d,J=11.5Hz,2H),2.45(s,3H),1.93(d,J=12.6Hz,2H),1.89(s, 1H),1.49-1.44(m,3H),1.30(dt,J=13.6,7.0Hz,2H),1.13(d,J=6.5Hz,3H),0.87(t,J=7.3Hz,3H).

[0373] Example Compound I-211 6-(4-(3,6-diazadicyclo[3.1.1]heptane-3-carbonyl)-2-methoxybenzyl)-2-amino-4-(((S)-1-hydroxypentan-2-yl)amino)pyrido[4,3d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-211, the synthesis of compound I-115 was followed, and intermediate I-158-1 was used instead of intermediate I-95-1 to prepare compound I-211. MS: 508.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.42(d,J=8.5Hz,1H),8.24(s,1H),7.65(d,J=7.5Hz,1H),7.12(s,1H),7.00(d ,J=2.3Hz,2H),6.62(s,1H),6.14(d,J=7.5Hz,1H),5.04(q,J=15.7Hz,2H),4.23 (s,1H),3.87(s,1H),3.73(t,J=11.8Hz,4H),3.59-3.43(m,9H),1.60(d,J=9.2 Hz,2H),1.55-1.42(m,1H),1.34(dd,J=14.2,6.0Hz,2H),0.92(t,J=7.3Hz,3H).

[0374] Example Compound I-212 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-(4-methylpiperazine-1-carbonyl)benzyl)pyrido[4,3d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-212 was carried out by referring to the synthesis of compound I-115, and intermediate I-158-1 was used instead of intermediate I-95-1 to prepare compound I-212. MS: 510.3 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 10.00(s,1H),8.00(d,J=7.6Hz,1H),7.17-7.08(m,2H),7.01(dd,J=7.6,1.4Hz,1H),6.38(d,J=7.4Hz,1H),5.23-5.04(m,2H) ,4.97(s,1H),4.27(s,1H),3.90(s,3H),3.53(s,3H),3.37(s,12H),2.79(s,3H),1.34(q,J=7.5Hz,2H),0.91(t,J=7.3Hz,3H).

[0375] Example Compound I-213 (R)-2-Amino-6-(4-((4-(2-aminoethyl)piperazin-1-yl)methyl)-2-methoxybenzyl)-4-(pentan-2-ylamino)pyrido[4,3d]pyrimidin-5(6H)-one [ka] For the synthesis of compound I-213, the synthesis of compound I-207 was referred to, and intermediate I-154-2 was used instead of intermediate I-158-2 to prepare compound I-213. MS: 509.5 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 10.47(s,1H),9.98(d,J=8.4Hz,1H),8.27(s,1H),8.05(d,J=7.4Hz,1H),7.77(s ,2H),7.23(s,1H),7.12-7.01(m,2H),6.40(d,J=7.4Hz,1H),5.15-5.03(m,2H), 4.30-4.24(m,2H),3.85(s,3H),3.55-3.25(m,8H),2.92(s,4H),2.56(s,1H),1. 57-1.43(m,2H),1.36-1.27(m,2H),1.19(d,J=6.5Hz,3H),0.88(t,J=7.3Hz,3H).

[0376] Example Compound I-214 (S)-2-Amino-4-((1-hydroxypentan-2-yl)amino)-6-(2-methoxy-4-((methylamino)methyl)benzyl)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-214 was carried out by referring to the synthesis of compound I-158, except that methylamine hydrochloride was used instead of pyrrolidine to prepare compound I-214. MS: 427.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6) δ 9.41(d,J=8.6Hz,1H),7.64(d,J=7.6Hz,1H),7.20(s,1H),7.03-6.98(m,2H),6.64 (s,1H),6.12(d,J=7.5Hz,1H),5.01(q,J=15.5Hz,2H),4.81(s,1H),4.28-4.17(m, 1H),4.14-4.07(m,4H),3.88(s,3H),3.54-3.42(m,2H),2.59(s,3H),1.60(dq,J=1 3.9,6.8Hz,1H),1.46(td,J=13.8,8.5Hz,1H),1.33(s,2H),0.90(t,J=7.3Hz,3H).

[0377] Example Compound I-216 (R)-2-Amino-6-(4-((4-(3-hydroxypropyl)piperazin-1-yl)methyl)-2-methoxybenzyl)-4-(pentan-2-ylamino)pyrido[4,3-d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-216 was carried out by referring to the synthesis of compound I-154. MS: 524.6 [M+H] + . 1H NMR(400MHz,DMSO-d6) δ 9.34(d,J=8.1Hz,1H),7.58(d,J=7.6Hz,1H),6.96(d,J=1.3Hz,1H),6.92-6.81(m,2H),6.6 3(s,2H),6.08(d,J=7.5Hz,1H),5.02-4.89(m,2H),4.29-4.16(m,1H),3.84(d,J=7.6Hz,3H) ),3.46-3.40(m,4H),2.72(s,1H),2.51(p,J=1.9Hz,6H),2.38(t,J=7.3Hz,4H),1.63-1.54 (m,2H),1.53-1.45(m,2H),1.38-1.28(m,2H),1.15(d,J=6.5Hz,3H),0.89(t,J=7.3Hz,3H).

[0378] Example Compound I-217 (S)-2-Amino-6-(4-((4-(6-aminohexyl)piperazin-1-yl)methyl)-2-methoxybenzyl)-4-((1-hydroxypentan-2-yl)amino)pyrido[4,3d]pyrimidin-5(6H)-one [ka] The synthesis of compound I-217 was carried out by referring to the synthesis of compound I-158. MS: 581.3 [M+H] + .

[0379] Example Compound I-220 [ka]

[0380] Step 1: Preparation of intermediate I-220-1 2,2-Dimethylbutyryl chloride (1.1 mL, 8.4 mmol) and pyridine (0.7 mL, 8.4 mmol) were added slowly in sequence to a dichloromethane (10 mL) solution of intermediate T13 (2.335 g, 16.89 mmol) at 0° C. under stirring, and the reaction mixture was reacted for 12 hours under stirring at 20° C. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with water and saturated saline respectively, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was purified by silica gel column chromatography to obtain a yellow oil intermediate I-220-1 (619 mg, 56%). MS: 630.2 [M+H] +

[0381] Step 2: Preparation of intermediate I-220-2 Methylpiperazine (164 microliters, 1.5 mmol) and sodium cyanoborohydride (312 mg, 1.5 mmol) were added to the reaction mixture of intermediate I-220-1 (619 mg, 1 mmol) in acetonitrile (5 mL) under the protection of nitrogen gas, and the reaction mixture was reacted for 2 hours with stirring at 20°C. Then, the reaction mixture was diluted with water and extracted with ethyl acetate, the organic phase was washed with saturated saline, dried over anhydrous sodium sulfate, and filtered and concentrated to obtain the crude product, which was purified by pre-HPLC to prepare yellow oil intermediate I-220-2 (238 mg, 34%). MS: 714.4 [M+H] +

[0382] Step 3: Preparation of compound I-220 The synthesis of compound I-220 was carried out by referring to the synthesis of compound I-11-2, and using intermediate I-220-2 instead of intermediate I-11-1 to prepare compound I-220. MS: 594.3 [M+H] + . 1H NMR (400MHz, CDCl3) δ 15.41(s,1H),10.05(s,1H),7.72(d,J=7.3Hz,1H),7.42(d,J=7.6Hz,1H),7.10(s,1H),6.95(d,J=7.5Hz ,1H),6.58(d,J=7.4Hz,1H),5.61(s,1H),5.22-4.95(m,2H),4.63(t,J=4.3Hz,1H),4.29-4.12(m,2H),3 .97(s,2H),3.91(s,3H),3.49(s,4H),3.31(s,4H),2.87(s,3H),1.70(q,J=7.5Hz,2H),1.61(q,J=7.5Hz ,2H),1.45(dt,J=14.9,7.3Hz,2H),1.20(d,J=4.4Hz,6H),1.00(t,J=7.3Hz,3H),0.84(t,J=7.5Hz,3H).

[0383] Example Compound I-221

change

[0384] Example Compound I-222

change

[0385] Example Compound I-223 [ka] The synthesis of compound I-223 was carried out by referring to the synthesis of compound I-220. MS: 580.3 [M+H] + . 1H NMR(400MHz,CDCl3) δ 9.97(s,1H),7.71(d,J=7.1Hz,1H),7.41(d,J=7.5Hz,1H),7.14(s,1H),6.98(d,J=7.6Hz,1H),6.58( d,J=7.3Hz,1H),5.73(s,1H),5.11(s,2H),4.62(d,J=6.9Hz,1H),4.29(dd,J=11.3,4.3Hz,1H),4.15 (dd,J=11.4,5.3Hz,1H),4.08(s,2H),3.91(s,3H),3.57(s,4H),3.43(s,4H),2.89(s,3H),2.36(t,J =7.5Hz,2H),1.63(p,J=7.4Hz,4H),1.53-1.31(m,4H),0.99(t,J=7.3Hz,3H),0.93(t,J=7.3Hz,3H).

[0386] Example Compound I-224 & Compound I-225 [ka] Butyl chloroformate (176 microliters, 1.4 millimoles) and pyridine (168 microliters, 2.1 millimoles) were added slowly in sequence to a solution of compound I-191 (333 milligrams, 0.7 millimoles) in dichloromethane (3 milliliters) while stirring at -10 degrees, and the reaction mixture was reacted for 0.5 hours while stirring at -10 degrees. The reaction mixture was poured into ice water and extracted with ethyl acetate. The organic phase was washed with water and saturated saline respectively, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Prep-HPLC to obtain white solid compound compound I-224 (85.4 milligrams) and compound I-225 (65.3 milligrams).

[0387] Compound I-224,MS:582.3[M+H] + . 1H NMR (400MHz, DMSO-d6) δ 9.57(d,J=8.5Hz,1H),7.68(d,J=7.5Hz,1H),7.02(s,1H),6.94(d,J=7.7 Hz,1H),6.90-6.76(m,2H),6.16(d,J=7.5Hz,1H),5.11-4.91(m,2H),4.3 5-4.15(m,1H),4.00(t,J=6.5Hz,2H),3.86(s,3H),3.55-3.41(m,11H),2 .40(s,3H),1.69-1.42(m,4H),1.41-1.24(m,4H),0.90(t,J=7.3Hz,6H). Compound I-225, MS: 682.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ 9.41(d,J=8.5Hz,1H),7.60(d,J=7.5Hz,1H),6.98(s,1H),6.91(d,J=7.7Hz,1H),6.85(d,J=7.5Hz,1H),6. 65(s,1H),6.11(d,J=7.5Hz,1H),5.08-4.82(m,1H),4.49(dt,J=8.6,4.6Hz,1H),4.25(dd,J=10.9,4.4Hz, 1H),4.14(dd,J=10.9,5.3Hz,1H),4.05(t,J=6.6Hz,2H),4.00(t,J=6.5Hz,2H),3.85(s,3H),3.47(s,8H), 2.34(t,J=5.1Hz,4H),1.55(ddt,J=8.0,5.6,3.2Hz,6H),1.44-1.19(m,6H),0.88(dt,J=12.8,7.4Hz,9H).

[0388] Example Compound I-226

change

[0389] Measurement of the agonist activity of the compound according to the present invention against human TLR7 or TLR8 HEK-Blue stably expressing human TLR7 or TLR8 TM The cells were used to assess the agonistic activity of the compounds of the present invention against TLR7 or TLR8 by detecting their ability to induce a SEAP reporter gene under the control of an IFN-β minimal promoter fusion to five NF-κB and ap-1 binding sites. HEK-Blue TM hTLR7 (Invivogen, 80,000 cells per well) or HEK-Blue TM hTLR8 (Invivogen, 60000 cells per well) was added to a 96-well cell culture plate, followed by the addition of test compounds at final concentrations ranging from 0.001 to 36 μM in the medium and incubation for 16–22 h. SEAP levels in the cell culture medium were detected using the HEK-Blue detection reagent Quanti-blue (Invivogen) according to the manufacturer's manual. Light absorption at 650 nm was measured using a Neo2 multifunctional microplate reader (Bio-tek). The half effective concentration EC of the drug was determined using GraphPad Prism. 50 was calculated.

[0390] Table 1: EC of the agonistic effect of the compounds according to the invention on human TLR7 / 8 50 value [Table 1]

[0391] Mouse pharmacokinetic (PK) evaluation Pharmacokinetic experiments were outsourced to Medicilon Preclinical Research (Shanghai) Co., Ltd., and ICR mice (Shanghai Sipur-Bikhai Experimental Animal Co., Ltd.) were used as experimental animals. Test compounds were administered to ICR mice by intravenous injection (iv). The iv dose was 2 mg / kg, and the solvent system was 100% Saline (0.9% saline). The animals were fasted overnight (10-14 hours) before administration and fed 4 hours after administration. Blood was collected into sodium heparin anticoagulant tubes at multiple time points (0.083, 0.25, 0.5, 1, 2, and 4 hours) after administration. Test compounds were administered orally (po) to ICR mice. The po dose was 5 mg / kg, and the vehicle was 100% saline (0.9% saline). Animals were fasted overnight (10-14 h) before dosing and fed 4 h after dosing. Blood was collected into sodium heparin anticoagulant tubes at multiple time points (0.5, 1, 3, and 5 h) after dosing. Test compounds were administered subcutaneously (sc) to ICR mice. The sc dose was 5 mg / kg, and the vehicle system was 100% Saline (0.9% saline). Animals were fasted overnight (10–14 h) before dosing and fed 4 h after dosing. Blood was collected into sodium heparin anticoagulant tubes at multiple time points (0.5, 1, 3, and 5 h) after dosing. Samples were processed and analyzed for drug concentration in plasma by LC-MS / MS, and pharmacokinetic parameters were calculated by Phoenix WinNonlin. As a result, it was shown that the compounds according to the present invention have specific pharmacokinetic properties, and the prodrug molecules are rapidly and completely metabolized in the animal body to release the parent drug after intravenous administration (iv). All documents mentioned in the present invention are incorporated by reference in the present invention as if they were incorporated by reference separately. Furthermore, it should be understood that those skilled in the art, after reading the above teachings of the present invention, can make various changes or modifications to the present invention, and their equivalents fall within the scope of the present invention as defined by the appended claims.

Claims

1. A compound represented by formula I or formula II, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof. 【Chemistry 1】 (In the formula, L 1 is -O-, -NH-, -S-, -S(=O)- and -S(=O) 2 - selected from the group consisting of; R 1 is H, C 1-12 Alkyl group, hydroxy-substituted C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 cycloalkyl and 4-12 membered heterocycloalkyl groups; 1 further comprises one or more R a may be substituted with a substituent, and R a is a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 Cycloalkyl group, -NR a1 R a2 , -NHC(=O)-R a3 , one or more R a4 5-6 membered heteroaryl group substituted with -OC(=O)R a5 , -C(=O)R a5 , -OC(=O)OR a5 and -C(=O)OR a5 Selected from the group consisting of: The R a1 , R a2 , R a3 Or R a4 is C 1-6 Alkyl group, C 1-6 Haloalkyl groups, and C 3-6 cycloalkyl groups; The R a5 is C 1-24 Alkyl group, C 1-24 Haloalkyl groups and C groups containing 1 to 10 heteroatoms 1-24 heteroalkyl groups, wherein said heteroatoms are selected from one or more of NH, N, O, and S; X is N or CR 2 and X 1 is H or NH 2 and X 2 is a substituted or unsubstituted C 1 -C 8 alkylene groups; R 2 and R 3 are each independently hydrogen, halogen, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 cycloalkyl groups, 4-6 membered heterocycloalkyl groups, 5-8 membered heterocyclic aryl groups, and 5-8 membered aryl groups; 2 and R 3 may be further substituted with one or more substituents selected from the group consisting of halogen, a hydroxy group, a cyano group, and an amino group; k is 0 or 1; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; 【Chemistry 2】 represents a single or double bond; B does not exist or C 3-12 Cycloalkyl groups, 4-12 membered heterocyclic groups, C 6-12 aryl groups, 5-12 membered heteroaryl groups, and 【Chemistry 3】 where each A is selected from C, CH, or N, and R 6 and R 7 C together with the carbon atoms adjacent to them 4-7 Cycloalkylene group or C 4-7 A heterocycloalkylene group is formed, 4-7 Any one or more methylene groups in the cycloalkylene group or the 4- to 7-membered heterocycloalkylene group are independently a carbonyl group or S(=O) 2 and in said 4-7 membered heterocycloalkylene group, the heteroatoms are selected from N, O, and S, and the number of heteroatoms is 1 to 3; L 2 is -(CR b R c ) p - (NR d ) q -, -O-, -S-, -(CR b R c ) p -C(=O)-, -(CR b R c ) p -C(=O)NH-, -(CR b R c ) p -NHC(=O)-, -S(=O)- and -S(=O) 2 -, wherein R b , R c is hydrogen, halogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups and C 1-6 haloalkyl groups; R d is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups, C 1-6 Haloalkyl and Hydroxy Substituted C 1-6 alkyl groups, p is 0, 1, 2, 3, 4, 5 or 6, and q is 0 or 1; R 4 is a hydrogen atom, a halogen atom, a cyano group, an amino group, a hydroxyl group, C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 Cycloalkyl groups, 4-12 membered heterocyclic groups, C 6-12 aryl groups and 5-12 membered heteroaryl groups; and R 4 is optionally one or more R e may be substituted with a substituent, where R e is hydrogen, halogen, hydroxyl group, carboxylic acid, amino group, C 1-6 an alkyl group, one or more R e1 C substituted with 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, C 3-12 Cycloalkyl groups, 4-12 membered heterocycloalkyl groups, C 6-12 Aryl groups, 5-12 membered heteroaryl groups, -N(R e2 R e3 R e4 ), -C(=O)OR e2 , -C(=O)NH-R e2 , -S(=O) 2 -R e2 Selected from the group consisting of: R e1 is a halogen, a hydroxyl group, -P(O)(OR e2 ) 2 Selected from the group consisting of: R e2 and R e3 is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl group, C 1-6 Haloalkyl and Hydroxy Substituted C 1-6 alkyl groups; R e4 does not exist or C 1-6 Alkyl group, C 3-6 Cycloalkyl group and C 1-6 haloalkyl groups; R 5 is a halogen, a hydroxyl group, a cyano group, an amino group, C 1-6 Alkyl group, C 3-6 Cycloalkyl groups, 4-6 membered heterocycloalkyl groups, C 1-6 Haloalkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, -C(=O)O-R f , -C(=O)NH-R f and -S(=O) 2 -R f wherein R f is hydrogen, C 1-6 Alkyl group, C 3-6 Cycloalkyl group and C 1-6 haloalkyl groups; n is 1, 2, 3, 4, 5 or 6; wherein each of said heterocyclic groups may be saturated or partially unsaturated (but without aromatic structures), and in said heterocyclic groups, the heteroatoms are selected from N, O, or S, and the number of heteroatoms is 1, 2, 3, or 4 (preferably 1 or 2); and in said heteroaryl groups, the heteroatoms are selected from N, O, or S, and the number of heteroatoms is 1, 2, or 3.

2. L 1 is selected from the group consisting of -O-, -NH- and -S-. The compound represented by formula I according to claim 1, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof.

3. R 1 is C 1-12 Alkyl group, hydroxy-substituted C 1-12 Alkyl group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-12 cycloalkyl groups and 4- to 12-membered heterocycloalkyl groups, where R 1 further comprises one or more R a may be substituted with a substituent, and R a is a halogen, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 Cycloalkyl group, -NR a1 R a2 , -NHC(=O)-R a3 , one or more R a4 5-6 membered heteroaryl group substituted with -OC(=O)R a5 , -C(=O)R a5 , -OC(=O)OR a5 and -C(=O)OR a5 2. The compound of claim 1, wherein the compound is selected from the group consisting of:

4. The compound of formula I according to claim 1, characterized in that the compound of formula I has a structure selected from the group consisting of: 【Chemistry 4】

5. B does not exist or C 3-8 Cycloalkyl group, 4-7 membered heterocyclic group, C 6-10 Aryl groups, and 【Chemistry 5】 2. The compound of claim 1, wherein the compound is selected from the group consisting of:

6. A compound represented by formula I according to claim 1, characterized in that B is absent or selected from the group consisting of a phenyl group and a pyridyl group, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof.

7. L 2 is -(CR b R c ) p - (NR d ) q -, -O-, -S-, -(CR b R c ) p -C(=O)-, -(CR b R c ) p -C(=O)NH-, -(CR b R c ) p -NHC(=O)-, -S(=O)- and -S(=O) 2 -, where R b , R c is hydrogen, halogen, C 1-6 alkyl groups; R d is hydrogen or C 1-6 A compound represented by formula I according to claim 1, characterized in that p is an alkyl group, p is 0, 1, 2 or 3, and q is 0 or 1, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof.

8. L 2 is -(CH 2 ) p -, -(CH 2 ) p -NR d -, -O-, -S-, -(CH 2 ) p -C(=O)-, -(CH 2 ) p -C(=O)NH-, -(CH 2 ) p -NHC(=O)-, and -S(=O) 2 -, where R d is hydrogen or C 1-6 A compound represented by formula I according to claim 1, characterized in that p is an alkyl group and p is 0, 1, 2 or 3, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof.

9. R 4 is hydrogen, halogen, amino group, hydroxyl group, C 1-12 Alkyl group, C 1-12 Alkoxy group, C 2-12 Alkenyl group, C 2-12 Alkynyl group, C 3-10 Cycloalkyl group, 4-10 membered heterocyclic group, C 6-12 aryl groups, and 5-12 membered heteroaryl groups; and R 4 is optionally one or more R e may be substituted with a substituent, where R e is hydrogen, halogen, hydroxyl group, carboxylic acid, amino group, C 1-6 an alkyl group, one or more R e1 C substituted with 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Haloalkoxy group, C 3-8 is selected from the group consisting of a cycloalkyl group, a 4- to 7-membered heterocyclic group, a phenyl group, and a 5- to 7-membered heteroaryl group, where R e1 is a halogen, a hydroxyl group, and P(O)(OR e2 ) 2 2. The compound of claim 1, wherein the compound is selected from the group consisting of:

10. R 4 is hydrogen, C 1-12 Alkyl group, C 1-12 An alkoxy group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, 【Chemistry 6】 wherein any position in the ring is missing an H atom to provide a linking site, and R 4 is optionally one or more R e 2. A compound represented by formula I according to claim 1, which is optionally substituted with a substituent, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof.

11. R 5 is a halogen, a hydroxyl group, a cyano group, an amino group, C 1-6 Alkyl group, C 1-6 Alkoxy groups, and C 3-6 2. The compound of formula I according to claim 1, wherein the compound is selected from the group consisting of cycloalkyl groups, or a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof.

12. The compound represented by formula I according to claim 1, characterized in that the compound represented by formula I is selected from the group consisting of: a solvate thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof. 【Chemistry 7-1】 【Chemistry 7-2】 【Chemistry 7-3】 【Chemistry 7-4】 【Chemistry 7-5】 【Chemistry 7-6】 【Chemistry 7-7】 【Chemistry 7-8】 【Chemistry 7-9】 【Chemistry 7-10】

13. A pharmaceutical composition comprising one or more of the compounds of formula I according to any one of claims 1 to 12, their medicament salts, racemates, R-isomers, S-isomers and mixtures thereof, and one or more medicament carriers, excipients, adjuvants, auxiliary agents and / or diluents.

14. Use of a compound of formula I according to any one of claims 1 to 12, its medicamentous salts, racemates, R-isomers, S-isomers or mixtures thereof in the preparation of a pharmaceutical composition for the treatment or prevention of tumors or viral infections.

15. The virus is selected from the group consisting of HBV, HCV, HIV, influenza virus, and combinations thereof; and / or 15. The use according to claim 14, characterized in that the tumor is preferably lung cancer, pancreatic cancer, renal cancer, head and neck cancer, breast cancer, lymphoma, skin cancer, urothelial cancer, gastric cancer, hepatocellular carcinoma and colorectal cancer.

Citation Information

Patent Citations

  • Novel heteroaryl and heterocycle compounds, compositions and methods

    WO2016119707A1